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RESUME 
Le concept des origines développementales des maladies et de la santé (DOHaD) émet 
l’hypothèse d’une origine périnatale des maladies non-transmissibles (NCD). Le modèle de 
stress de séparation maternelle (MS) est largement utilisé chez le rongeur comme un paradigme 
d’événements adverses en période néonatale. Mon projet de doctorat, a eu pour but d’étudier 
les effets à long-terme du MS sur les fonctions de barrière intestinale, le métabolisme, la 
réponse immunitaire, l’auto-immunité ainsi que sur le microbiote, chez des souris mâles et 
femelles sauvages âgées sous régime standard. Le but étant de fournir des données 
expérimentales soutenant le lien entre stress néonatal et développement de désordres 
métaboliques ou auto-immuns à l’âge adulte. 
Dans une première étude, nous avons montré que, le MS a induit une intolérance au 
glucose et une perte de la sensibilité à l’insuline associée à une dysbiose fécale chez des souris 
mâles sauvages C3H/HeN âgées de 350 jours (PND350). Le MS a diminué les concentrations 
d’IgG fécales et a augmenté les IgG anti-E. coli plasmatiques, représentant la réponse humorale 
contre le microbiote commensal. Le MS a diminué significativement la sécrétion d’IL-17 et IL-
22 en réponse à une stimulation du TcR et a augmenté la sécrétion de TNFα en réponse à une 
stimulation LPS dans une culture de cellules de la lamina propria de l’intestin grêle (siLP). Les 
mêmes résultats ont été obtenus au niveau systémique (rate). Nous avons ainsi démontré pour 
la première fois que le stress néonatal est un facteur de risque pour le développement des 
désordres métaboliques chez la souris sauvage âgée sous régime standard. Nous avons écarté 
un rôle exclusif du microbiote dans l’intolérance au glucose induite par le MS avec des 
expérimentations de transfert de microbiote fécal. 
Dans une seconde étude, chez les femelles PND350 soumises au MS, on a observé une 
augmentation de la sécrétion d’IL-17 et IL-22 en réponse à une stimulation du TcR, et de TNFα 
avec ou sans stimulation au LPS par les cellules de la siLP. Nous avons observé en plus une 
inflammation systémique. Les souris MS ont développé une intolérance au glucose associée à 
une baisse de la sécrétion de l’insuline en réponse à un challenge au glucose. Le ratio de la 
surface des cellules β sur la surface du pancréas a légèrement diminué chez les MS et la valeur 
de ce ratio a corrélé positivement avec la sécrétion d’insuline induite par le glucose. En somme, 
le MS induit chez les souris femelles des effets à long terme sur l’immuno-métabolisme et 
l’homéostasie du pancréas. 
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Enfin, nous avons comparé les mesures de perméabilité intestinale in vivo (gavage) et 
ex vivo (chambres de Ussing) avec du FITC-Dextran 4 kDa dans un modèle de diabète de type 
1 (NOD - souris non-obese diabetic). De façon inattendue, les résultats ont différé en fonction 
des méthodes et cette différence n’est pas due à un défaut de la fonction rénale induite par le 
diabète. Par contre, nous avons observé un allongement de l’intestin grêle chez les souris 
diabétiques qui a corrélé positivement avec la perméabilité intestinale in vivo. Le diabète n’a 
pas modifié le transit intestinal, l’humidité des fèces et l’apparence histologique de l’intestin. 
En somme, nos résultats soulignent l’importance de distinguer la perméabilité intestinale, 
exprimée en cm/s mesurée ex vivo, et la notion d’exposition systémique aux antigènes luminaux 
mesurée in vivo. 
Mon travail de thèse montre que les événements adverses néonataux sont un facteur de 
risque pour les NCD. Il est intéressant de noter que nos observations sur les souris âgées sont 
similaires aux observations épidémiologiques. En effet, nos résultats préliminaires suggèrent 
que les souris MS femelles développent des désordres métaboliques avec des caractéristiques 
auto-immunes; alors que les mâles développent des désordres métaboliques plus classiques : 
résistance à l’insuline. Mon travail sur le modèle MS souligne l’importance de la vie néo-natale 
dans l’établissement de l’homéostasie et conforte le concept de DOHaD. 
Stress social, Métabolisme glucidique, Barrière intestinale, Réponse immunitaire, 
Origines développementales des maladies et de la santé. 
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SUMMARY 
The concept of Developmental Origins of Health and Disease (DOHaD) highlights the 
importance of early life period and raises the hypothesis that Non Communicable Diseases 
(NCD) could find their origins in perinatal environment. Neonatal maternal separation (MS) is 
a stress model widely used in rodents as a paradigm of early life adverse events. In my PhD 
project, I aimed to investigate in aging male and female wild-type mice under normal diet the 
long-term effects of neonatal MS on intestinal barrier function, metabolism, immunity, auto-
immunity, as well as on microbiota. My work aimed to provide experimental data to support a 
link between early life stress and development of metabolic or autoimmune disorders with 
aging.  
In our first study, MS led to glucose intolerance and loss of insulin sensitivity associated 
with fecal dysbiosis in Post Natal Day (PND) 350 wild-type C3H/HeN male mice fed a standard 
diet. Fecal IgG concentrations were decreased in MS mice compared to control mice, whereas 
anti-E. coli IgG, representing humoral response toward commensal microbiota, were 
significantly increased in plasma of MS mice. MS significantly decreased IL-17 and IL-22 
secretion in response to TcR stimulation in small intestine lamina propria (siLP) culture. 
Besides, TNFα secretion in response to LPS-stimulation was slightly increased. The same 
results were obtained at systemic level (spleen). For the first time, we demonstrated that early 
life stress alone is a risk factor for metabolic disorders development in aging wild type mice 
under normal diet. The result of this project gave us the opportunity to question the role of 
microbiota in MS-induced glucose intolerance. Fecal microbiota transfer of MS mice 
microbiota was not sufficient to induce glucose intolerance. 
In our second study in PND350 female, MS increased IL-17 and IL-22 by siLP cells in 
response to TcR stimulation. TNFα secretion with and without LPS stimulation was also 
increased by MS. Additionally, we observed systemic low-grade inflammation. MS mice 
developed glucose intolerance associated with decreased insulin secretion in response to 
glucose stimulus. Ratio of β-cell surface to pancreas surface was slightly decreased in MS mice 
compared to control. This ratio positively correlated with insulin secretion induced by glucose. 
Taken together, the results of our study showed that MS in wild type female mice under normal 
diet leaves a long-lasting imprinting on immune-metabolism and pancreas homeostasis.  
We compared in vivo and ex vivo intestinal permeability measurements in a model of 
type 1 diabetes (NOD – non-obese diabetic mice). Intestinal permeability was assessed in vivo 
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by gavage and ex vivo in Ussing chambers with the marker FITC-Dextran 4 kDa. Surprisingly, 
the results of both methods were divergent. The difference between in vivo and ex vivo 
measurements could not be explained by altered renal excretion. Curiously, diabetic NOD mice 
had significantly longer small intestine than non-diabetic NOD mice and small intestine length 
positively correlated with intestinal permeability in vivo. However, there were no difference in 
intestinal transit time, feces humidity and histological appearance. Altogether, our results 
highlighted the importance to distinguish intestinal permeability, which is expressed as cm/s 
measured ex vivo, and the notion of systemic exposition to luminal antigen measured in vivo.  
My PhD project shows that early life adverse events are a risk factor for NCD. 
Interestingly, our observations in aging mice are similar to epidemiological observations. 
Indeed, preliminary results suggested that female MS mice develop metabolic disorders with 
autoimmune characteristics but male MS mice develop classical metabolic disorders with 
insulin resistance. My work in MS model highlights the importance of early life in the 
establishment of homeostasis and comforts the concept of DOHaD. 
Social stress, Glucose metabolism, Intestinal barrier, Immune response, Developmental 
origin of health and diseases (DOHaD). 
 
  
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
  
6 
 
The incidence of non-communicable diseases (NCDs) is constantly increasing in the last 
decades. Among NCDs, there are metabolic disorders, like obesity and type 2 diabetes, 
autoimmune diseases, as for example type 1 diabetes and allergies. Explications for the 
important rise in NCDs are numerous and diverse. There are for example, changes in lifestyle, 
nutrition, increased exposure to environmental contaminations and pollutants,  
Early life is an important period for the establishment of lifelong beneficial homeostasis 
between the organism and its environment, especially its microbiota. The concept of 
developmental origins of health and disease (DOHaD) suggests that early life can have potent 
imprinting mechanism on host’s physiology and that adverse perinatal physical and social 
environment can lead to higher susceptibility to NCDs. Indeed, the thousand first days of our 
life, from conception to our second year’s birthday, are described to be decisive for future 
health. 
The intestine is the body’s greatest surface in contact with its environment. In order to 
protect the organism from harmful substances and microorganisms but maintaining at the same 
time efficient nutrient absorption, the intestinal barrier is highly developed and regulated. 
Principal actors of the intestinal barrier are microbiota, intestinal epithelium with its highly 
regulated permeability and intestinal immune system. Interestingly, a tremendous amount of 
studies has shown that disturbed microbiota homeostasis (dysbiosis) is associated with a 
multitude of diseases, especially NCDs. Indeed, the gastro-intestinal tract seems to play a 
crucial role in organism’s health and disease.  
This work is the continuation of previous studies performed in our laboratory, which 
highlighted the impact of stress on the integrity of the intestinal barrier. Especially early life 
stress has been of particular interest in our laboratory. Indeed, early life stress is known to 
impair intestinal barrier through induction of intestinal hyperpermeability, low-grade 
inflammation and microbiota dysbiosis in young rodents. Maternal separation (MS) is a 
paradigm of early life stress in rodents. 
During my PhD I had the opportunity to write a review article, submitted and under 
review for the journal Frontiers in Immunology. Some parts of this article are quoted in I. Part: 
State of the Art. 
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CHAPTER I 
INTESTINAL BARRIER AND INTESTINAL HOMOEOSTASIS 
The human intestine is about six meters long and due to multiple folding through crypts 
of Lieberkühn, villi and microvilli, the surface is about 400 m2. This makes the intestinal 
epithelium the mammalian organism’s biggest surface in contact with the environment (Figure 
1). A principal role of intestine is to complete the digestion and absorb the nutrients but at the 
same time, the intestine filters and defends the organism from harmful luminal content 
(pathogens, toxins…), while maintaining tolerance towards commensal microbiota and food 
antigens. Hence, the intestine is acting as a selective barrier. Considering the challenging, 
various, decisive and conflicting roles, it is not surprising that intestinal barrier function is 
highly diverse and well developed. 
 
Figure 1 Intestinal anatomy. The intestinal tube is surrounded by two muscle layers, the longitudinal outer and 
the circular inner layer. The mucosal surface is increased by circular folds. Villi are finger-like extensions of 
mucosa into the intestinal lumen increasing further the intestinal surface. Intestinal epithelial cells have 
microvilli on apical site, which are also increasing the intestinal surface. 
(https://histaminefriendlykitchen.com/wp-content/uploads/2017/08/TheVilliandmicrovilli.jpg) 
1. Actors of intestinal barrier 
Among the main actors of intestinal barrier, there are intestinal microbiota, mucus, 
intestinal epithelium, intestinal immune system with its innate and adaptive response, harbored 
within the lamina propria (LP), and muscular layer, responsible for gut motility. 
1.1 Intestinal microbiota 
The intestinal microbiota is a complex bacterial community colonizing the gut. There 
are more than 100 trillions of microorganisms from two major phyla, Bacteriodetes and 
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Firmicutes, representing around 90% of gut microbiota (Rinninella et al., 2019). Other 
represented phyla are for example Actinobacteria and Proteobacteria. Colonization density is 
increasing from stomach (101-103 bacteria/g), via duodenum (104-105 bacteria/g) and 
jejunum/ileum (108 bacteria/g) to colon (1012-1014 bacteria/g) (Nicolas, 2013). Microbiota plays 
an important role by providing, extracting and absorbing various nutritional compounds and 
metabolites, as for example bile acids, amino acids, vitamins, lipids, short-chain fatty acids 
(SCFAs) (Jandhyala et al., 2015). Lactate, as an example for a bacterial metabolite, has 
stimulating effect on colonic proliferation (Okada et al., 2013). Also small intestinal stem cells 
are using lactate as an energy source (Rodríguez-Colman et al., 2017). Microbiota cans also 
influence host’s physiology through its metabolites. For example, butyrate, a SCFA produced 
by gut microbiota, is able to regulate host metabolism and immunity via its utilization as energy 
source through β-oxidation in enterocytes and inhibition of histone deacetylases, affecting 
host’s gene expression (Stilling et al., 2016). As an example, in cell cultures of murine mast 
cells and primary bone marrow mononuclear cells, butyrate has been shown to suppress 
proliferation and the production of the cytokines IL-6 and TNFα via the inhibition of histone 
deacetylase (Zhang et al., 2016). Microbiota participates also in the protection against 
pathogens colonization by occupation of ecological niches (competition for nutrients and space) 
(Jandhyala et al., 2015). Additionally, microbiota contributes to maturation of intestinal 
epithelium and immune system. This fact particularly strikingly visible in germ-free (GF) 
animals, which are living in sterile isolators, devoid of any microbiota. Indeed, GF mice are 
described to have thinner small intestine lamina propria (siLP) (Round and Mazmanian, 2009) 
and a great deficit in gut associated lymphoid tissue, as small Peyer’s patches containing only 
a little number of germinal centers (Macpherson et al., 2001). They have immature immune 
system, namely reduced number of IgA producing and CD4+ cells. Colonization by microbiota 
can restore these defects (Falk et al., 1998; Helgeland et al., 1996; Macpherson et al., 2001). 
1.1.1 Microbiota during life-time 
Microbiota is depending on lots of different factors and can evolve during lifetime. In 
utero the fetus is considered sterile (Hornef and Penders, 2017), even if this assumption is 
debated. Some affirm that there is a microbiota in utero (Aagaard et al., 2014; Jiménez et al., 
2008). However, the presence of bacteria is often confirmed by qPCR and rarely by culture of 
living bacteria and critics are highlighting potential contamination and missing controls (Perez-
Muñoz et al., 2017). By definition, sterile is “devoid of life”. Detecting bacteria by qPCR 
demonstrate the presence of bacterial DNA but not living bacteria. In the following, I will 
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assume that fetus in utero is sterile and that first colonization takes place at birth. Highly 
dynamic microbiota during early life will be treated separately (cf. Chapter I 4. Ontogeny of 
intestine in early life 4.1 Colonization). 
In adulthood, microbiota is more stable than in early life (Borre et al., 2014; Palmer et 
al., 2007) and less sensitive to external insults. Indeed, highly diverse microbiota is resilient to 
a certain amount of time-limited stressors, as for example disease, antibiotic treatment. 
Resilience means that the microbiota can recover its initial state (equilibrium) after an external 
insult. This is due to a variety of host-microbiota and inter-community interaction at one side 
and on the other side host-bacteria and bacteria-bacteria antagonisms (Sommer et al., 2017). 
Another factor modifying microbiota is aging. Claesson et al. observed in elderly Caucasians 
compared to younger individuals, a shift from Firmicutes towards Bacteriodetes (Claesson et 
al., 2011). 
1.1.2 Dysbiosis 
There are several external parameters able to influence microbiota composition. For 
example, diet is a potent influencer of microbiota composition (Rothe and Blaut, 2013). In 
addition, our environment is influencing the microbial community of our gut. Medical 
treatment, as for example antibiotics, and disease state influence gut microbiota as well (Ottman 
et al., 2012). If the pressure on the microbiota ecosystem is long-lasting or more important, or 
if initial microbiota is less resilient, there can be a shift towards a new equilibrium, perhaps a 
detrimental one, also called dysbiosis (Sommer et al., 2017). 
It has been shown, that microbiota is different between different geographic 
environments. Indeed, people in countries with westernized lifestyle and non-westernized 
lifestyle have distinct microbiota (Pasolli et al., 2019). Migration of Hmongs and Karens 
towards the United States changes the microbiota composition strongly. A loss in diversity has 
been observed. These changes, increasing in long-term residents and the second generation 
post-immigration, were associated with increased incidence of obesity (Vangay et al., 2018).  
Dysbiosis is defined by Petersen and Round as a disturbance in the microbiome structure 
that may consist in a loss of beneficial microorganisms, and/or expansion of pathobionts or 
harmful microorganisms (Figure 2) (Petersen and Round, 2014). Gut dysbiosis is described in 
tremendous diseases. Autoimmune disorders (AD), metabolic disorders, inflammatory bowel 
diseases (IBD), irritable bowel syndrom (IBS), even psychological disorders are associated with 
gut microbiota dysbiosis. 
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Figure 2 Dysbiosis. “A loss of beneficial microbes, expansion of pathobionts, and loss of diversity are events 
that encompass dysbiosis. During healthy, homeostatic conditions the microbiota is composed of a diversity 
organisms that are known to benefit host development and health.” (Petersen and Round, 2014) 
Important inter-individual microbiota composition has been observed (Franzosa et al., 
2015). Further, regarding the high dynamics of microbiota during lifetime and the multiplicity 
of influencing factors, important questions seem to be: “Are there common elements to healthy 
microbiomes, in absence of overt disease? Which molecular elements of a personalized 
microbiome might be responsible for health outcomes, and how do they integrate with and 
maintain physiological processes such as the immune system and metabolism?” (the integrative 
HMP (iHMP) research Network consortium, 2019). The integrative Human Microbiome 
Project (HMP) address these question and was designed to gain a more complete view of 
microbial-host interactions in time. In this work frame, they found for example that not the 
microbiome but its prevalent molecular functions are correlated with host’s phenotype. Another 
finding of the more than 42 terabytes sampled omic data is that during disease microbiota is 
highly dynamic and could explain difficulties in cross-sectional studies to extract conclusive 
information (the integrative HMP (iHMP) research Network consortium, 2019). 
1.2 Mucus 
The gastrointestinal tract is covered by a mucus layer, protecting the epithelium from a 
direct contact with its microbiota. Mucus is secreted by goblet cells in the epithelial cell line 
and is made up mainly of mucin protein MUC2. The protein includes a high number of hydroxyl 
amino acids which serve as attachment sites for the O-glycans. After posttranslational 
modification in the Golgi apparatus, glycans represent around 80% of total mucin mass. O-
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glycans can bind a great amount of water, which is giving the mucus its gel-forming property 
There are also transmembrane mucins, expressed by enterocytes (MUC1, 3A/B, 4…) but in 
smaller quantity (McGuckin et al., 2011). 
The mucus structures in small intestine and colon are different (Figure 3). In small 
intestine, there is one mucus layer; bacteria can penetrate into the mucus (Johansson and 
Hansson, 2016). In colon mucus is fourfold thicker and in animal models, two distinct mucus 
layers have been described: the outer, loose mucus layer, penetrated by gut bacteria; and the 
inner, firm, sterile mucus layer tightly attached to the epithelium (Atuma et al., 2001; Johansson 
et al., 2008).  
 
Figure 3 Mucus layer organization in small intestine and colon. Mucus is produced and secreted by goblet 
cells. The mucus layer in the small intestine is loose and not attached to the epithelium. Antibacterial products 
are present in mucus, limiting the penetration of bacteria towards the epithelium. In the colon, mucus is 
organized in outer and inner mucus layer. The outer loose mucus layer is enriched in bacteria, whereas the inner 
mucus layer attached to the epithelium is almost free of bacteria (Johansson and Hansson, 2016). 
This vision of mucus organization, though, is debated. Notably Kamphuis et al. propose 
a mucus organization shaped by colonic content. They found the firm and sterile mucus layer 
attached to fecal pellet but not to colonic epithelium in histological staining in rat. In empty 
colon, the epithelium is covered with a loose, discontinuous mucus layer and devoid of bacteria 
(Kamphuis et al., 2017). However, Kamphuis et al. believe that the principal role of the mucus 
layer, even though attached to fecal pellet and not to epithelium, is the containment of bacteria 
in a restricted location in intestine in order to protect the host’s epithelium from invasion 
(Kamphuis et al., 2017). 
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Mucus is enriched with antimicrobial peptides (Dupont et al., 2015) and secretory IgA 
(sIgA) (McGuckin et al., 2011), hence mucus invading bacteria will encounter antimicrobial 
peptides and sIgA and might be killed in this process. Indeed, it has been demonstrated that 
mucus has microbiota killing activity (Meyer-Hoffert et al., 2008). Invading bacteria in mucus 
are mainly detected by FISH technic that do not prove that bacteria are alive. The concerted 
action of physical, biochemical and immunological barrier components in the mucus are 
effective to keep bacteria away from epithelium and protect the host from infection. 
1.3 Intestinal epithelium  
The intestinal epithelium is formed by distinct cell types distributed along the crypt–
villus axis. Although they all derived from a common stem cell progenitor located in the crypts, 
their morphology and roles differ (Figure 4) (for review (Gehart and Clevers, 2019)). The 
intestinal epithelium is renewed every five days, a part from Paneth cells whose lifespan has 
been estimated at about 60 days in mice (Ireland et al., 2005), and this constant renewing confers 
high plasticity and protection to the intestinal barrier since defective cells are removed rapidly 
(Gordon and Hermiston, 1994). 
1.3.1 Different cell types in the intestinal epithelium 
(a) Enterocytes 
Enterocytes are present all over intestine, namely in small intestine and colon. They 
serve as physical barrier. Their main role is the absorption of nutrients and water. Additionally, 
they can also secrete antimicrobial components and they are non professional antigen presenting 
cells (expression of MHC2 without co-stimulatory molecules). 
(b) Enteroendocrine cells 
Enteroendocrine cells can be found in colon and small intestine. The high variety of 
enteroendocrine cells secrete different hormones. They exert regulation on intestinal motility 
and digestive processes but they can also influence central nervous system, via their 
anorexigenic effect. Some examples are mentioned in Table 1.  
(c) Goblet cells 
The mucus producing and secreting goblet cells are present all over the intestine but 
more abundant in colon. Goblet cells are not restricted to the production of mucus, they also 
can secrete antimicrobial components and play a role in antigen passage of antigens via goblet 
cell-associated passage (GAP), which will be developed later.  
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Table 1 Hormones produced by intestinal epithelial cells (examples). 
Hormone Cell Functions (selection) 
PYY L-cells Inhibits gastric emptying and intestinal motility; inhibits 
gastric acid secretion and pancreatic exocrine function; 
anorexigenic; stimulates mucosal enterocyte proliferation 
GLP-1 L-cells Incretin effect; delays gastric emptying; postprandial satiety 
5-HT 
(Serotonin) 
Enterochromaffin 
cells 
Intestinal motility; intestinal secretion; visceral sensation; 
appetite 
Somatostatin D cells Major inhibitory hormone for digestive endocrine and 
exocrine function; stimulates colonic peristalsis 
GIP K-cells Inhibition of gastric acid secretion, stimulation of insulin 
secretion 
Cholecystekinin 
(CKK) 
I-cells Anorexigenic,  
 
(d) Paneth cells 
Paneth cells are only present in the small intestine. They are located at the bottom of the 
crypt in proximity with intestinal stem cells. Paneth cells secrete antimicrobial peptides (AMP), 
as for example lysozyme. Due to their location, they also contribute to the protection of stem 
cells by secreting AMP highly enriched in the bottom of the crypt and thus support the stem 
cell niche.  
(e) M cells 
Microfold (M) cells can be found in small intestine in the follicle-associated epithelium. 
They play an important role in the antigen uptake, facilitated by microfolds (short fold-like 
invaginations) on apical site. On their basolateral site, they have a large pocket promoting close 
contact with dendritic cells (DC) or lymphocytes. Additionally, the follicle-associated 
epithelium secrete less mucus, less AMP and sIgA, which help bacteria and antigens to reach 
M cells in order to be processed and transported for antigen presentation. Even though M cells 
represent a facilitating pathway for antigen to prime oral tolerance, they are not mandatory 
(Spahn et al., 2002). 
(f) Tuft cells 
Tuft cells are present all along intestine. They are important for helminth detection and 
innate lymphoid cell 2 (ILC2) expansion (Gerbe et al., 2016). They are also responsible for 
opioid production and secretion in the intestinal epithelium (Gerbe et al., 2011). 
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Figure 4 Different cell types in (A) small intestine and (B) colon. (A) Most of small intestinal epithelial cells 
are enterocytes, secreting antimicrobial peptides (RegIIIγ, β-defensins and cathelicidins). Paneth cells are located 
at the base of the crypts, they secrete antimicrobial peptides (sPLA2, lysozyme and α-defensins). Goblet cells are 
secreting mucus. Antigens can enter into lamina propria via M cells on the surface of Peyer’s Patches and via 
goblet cell associated passage (GAP); Underlying dendritic cells (DC) are sampling entered antigens. The lamina 
propria is rich in innate (macrophages, monocytes, dendritic cells) and adaptive (B cells, T cells, intraepithelial 
cells -IEL) immune cells. (B) Colonic epithelium consists mainly out of colonocytes and goblet cells. Goblet 
cells are forming the mucus layer via production of Muc2 but they are also secreting other proteins (RELMβ, 
CLCA1, Zg16,Agr2). (Allaire et al., 2018) 
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claudins (Furuse et al., 1993), occludins (Furuse et al., 1998), junctional adhesion molecule 
(JAM) (Martìn-Padura et al., 1998) and tricellulin (Ikenouchi et al., 2005). In the cell, these 
protein complexes are linked via cytosolic scaffold proteins (zonula occludens) with the 
perijunctional actomyosin ring. Myosin light chain (MLC) phosphorylation by MLC-kinase 
(MLCK) is regulating contraction and tension of actomyosin ring (Madara et al., 1987). 
 
Figure 6 Intercellular junctions of intestinal epithelial cells. “The intercellular junctions are organized by 
different protein complexes, including tight junctions (TJs), adherens junctions (AJs), and desmosomes. TJ 
complexes locate at the apical ends of the lateral membranes of intestinal epithelial cells and consist of 
transmembrane and intracellular scaffold proteins. Extracellular loops of the trans- membrane proteins (occludin, 
claudins, JAMs, and tricellulin) are regulating paracellular permeability. The intracellular domains of the 
transmembrane proteins interact with the intracellular scaffold proteins such as zonula occludens (ZO) proteins, 
which in turn anchor the transmembrane proteins to the actin cytoskeleton. Myosin light chain kinase (MLCK) is 
associated with the perijuctional actomyosin rings and regulates paracellular permeability through myosin 
contractility. The AJs along with desmosomes provide strong adhesive bonds between the epithelial cells and 
also intercellular communication” (Suzuki, 2013). 
Another paracellular passage has been described by Rescigno et al. Dendritic cells (DC) 
can extent dendrites through the paracellular space and sample bacteria directly in the lumen. 
Since DC also express tight junction proteins intestinal barrier remains preserved (Rescigno et 
al., 2001). 
(b) Transcellular permeability 
Bigger molecules (> 600 Da), such as peptides and food antigens can be transported 
through the epithelial cell via transcellular transport route (Figure 5) (Gardner, 1988; Heyman 
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et al., 1982). Most of transcellular passage takes place in M cells, but enterocytes are also able 
to transport peptides. In the great majority the molecules are processed by the lysosome during 
their passage through cells, only a small quantity can reach LP intact (Heyman et al., 1996, 
1982).  
Transcellular passage can also be mediated by retro-transport of immunoglobulins from 
the lumen to the serosal compartment via receptor expression on the intestinal epithelium, as 
for example the neonatal Fc receptor (FcRn) observed in suckling rats responsible for the 
transmission of passive immunity by the mother (Blumberg et al., 1995; Jones and Waldmann, 
1971; Simister and Mostov, 1989). FcRn has also been described on human fetal intestinal 
epithelial cells (Israel et al., 1997). 
Goblet cells in the small intestine have been shown in the steady state, to let pass low 
molecular weight soluble antigens from the intestinal lumen to underlying tolerogenic-dendritic 
cells (DC) (McDole et al., 2012). This phenomenon is called goblet-cell associated passage 
(GAP). However in the colon, this antigen passage via goblet cells is restricted to a precise time 
window, from post-natal day 10 (PND10) to PND20 and later downregulated by microbiota in 
rodents (Knoop et al., 2017). As a consequence, induction of gut microbiota tolerance by the 
colonic immune system is crucial in early-life period and supporting the hygiene hypothesis, 
which proposes that the increased incidence of immune-mediated diseases is due to decreasing 
exposure to microorganisms in early life (Al Nabhani and Eberl, 2017; Bach, 2018).  
There are multiple methods for the determination of intestinal permeability (IP) 
including in vivo and ex vivo measurements. First, in vivo methods are often used due to the 
simplicity of protocol and the absence for the need of complex device. Indeed, several non-
metabolized molecules can be used to determine their passage across intestinal barrier in vivo 
in animal and human. The individual is receiving the molecule via the oral route and after a 
fixed time, blood or urine is collected and the marker is detected according to its properties 
(radioactivity, fluorescence, etc). Thanks to distinct chemical characteristics and degradation 
process by intestinal microbiota, different markers can be used to assess permeability of 
different intestinal segments (Travis and Menzies, 2015). Another possibility to assess intestinal 
permeability is by dosing serological markers without any previous gavage, as for example 
zonulin-1 (Fasano, 2011) or endotoxin (Cani et al., 2007) that will represent respectively 
intestinal homolog of a Vibrio cholerae enterotoxin that reversibly increase IP and a marker of 
intestinal lipopolysaccharide translocation in the blood. 
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1.4 Intestinal immune system  
As the previous paragraph shows, the intestinal immune system is in close relationship 
with the other actors of the intestinal barrier and important to confer tolerance but at the same 
time protection to the host. Intestinal immune system is highly developed. Indeed, it is the 
largest immune system in the organism. There are particular structures – the gut-associated 
lymphoid tissue (GALT), numerous innate and adaptive immune cells and a large variety of 
immune active actors. 
The first line of host defense is the innate immune system. 
1.4.1 Antimicrobial peptides 
Antimicrobial peptides (AMP) are crucial for the maintenance of intestinal homeostasis. 
They are controlling intestinal colonization. AMP are oligopeptides or even small proteins (5-
100 amino acids), targeting a vast spectrum of microorganisms (bacteria, fungi, ..) (Bahar and 
Ren, 2013; Ganz and Lehrer, 1998). All AMP derive from bigger precursors and undergo 
important posttranslational modifications (Wilson et al., 1999). AMP repertoire is different 
between all species, even those who are related (Zasloff, 2002). Even different mouse strain 
have different AMP repertoire (Gulati et al., 2012). These differences can largely influence the 
microbiota and explain inter-species and inter-strain discrepancies in microbiota composition. 
Besides, it could confer diverse resistance capacities towards pathogens.  
The presence of AMP in the intestine is also highly regionalized. AMPs are produced 
by enterocytes and goblet cells, but also by specialized cells, the Paneth cells. Paneth cells are 
only present in the small intestine, they produce and secrete α-defensins, RegIIIγ, sPLA2 
(phospholipase-A2), and lysozyme (Vaishnava et al., 2008). 
Lysozyme can also be produced by neutrophils; it is present in saliva and maternal milk. 
Defensins possess three intramolecular disulfide bonds and a β-sheet structure. In vertebrates, 
there are two families, α-defensins, β-defensins. In mice, α-defensins are called cryptidins. 
Cathelin-related antimicrobial peptide (CRAMP) is member of the cathelicidin family, present 
in mice and similar to LL37 in human  
Some AMP are targeting a fundamental differences between microbes and multicellular 
animals: microbes’ surface is negatively charged whereas plants and animals cell membranes 
are composed of lipids without charge (Matsuzaki, 1999). Cationic AMP attack microbes by 
interaction with their membrane, lipids are displaced, membrane structure is altered as a 
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consequences and sometimes AMP enters into the cell. This mechanism is called Shai–
Matsuzaki–Huang (Matsuzaki, 1999; Shai, 1999; Yang et al., 2000).  
Due to their high aggressiveness, AMP are highly regulated and undergo numerous 
maturation steps. AMP are secreted either constitutively or after pattern recognition receptor 
(PRR) activation by microbe-associated molecular patterns (MAMPs) (Yokoi et al., 2019). 
 
Figure 7 Functions of AMP. AMP can directly kill bacteria, virus and fungi. They can favor pathogen clearance 
by opsonisation of bacteria, they contribute to angiogenesis. AMP have immunomodulatory function through 
chemotaxis towards immune cells. They inhibit proteases and can bind endotoxin thus influencing TLR signaling 
(Frew and Stock, 2011). 
AMP also have immunomodulatory functions (Figure 7). They have chemiotactic 
properties towards monocytes, macrophages, neutrophils and mast cells (Oppenheim et al., 
2003). They can recruit T cells via induction of inflammatory cytokines (Lai and Gallo, 2009). 
They can favor bacterial clearance by opsonisation (Wilkinson et al., 2009). Immune response 
can also regulate AMP as for exemple IL-22 can induce RegIIIγ release (Wang et al., 2018). 
1.4.2 Innate immune cells 
Additional to secreted AMP, which are regulating microbiota in the lumen, the lamina 
propria (LP) harbors a wide variety of innate immune cells, supporting the defense of host’s 
integrity. 
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(a) Dendritic cells, macrophages 
Dendritic cells (DCs) and macrophages are mononuclear phagocytes able to present 
antigens via major histocompatibility complex II (MHCII). In the intestine about 80% of 
CD11chi are CD103+, which is a tolerogenic phenotype of DCs, since they induce FoxP3+ 
regulatory T cell (Treg) development (Chirdo et al., 2005; Coombes et al., 2007). This is 
underlining the fact, that tolerance to luminal antigens is of great interest throughout the 
intestine. 
(b) Neutrophils 
Neutrophils can initiate the immune response via leukotrienes and prostaglandins; kill 
pathogens by releasing AMPs or reactive oxygen species; or phagocyte cellular debris. They 
can also release IL-17 and IL-23 (Mei et al., 2012). Neutrophils also produce lipocalin-2 (lcn-
2), a marker of intestinal inflammation, which is sequestrating iron and thus limiting bacterial 
growth (Cowland and Borregaard, 1997; Yang et al., 2002) and myeloperoxidases (MPO) with 
great antimicrobial activity due to their oxidative potential (Serteyn et al., 2003). In the intestine 
neutrophils are not very numerous, unless pathological conditions, such as ulcerative colitis 
(Robinson et al., 1997), coeliac disease and infection (Bennouna et al., 2003). 
(c) Eosinophils 
Eosinophils are leucocytes with pro-inflammatory properties. Only a small percentage 
of circulating blood cells are eosinophils. In steady-state condition, most of them reside in the 
gastrointestinal tract within the LP (Powell et al., 2010; Zuo and Rothenberg, 2007). Most of 
them are localized in the duodenum (Mishra et al., 1999). The roles of eosinophils are multiple. 
Following cellular activation, eosinophils secrete toxic inflammatory mediators (proteins and 
peroxidase) that are stored in intracellular vesicles. These mediators destroy tissues and insert 
pores into membranes of target cells. By generating toxic oxygen radicals, they increase smooth 
muscle reactivity (Al-Haddad and Riddell, 2005). Eosinophils are also supporting plasma cell 
(Chu et al., 2011) function and the recruitment of DCs (Jacobsen et al., 2011).They are playing 
a role in inflammatory bowel disease (IBD), mainly acting as pro-inflammatory and pro-
motility agent (Al-Haddad and Riddell, 2005). 
(d) Mast cells 
In the immune response to infection, mast cells are important effector cells. They release 
inflammatory mediators and recruit other immune cells, driving the pro-inflammatory immune 
response. Mast cells have an important role in the intestinal barrier, since epithelial function 
and integrity are regulated by them. Additionally, mast cells modulate innate and adaptive 
22 
 
mucosal immunity, and maintain neuro-immune interactions (Albert-Bayo et al., 2019). They 
have a great variety of receptors which permit them to react to a lot of different stimuli 
(chemical, microbial, neural; immune and metabolic) (Bischoff, 2007). Mast cells play a crucial 
role in gut-brain axis via mast cell-nerve interaction (Forsythe and Bienenstock, 2012). 
Additionally, they are described to play an important role in the pathogenesis of allergy. 
Allergen binding to serum IgE attached to mast cell’s FcɛRI receptors activates them, in 
consequence mast cells are releasing cytokines, eicosanoids and their secretory granules (Amin, 
2012). In their granules they stock histamine, cytokines, granulocyte macrophage colony-
stimulating factor (GM-CSF), leukotrienes, heparin, and many proteases. Those mediators are 
responsible for the characteristic symptoms of allergy (Amin, 2012). 
(e) Innate lymphoid cells 
Innate lymphoid cells (ILCs) are lymphocytes that do not express the type of diversified 
antigen receptors expressed on T cells and B cells. Like innate immune cells, they respond to 
infection quickly; but they secrete analogous inflammatory mediators as T lymphocytes. ILCs 
are largely tissue-resident cells, especially in mucosal surfaces, participating in tissue 
homeostasis. They are co-coordinating the development and maintenance of lymphoid tissue, 
act early during infection against pathogens and regulation of commensal bacteria. The secreted 
mediators of ILCs are similar to their adaptive T helper (Th) counterparts. However, ILCs are 
reacting to non-specific danger signals and this more rapidly than Th cells, giving them a role 
in the frontline of immune reaction. (for review (Eberl et al., 2015; Rankin et al., 2013)). ILCs 
develop in fetal liver from common lymphoid progenitors (CLPs). CLPs give rise to the 
lymphoid lineage: T cells, B cells and ILCs among others (Sawa et al., 2010; Vonarbourg et al., 
2010). There is a great heterogeneity of ILCs; different ILCs subsets can have surface receptors 
and cytokine profile in common. However, they are distinct for transcription factors required 
and the need to classify led to three broad populations (Figure 8) (Spits et al., 2013; Tait Wojno 
and Artis, 2012). 
ILC1 and natural killer (NK) cells respond to intracellular microbes, viruses and 
tumors. They produce IFNγ and are dependent on the transcriptional factor t-bet. 
ILC2 are sensitive to large parasites, adipose tissue, tissue injury and allergens. They 
produce cytokines similar to Th2 profile, play a role in tissue repair and mucus production and 
are dependent on transcription factor GATA3. 
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Figure 8 Innate lymphoid cells. Infected or damaged tissue are liberating signal, inducing ILC activation and 
expansion. Type 1 signals (intracellular microbes, viruses and tumors) induce natural killer cells (NK) and ILC1, 
type 2 signals (large parasites, adipose tissue, tissue injury and allergens) ILC2 and type 3 signals (extracellular 
microbes: bacteria, fungi) ILC3 with different effector cytokines and effector functions (Eberl et al., 2015). 
ILC3 and its member lymphoid tissue inducer (LTi) respond to signals of extracellular 
microbes, bacteria and fungi. LTi are necessary for the development of secondary lymphoid 
tissue during fetal life. ILC3 and LTi can produce IL-17 and IL-22. ILC3 are playing an 
important role in intestinal homeostasis. Indeed, Lymph node resident ILC3 have been shown 
to present antigen to T follicular helper cells (TfH), thus inhibiting the interaction of TfH and 
B cells. As a result, mucosal IgA responses are limited. The restriction of TfH response is 
especially developed in case of colonic antigen presentation rather than small intestine. ILC3 
thus maintain tissue homeostasis and mutualism with the commensal colonic microbiota (Melo-
Gonzalez et al., 2019). Another member of the ILC3 family producing IL-22 has been identified 
playing a crucial role in the immune response against Citrobacter rodentium (Satoh-Takayama 
et al., 2008). 
1.4.3 Pattern recognition receptors 
Sensing of luminal exogenous fragments by the epithelium or the immune system takes 
place via pattern recognition receptors (PRR). Indeed, PRR, notably Toll-like receptors (TLR) 
and nucleotide-binding oligomerization domain (NOD) recognize and detect a variety of 
bacterial components (LPS, peptidoglycan, lipoproteins, flagellin, profiling, dsRNA, ssRNA 
and CpG DNA) (Figure 9). These molecules are also called microbe-associated molecular 
patterns (MAMPs). They are found on commensal and pathogenic bacteria. The activation of 
PRRs by MAMPs is initiating a cascade of signaling inside the cell, leading to gene expression 
of innate immune response. Consequently, a suitable immune reaction restores intestinal 
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homeostasis. Thus, PRRs play a crucial role in regulating the interface gut microbiota-host and 
in the defense of bacterial infection. They are also important for the integrity of the epithelium.  
Proliferation of intestinal epithelial cells has been shown to be dependent on toll-like receptor 
(TLR) recognition of commensal bacteria in DSS-induced colitis (Rakoff-Nahoum et al., 2004). 
 
Figure 9 Pattern recognition receptors. TLR Toll-like receptors located at the cell membrane or the nucleus 
membrane. Intracellular NOD Nucleotide-binding oligomerization domaine. DAP, diaminopimelic acid; ds, 
double-stranded; MDP, muramyl dipeptide; LPS, lipopolysaccharide; LAM, lipoarabinomannan; ss, single-
stranded (Kaufmann, 2007). 
1.4.4 GALT 
The gut associated lymphoid tissue (GALT) comprises as induction sites the Peyers’ 
patches (PPs), the appendix and isolated lymphoid follicles (ILFs) where immune cells are 
primed. Together with mesenteric lymph nodes (MLN) they are considered inductive sites for 
mucosal B and T cells. Naïve T cells from the vascularization home these structures and meet 
antigen-presenting cells, which arrived via afferent lymphatics from the inflammation sites in 
the gut. Naïve T cells undergo antigen-driven priming/activation, polarization, and expansion 
into effector cells. Via efferent lymphatics, they enter the lymphatic system and home to the gut 
lamina propria, the effector site, supporting the local immune response against pathogens 
(Figure 10, for review (Koboziev et al., 2010)). 
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Figure 10 Inductive and effector sites of the gut-associated lymphoid tissue. (a) Antigens enter via M cells 
into Peyers’ patches and are transferred to DCs, (b) and presented directly in the Peyers’ patch to T cells or 
alternatively (c) migrate via the afferent lymphatics to mesenteric lymph nodes. (d) T cells will recognize 
presented antigens. (e) Alternatively antigens can enter directly the lamina propria via the intestinal epithelium. 
(f) enterocytes can serve as antigen presenting cells and directly activate T cells or antigens are transferred to 
DC. (g) Activated T cells enter via efferent lymphatics or (h) activated T cells, free antigens and DC via blood 
stream (i) peripheral lymph nodes and systemic distribution (Calder, 2013). 
1.4.5 Adaptive immune cells 
The second line of defense is the adaptive immune response. Studies in germ-free 
animals have shown that the adaptive immune response in the gut is extremely shaped by gut 
microbiota. Indeed, colonization contribute to the growth of inductive sites as PP (Shroff et al., 
1995), IgA producing plasma cells expand (Benveniste et al., 1971), and the number of CD4+ 
and CD8+ cells increase (Guy-Grand et al., 1991). Numerous adaptive immune cells are 
harbored in the lamina propria. 
(a) B cells 
B cells, antibody producers, are important actors of the adaptive intestinal immune 
response mostly by secreting IgA. Each day 3-5 mg of antibodies are secreted into the lumen 
by intestinal IgA plasma cells (Brandtzaeg and Pabst, 2004). Plasma cells are most abundant in 
intestine, predominantly in LP of small intestine and are found in large intestine in smaller 
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numbers (Bowcutt et al., 2014). The humoral response in the intestine can be divided in four 
stages: predominant IgA induction in mucosal B cells, recirculation of IgA plasma blasts and 
homing into the intestinal mucosa, terminal B cell differentiation to plasma cells with local IgA 
production and export of IgA through the intestinal epithelial layer (Figure 11) (for review 
(Mora and von Andrian, 2008)).  
 
Figure 11 Cycle of B cells in the lamina propria of intestine. Antigens are sampled by DCs below M cells or 
through the epithelial layer by DC extensions. In Peyers’ patches and mesenteric lymph nodes DCs induce B 
cells via antigen presentation to differentiate into IgA+ cells which are homing to lamina propria, secreting 
dimeric IgA, released into the lumen via transcytosis (Hooper and Macpherson, 2010). 
The intestine is also secreting IgG, this has been shown to be exacerbated in IBD. 
Indeed, in intestinal mononuclear cells of IBD patients a modified Ig secretory pattern has been 
observed. There is a decreased spontaneous IgA secretion, but increased IgG secretion 
compared with intestinal mononuclear cells from healthy control (MacDermott et al., 1983, 
1981). Food-specific IgE in the intestine are playing a crucial role in food allergies. Indeed, in 
allergic condition IgE-receptor mediated antigen transport from the lumen to the lamina propria 
via an IgE/allergen complex has been described to enhance epithelial antigen transport 
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(Bevilacqua et al., 2004; Yu et al., 2001). IgE are responsible for the activation of mast cells, 
triggering the allergic symptoms, as for example diarrhea (Ahmed and Fuchs, 1997).  
(b) T cells 
Most intestinal T cells mature in peripheral lymphoid organs. These cells gain the 
expression of intestinal homing receptors to migrate to the intestine. Intestinal lymphocytes are 
continuously exposed to food and microbial antigens. These lymphocytes help maintaining the 
integrity of the intestinal barrier and immune homeostasis. Due to their close location to luminal 
antigens they have both regulatory and effector capabilities, including the prevention of 
pathogenic invasion and maintenance of tolerance to prevent extensive tissue damage (for 
review (Hooper and Macpherson, 2010; Ma et al., 2019)). 
Intestinal intraepithelial lymphocytes (iIEL) are in close contact with the intestinal 
epithelium, express the integrin CD103 (Dalton et al., 2006; Matsumoto et al., 1999) whose 
ligand is E-cadherin (Hadley et al., 1997) and contribute to the maintenance of barrier integrity 
(Culshaw et al., 1997; Inagaki-Ohara et al., 2006). 
The principal CD4+  cells in the gut are T helper 17 (Th17), Th22 and regulatory T cells 
(Treg).  
CD4+ Th17 are producing IL-17, they appear only after colonization (Gaboriau-
Routhiau et al., 2009; Ivanov et al., 2008) and represents around 10-15% of CD4+  cells in SI 
(Maynard et al., 2007). They can stimulate mucin and AMP production, thus maintaining 
intestinal homeostasis. 
CD4+ Th22 are producing IL-22, which is promoting innate immune response (Wolk et 
al., 2004). In the case of allergic asthma, IL-22 has been shown to induce the expression of 
REG3G in lung epithelial cells thus improving induced asthma (Ito et al., 2017). Also in murine 
intestinal epithelial cells, IL-22 induced the expression of the AMP REG3G. Additionally, IL-
22 increased paracellular permeability in Caco-2 cell culture (Wang et al., 2017). Decreased 
Th22 cells are described in lamina propria mononuclear cells of patients suffering from 
ulcerative colitis compared to healthy control (Leung et al., 2014). 
CD4+ Th1 produce IFNγ, which is enhancing macrophage activity.  
Regulatory T cells (Treg) are crucial to regulate containment of immune response. Treg 
are under the control of transcription factor FoxP3+ and produce the cytokines IL-10 and TGFβ. 
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CD4+ Th2 have a role in allergy, tissue repair and parasite infection. Th2 are crucial for 
the fight against helminth infection. Th2 stimulate intestinal functions in order to kill and 
expulse the multicellular parasite by inducing smooth muscle hypercontractility, enhanced 
mucus secretion and activation of intestinal mast cells (Bamias and Cominelli, 2015). However, 
over-activation of Th2 response can lead to excessive collagen deposition, probably responsible 
for fibrogenesis in ulcerative colitis and Crohn’s disease (Principi et al., 2013). 
1.5 Intestinal motility 
As seen in the previous paragraph, intestinal motility is an important actor of intestinal 
barrier, since it is crucial for the expulsion of pathogens or toxic substances. There are two 
smooth muscles layers enveloping the intestine, the inner, circular muscle and the outer, 
longitudinal muscle (Figure 12). The main task of intestinal muscles is the aboral transport of 
the bolus from esophagus to anal sphincter by longitudinal muscle contraction above and 
relaxation below bolus (peristaltsis). On the other side, contractions and segmentations by 
circular muscles favor also the mixing of the luminal content with the digestive juice. (Kumral 
and Zfass, 2018) 
 
Figure 12 The enteric nervous system. The ENS consists of the myenteric plexus, located between the 
longitudinal and circular muscle, and the submucosal plexus (SMP, Meissner plexus) located between the 
muscularis mucosae and the circular muscle (Furness, 2012). 
The intestinal motility is autonomously regulated by the enteric nervous system (ENS). 
The movements are initiated by distention of the intestinal tube and triggered by the myenteric 
plexus, located in between both muscle layers. The sympathetic and parasympathetic nervous 
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system, elements from the autonomous nervous system (ANS), have only modulating influence 
on gut motility. 
2. Enteric nervous system 
The enteric nervous system (ENS) is located in the wall of digestive tube (Figure 12). 
The ENS in human contains 200-600 million neurons, which are distributed in many thousands 
of small ganglia. They can be found in the myenteric and submucosal plexuses. The myenteric 
plexus is located between the two smooth muscle layers, covering the intestine from esophagus 
to anal sphincter. The efferent limbs end in the smooth muscle layer, stimulating peristalsis and 
segmentation. Submucosal ganglia are present in the small and large intestine. It is regulating 
secretory functions of epithelial cells in the mucosa (Furness et al., 2014). There is close 
communication between the ENS and the central nervous system (CNS) and the ANS and also 
regulation by numerous hormones. 
3. Gut-Brain Axis 
“The gut-brain axis consists of bidirectional communication between the central and the 
enteric nervous system (ENS), linking emotional and cognitive centers of the brain with 
peripheral intestinal functions” (Carabotti et al., 2015). The gut-brain axis includes the central 
nervous system (CNS), the autonomic nervous system (ANS) including sympathetic and 
parasympathetic limb, ENS and the hypothalamic pituitary adrenal (HPA) axis (Figure 13). 
The HPA axis is playing a crucial role in the response to stressors (cf. Chapter II Stress). 
Top-down communication appear through neurons (vagus nerve) and hormones 
(cortisol) which can influence gut motility, immunity, intestinal permeability and mucus 
production. Bottom-up communication happens via hormones (5-HT), cytokines produced by 
immune cells and mast-cell neuron interaction. In case of invading microorganisms in the 
periphery, pro-inflammatory cytokines are produced by activated neutrophils and macrophages 
and shown to induce in brain sickness behavior (Konsman et al., 2002). These findings 
underline the role of cytokines in communication with CNS. Microbiota can also influence gut-
brain axis via metabolites as for example SCFAs and microbiota-produced or degraded 
neurotransmitter. Indeed, bacteria can produce themselves a big variety of neurotransmitter 
(Lyte, 1993) but also influence host’s neurotransmitter. Serotonin (5-HT) is decreased in GF 
colon and blood (Wikoff et al., 2009) and can be restored by colonization. Spore-forming 
bacteria have been shown to stimulate 5-HT secretion by enterochromaffin cells via different 
SCFAs, among them butyrate and propionate (Yano et al., 2015). 5-HT plays a crucial role in 
gut motility, thus a restoration of 5-HT levels by gut microbiota modifications could be 
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beneficial in gastro-intestinal disorders associated with motility. Indeed, Yano et al. showed 
that colonization with their spore-forming bacteria increases gut motility in GF mice (Yano et 
al., 2015). 
 
Figure 13 The gut-brain axis. Top-down communications via 1) vagus nerve which is enervating enteric 
muscles and sending signals to intestinal epithelial cells, 2) Hypothalamus-Pituary-Adrenal axis by cortisol, 
which is influencing immune cells, intestinal permeability. Bottom-up communication by 1) intestinal hormone 
secretions (5-HT by EC and GLP-1 and PYY by EEC), 2) cytokine secretion by immune cells. Microbiota is also 
playing a role in gut-brain axis by the production of SCFAs and neurotransmitters, which can influence intestinal 
epithelium but also enter into the system. NE, norepinephrine; GABA, γ-aminobutyric acid; BBB, blood brain 
barrier; EEC, enteroendocrine cell; EC, enterochromaffin cell); GLP-1, glucagon-like peptide-1; PYY, peptide 
tyrosine tyrosine; 5-HT, 5-hydroxytryptamine; SCFAs, short-chain fatty acids (Kim et al., 2018). 
4. Ontogeny of intestine in early life 
At birth, the intestine is immature, especially in rodents, and needs to undergo various 
maturation processes. The organism has to face colonization by microorganism, must develop 
immune tolerance to commensal and food antigens and establish a robust immune response 
against pathogens. 
31 
 
4.1 Colonization 
A first great change in the neonatal gut is the colonization by microbiota. In utero, the 
organism is sterile and at birth, it is facing microorganism for the first time. Delivery mode is 
greatly shaping microbiota in the newborn. Infants born by vaginal delivery are colonized by 
vaginal microbiota of the mother, whereas infants born by caesarian section (CS) have first gut 
microbiota similar to skin microbiota of the mother (Dominguez-Bello et al., 2010). During the 
first days microbiota is evolving, at 1 week of age, microbiota of neonates vaginally delivered 
is characterized by abundant levels of Bifidobacterium and Bacteroides. Infants delivered by 
CS have a microbiota characterized by blooming Clostridium (Hesla et al., 2014).  
 
Figure 14 Intestinal microbiota composition over lifetime. “The graph provides a global overview of the 
relative abundance of key phyla of the human microbiota composition in different stages of life. Measured by 
either 16S RNA or metagenomic approaches (DNA)” (Ottman et al., 2012). 
Early life nutrition affects also microbiota composition. Breast-fed and formula-fed 
children have distinct microbiota. Introduction of solid food induces important changes in 
microbiota composition (Hill et al., 2017). Bifidobacteria diminish with introduction of solid 
food and microbiota is more and more similar to classical adult-like microbiota (Palmer et al., 
2007). Aerobic and facultative anaerobic bacteria will decrease in favor of anaerobic species, 
the postulate is, that facultative anaerobic bacteria prepare the intestinal niche for strict 
anaerobic bacteria by diminishment of intestinal oxygen (Jost et al., 2012; Timmerman et al., 
2017). At adulthood, anaerobic bacteria are dominant in the gut (Figure 14). 
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4.2 Gut closure 
 
Figure 15 Intestinal permeability and gut microbiota diversity in lifetime. “Starting early in life, 
environmental factors influence microbial diversity (blue) and gut permeability (green), affecting the duration of 
resilience and metabolic health (different shadings). (A) During pregnancy, the developing foetal gut is ‘primed’ 
by the maternal gut microflora and intestinal permeability (diagonal lines), particularly towards the latter stages 
of gestation and prior to the imminent microbial colonization post-birth. (B) Following birth, the gut is colonised 
with bacteria and diversity develops throughout infancy and childhood with a subsequent decrease of the initially 
very high intestinal permeability. (C) In adulthood, events in early life have combined with tight intestinal 
permeability to influence the ‘resilience’ of adult gut’s microflora. This is positively correlated with diversity 
and determines the health trajectory for the remaining lifespan. (D) In later years, after a period of ‘resilience’, 
the diversity in the gut microbiome declines and the leakiness increases during normal ageing. A low diversity or 
high leakiness can lead to the accelerated decline and places the individual at risk of developing a range of 
chronic metabolic diseases” (Kerr et al., 2015). 
During the first days of our life, the gut is hyperpermeable in order to receive maternal 
nutritional compounds but also immune modulatory mediators (van Elburg et al., 2003). In rats, 
intestinal permeability measured in vivo by FITC-Dextran 4 kDa gavage, has been shown to 
decrease constantly from 10 days after birth to 50 days after birth (Moussaoui et al., 2014). 
Intestinal hyperpermeability in neonates is a normal function (Catassi et al., 1995; Weaver et 
al., 1984) However, in premature infants intestinal permeability is excessively increased 
(Weaver et al., 1984), which can lead to uptake of pathogens and infection in pathogenic context 
(Insoft et al., 1996). The physiological decrease in intestinal permeability after birth is called 
“gut closure” (Figure 15) (Drozdowski et al., 2010). The work of Vukavic et al. suggest that 
early beginning of breastfeeding (1h-6h after birth) leads to a more rapid gut closure than late 
start of breastfeeding (12h-15h after birth) (Vukavić, 1984), underlining the impact of 
breastmilk on intestinal permeability. The start time of breastfeeding influences the 
composition of the microbiota through maternal Ig and AMP present in high concentrations in 
colostrum (Menchetti et al., 2016). 
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4.3 Development of intestinal barrier 
 
Figure 16 Ontogeny of intestinal barrier in rodents. The intestinal barrier is highly dynamic in early life. 
Immature prenatal intestine matures after birth and with weaning towards adult intestine. Epithelial cells 
proliferation increases around weaning, crypts appear. Prenantal and neonatal CRAMP production ceases and is 
replaced by Paneth cell derived peptides. Paneth cells appear with weaning. Bacterial colonization takes place 
from birth on and microbiota gains in diversity and density. Innate immune sensing undergoes maturing 
processes as well. TLR4 and IκBα expression evolve during early life. IgA-producing plasma cells appear and 
replace secretory IgA delivered through breastmilk by the mother. Lymphocyte homing and differentiation takes 
place from birth on (Renz et al., 2011). 
The expression of AMP undergoes a switch in the first days of life. In rodents, during 
the first days the AMP CRAMP is constitutively expressed in neonates gut epithelium and 
regulates the microbiota. The intestine mature, microbiota is diversifying. Crypts that are absent 
in neonatal rodent intestinal epithelium appear with time (Hirano and Kataoka, 1986), CRAMP 
disappears after the first 15 days and is replaced by Paneth cells with larger AMP repertoire. 
Paneth cells are localized in the bottom of the crypts and appear only 15 days after birth (Ménard 
et al., 2008) coinciding with microbiota expansion and diversification of food. In this period, 
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intestinal epithelial cell proliferation accelerates (van der Flier and Clevers, 2009), and crypts 
multiply. Paneth cells are playing an important role in the fision of one crypt into two daughter 
crypts (Langlands et al., 2016). All this changes in intestinal physiology coincide with the 
changes around the weaning period: introduction of solid food and diversification of diet and 
consequently arrival of new commensal bacteria in the gut (Figure 16). 
In human, intestine is more mature at birth. Crypts are formed; Paneth cells and Peyer’s 
patches are present. However, the intestinal immune system, structurally complete, undergoes 
great maturation and expansion during this period (Stockinger et al., 2011). The neonatal 
immune response is distinct from adult one. Indeed, CD4+ cells tend to differentiate into 
regulatory T cells in response to stimulation (Wang et al., 2010). B cells expand in plasma cells, 
producing sIgA, important for the neutralization of nutritional and microbial antigens (Pabst et 
al., 2008). 
4.4 Glucocorticoide sensitivity 
Moussaoui et al. described that glucocorticoid receptor (GR) expression in colon of rat 
pups (PND10) is significantly higher than in PND20 rats. This increased expression comes 
along with higher sensitivity to dexamethasone a GR agonist in PND10 vs PND20 pups. The 
higher sensitivity for glucocorticoids leads to increased intestinal permeability in PND10 but 
not PND20 pups in response to a single maternal separation stress (Moussaoui et al., 2014). 
Intriguingly, dexamethasone or hydrocortisone are often used to prevent bronchopulmonary 
dysplasia in preterm children. Effects of these GR agonists on gut has to be assessed. Indeed, 
preterm gut resembles PND10 rat pups gut in maturity and glucocorticoid sensitivity. Morris et 
al. report in a meta-analysis that early hydrocortisone treatment in preterm increases 
significantly the risk for intestinal perforation (Morris et al., 2019). Thus, clinical practice 
should be probably reconsidered in order to develop save long-term treatment for neonates, 
taking into account their special physiology.  
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CHAPTER II 
GLUCOSE METABOLISM 
In the previous chapter, I presented the different components of the intestinal barrier and 
their development in early life period. During my PhD, we were also interested in the effects of 
early life stress on glucose metabolism. First, we were focused on metabolic disorders 
characterized by glucose intolerance associated with insulin resistance and obesity. Afterwards, 
we were interested in autoimmune diabetes.  
1. Regulation of blood glucose  
The regulation of blood glucose levels is crucial for survival and for that reason 
submitted under tight control. Various hormones and neuropeptides are implicated in the 
regulation of glycaemia. They are released mainly from the brain, pancreas, liver, and intestine 
as well as adipose and muscle tissues.  
1.1 Regulation by pancreatic hormones 
Pancreas is a key player in the regulation of blood glucose levels, secreting insulin and 
glucagon. Insulin, at one hand, has a blood-glucose lowering effect, glucagon, at the other hand, 
a glucose mobilizing glucose from tissue towards the circulation. Both hormones are produced 
in islets of Langerhans in the pancreas, insulin from pancreatic β-cells, glucagon from α-cells.  
In postprandial state, insulin is released in response to glucose entry via GLUT2 into the 
β-cell. ATP/ADP ratio is increasing, ATP-sensitive K+ channel close and as a consequence 
membrane is depolarized, voltage-dependent Ca2+-channel open and increasing Ca2+ levels lead 
to fusion of vesicles of insulin with the membrane (for review (Röder et al., 2016)). Insulin is 
stimulating glucose uptake by peripheral organs (liver, muscles, adipose tissue) via insulin 
receptor whose activation stimulates GLUT4 translocation to the membrane. In liver, insulin 
stimulates glycogenesis and inhibits gluconeogenesis (Figure 17). 
In fasted state, glucose levels are decreasing and glucagon is secreted, which stimulates 
gluconeogenesis and glycogenolysis in liver in order to liberate glucose to normalize blood 
glucose levels (Figure 17). 
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Figure 17 Glucose metabolism. After a meal blood glucose is rising, GLUT2 receptors in pancreatic β-cells 
trigger insulin release, which stimulates glucose uptake in peripheral organs (adipose tissue, muscles). In liver 
insulin upregulates glycogenesis and downregulates gluconeogenesis. These processes lead to normalization of 
blood glucose levels. During night, when blood glucose diminishes, pancreatic α-cells release glucagon. 
Glucagon stimulates glycogenolysis and gluconeogenesis in the liver and as a consequence restores normal 
blood glucose levels (Röder et al., 2016). 
1.2 Role of gut hormones in blood glucose regulation 
Besides pancreatic regulation of glucose metabolism there are numerous intestinal 
hormones playing a role in glucose homeostasis. Ghrelin is secreted by stomach mucosa in 
fasted state (Ariyasu et al., 2001). It can also be secreted by endocrine pancreas. Ghrelin plays 
an orexigenic role (Nakazato et al., 2001) but influences also gastric emptying, growth hormone 
release and body weight regulation (Verhulst and Depoortere, 2012). Ghrelin has an inhibitory 
function on insulin secretion and therefore a role in glucose metabolism (Broglio et al., 2001; 
Dezaki et al., 2008). GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 
(glucagon-like peptide-1) are important incretins regulating blood glucose. GIP is secreted by 
K cells and GLP-1 by L cells. Both have important roles in the regulation of postprandial blood 
glucose levels. Indeed, they stimulate insulin secretion and contribute to glucose homeostasis 
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(for review (Nauck and Meier, 2018)). In diabetic state, a reduced incretin effect, characterized 
by GLP-1 and GIP resistance, has been observed (Nauck et al., 1986; T. et al., 2002). 
2. Metabolic syndrome and associated complications 
 
Figure 18 Disturbed body systems in metabolic disorders. Metabolic disorders are characterized chronic 
inflammation of the adipose tissue and increased lipid metabolism. In liver, increased gluconeogenesis and 
modified lipogenesis lead to steatosis. Peripheral insulin resistance alters also β-cell homeostasis in the pancreas. 
In intestine modified antimicrobial response, microbiota dysbiosis and altered intestinal integrity are observed. 
Intestinal hormones such as PYY are also impacted in metabolic disorders, leading to modified satiety signalling. 
Systemic inflammation is another hallmark of metabolic disorders. Figure modified from (Rutz et al., 2014). 
Metabolic syndrome “is the name given to the aggregate of clinical conditions 
comprising central and abdominal obesity, systemic hypertension, insulin resistance (or type 2 
diabetes mellitus), and atherogenic dyslipidemia” (McCracken et al., 2018). Type 2 diabetes 
mellitus (T2D) is a common metabolic disorder characterized by glucose intolerance and insulin 
resistance. “Insulin resistance is defined clinically as the inability of a known quantity of 
exogenous or endogenous insulin to increase glucose uptake and utilization in an individual as 
much as it does in a normal population” (Lebovitz, 2001). Insulin action is mediated by its 
binding on insulin receptor (IR) and subsequent cascade signaling. MAPK (pathway for 
mitogenesis) and PI3K (pathway for glucose metabolism regulation) are activated via IRS-1 
and IRS-2. Various factors can interfere with elements of the signaling cascade and therefore 
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inhibit insulin action in the cell. Among them are cytokines and free fatty acids, which 
accumulate in inflammatory state and increased adipose tissue (for review: (Guo, 2014)). 
The metabolic syndrome is underlining the fact that obesity, insulin resistance, 
dyslipidemia and hypertension are tightly linked. They have shared hallmarks, whereas not 
every single appear in the isolated pathology. Indeed, chronic systemic and local inflammation 
(adipose tissue, liver), intestinal barrier dysfunction, insulin resistance and disturbed insulin 
homeostasis, microbiota dysbiosis have been observed in metabolic syndrome (Figure 18). 
Thus, the set of metabolic diseases is associated with several complications. Patients with 
metabolic syndrome have faster developing atherosclerosis and increased risk for 
cardiovascular diseases due to high blood pressure and the increased circulating triglycerides 
and lipoproteins. The risk for chronic kidney disease is also increased in patients suffering from 
metabolic syndrome (McCracken et al., 2018). 
There are different models to study metabolic disorders like T2D and obesity. First, 
there is diet-induced metabolic disorder: animals receiving high-caloric, which could be high-
fat (HFD) or high-fat high sugar diet (HFHSD). Second, there are genetically induced metabolic 
disorders. In particular ob/ob mice – deficient for leptin, a satiety hormone, and db/db mice – 
deficient for leptin receptor. Both leading to the same phenotype: severe obesity due to 
hyperphagia and T2D. Obesity and T2D are often associated in animal models, thus obesity and 
diabetes will be treated together in the following paragraphs. 
3. Incidence of metabolic disorders 
Metabolic disorders are worldwide epidemic problems and as such a growing global 
challenge. The World Health Organization estimates that worldwide obesity has nearly doubled 
since 1980. In 2012, 3.7 million deaths were related to higher-than-optimal blood glucose and 
diabetes. In 2014, 422 million adults were diabetic (T1D and T2D) (World Health Organization, 
2016). Blood hyperglycemia was ranked as 5th global risk factor for DALYs (disability-adjusted 
life-years) (Forouzanfar et al., 2015). Until recently, only adults were affected, but now children 
are becoming more often diabetics. Even if the signification of metabolic syndrome and T2D 
are increasing, the understanding of those pathologies is still unsatisfactory and preventive and 
therapeutic strategies still fail to face this epidemy. 
Metabolic disorders are multifactorial diseases involving genetic and environmental 
factors. Among environmental factors, dietary habits such as overnutrition and western diet 
(high fat and high carbohydrates contents) as well as sedentarity associated with a reduction of 
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physical activity, are major contributors in metabolic diseases development (Freedman et al., 
1999; Wing et al., 2001). Beside diet and life style habits, epidemiological studies highlighted 
an association between post-traumatic stress disorder (PTSD) (Agyemang et al., 2012; 
Goodwin and Davidson, 2005; Lukaschek et al., 2013) or adverse childhood experience 
(Alastalo et al., 2009; Huang et al., 2015) and T2D incidence. 
4. Link between metabolic disorders and microbiota 
Over the last decade, several studies have linked intestinal microbiota to the 
development of metabolic disorders. Along with genetic and environmental susceptibilities, the 
intestinal microbiota could trigger impairment in the energy homeostasis leading to diseases. 
Several studies, showed that intestinal microbiota is a signature of metabolic disorders (Amar 
et al., 2011; Bäckhed et al., 2004; Hotamisligil, 2006).  
Genetically obese (ob/ob) mice had less Bacteriodetes and more Firmicutes than their 
lean siblings (Ley et al., 2005). In diet-induced obesity (HFD 60%) similar changes in the ratio 
of Bacteriodetes and Firmicutes were observed (Guo et al., 2017). A change in the ratio of those 
major phyla (Bacteroidetes to Firmicutes) leads to a new microbiota with an increased capacity 
to digest dietary fibers to produce monosaccharaides and short-chain fatty acids (SCFA) able 
to be absorbed by the host. Thus, microbiota has an impact on the energy harvest of the host 
(Turnbaugh et al., 2006).  
This is not surprising as microbiota has a role on host metabolism in physiological 
conditions. Indeed, intestinal microbiota could down-regulate the production of fat-induced 
adipocyte factor (FIAF) by the intestinal cells, which in turn inhibits the activity of the 
lipoprotein lipase. These results are in agreement with other studies showing that GF mice fed 
HFD are resistant to diet-induced metabolic disorders and gain less weight than their 
conventional counterparts (Bäckhed et al., 2007; Nicholson et al., 2012). GF mice genetically 
lacking FIAF are not protected from diet-induced obesity (Bäckhed et al., 2007). Colonization 
of GF mice showed a dramatic increase in body fat within 10-14 days, despite an associated 
decrease in food consumption after colonization in comparison with GF state (GF mice are 
described to be hyperphagic) (Bäckhed et al., 2004). In addition, mice colonized with 
microbiota from obese mice gained more weight than those transferred with microbiota from 
lean mice, demonstrating a causal role of microbiota in the development of metabolic diseases 
(Turnbaugh et al., 2006).  
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In human, 16S ribosomal RNA sequencing of microbiota of obese individuals have been 
shown to be characterized by increased Firmicutes and decreased Bacteriodetes. This obese 
microbiota phenotype could be reversed by dietary interventions (Ley et al., 2005). Serino et 
al. observed that caecal microbiota is distinct between insulin resistant and insulin sensitive 
obese patients (Serino et al. 2012). Microbiota dysbiosis was observed in T2D patients (Qin et 
al., 2012). Microbiota of T2D patients and healthy control were distinct, even after stratification 
for metformin treatment (Forslund et al., 2015). In patients suffering from metabolic syndrome, 
microbiota transfer of lean donors improves hepatic insulin sensitivity 6 weeks after transfer 
(Vrieze et al., 2012). The integrative Human Microbiome Project (iHMP) aimed to focus on the 
role of microbiota on the onset of diseases including type 2 diabetes (T2D) (Zhou et al., 2019). 
The strength of iHMP in T2D is the following of participants (healthy and pre-diabetics) for 
four years (Zhou et al., 2019). This allows to associate microbiome profile to insulin sensitivity 
status that confirm microbiota dysbiosis associated to T2D and might contribute to early 
detection of T2D (Zhou et al., 2019). 
Microbiota could trigger metabolic syndrome via its ability to modify intestinal 
permeability and/or immune response. Microbiota dysbiosis could lead to intestinal 
hyperpermeability and increased translocation of bacterial fragments that could reach the 
circulation. 
5. The role of intestinal permeability in metabolic disorder 
Indeed, intestinal hyperpermeability has been reported in metabolic disorders. In HFD-
induced metabolic disorders in mice, intestinal permeability measured in vivo by FITC-Dextran 
4 kDa (FD4) gavage was increased (Cani et al., 2008; Johnson et al., 2015). This was linked to 
reduced expression of genes coding for proteins of the tight junctions (Cani et al., 2008). 
Measurements in Ussing chambers confirmed increased intestinal permeability to FD4. 
Additionally, transepithelial conductance, an indicator for paracellular permeability, was also 
increased by HFD (Johnson et al., 2015). Of interest, Rohr et al wrote a complete review 
regarding the negative effects of HFD on intestinal permeability (Rohr et al., 2019). 
Intestinal hyperpermeability is pointed out as a factor leading to translocation of 
bacterial products (Cani et al., 2007). It is found that plasma levels of bacterial 
lipopolysaccharides (LPS), components of the outer membranes of gram-negative bacteria, 
increase under HFD (Cani et al., 2007). Interestingly, LPS levels in mice are fluctuating in 
function of food intake, highlighting a potential link with intestinal barrier (Cani et al., 2007). 
LPS are highly inflamatogenic molecules (Schumann et al., 1990; Sweet and Hume, 1996; 
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Wright et al., 1990). Increased plasma LPS level is defined as metabolic endotoxemia. The 
increase is 10-50 times lower than values which could be reached during septicemia or other 
infections (Cani et al., 2007). Intestinal phagocytes (DC and macrophages) capture bacterial 
intestinal antigens, LPS, and transfer them into lysosomes for degradation (Sansonetti and Di 
Santo, 2007). These antigens activate CD14/TLR4 positive immune cells, which secrete 
cytokines contributing to low-grade inflammation. LPS can induce macrophage accumulation 
in white adipose tissue, but it is not essential for the impaired glucose metabolism associated 
with gut colonization (Caesar et al., 2012). Therefore, other substances besides the LPS could 
be responsible for the low-grade inflammation. The bacterial Peptidoglycan (PGN), piline, 
flageline, fimbriae and bacterial DNA can also be transferred via intestinal barrier, taking para 
or transcellular route (Cani et al., 2007). LPS perfusion in mice under normal diet induced 
similar phenotype as HFD, namely fasted hyperglycemia, insulinemia, weight gain and increase 
in adipose tissue but also macrophage infiltration in adipose tissue and liver insulin resistance 
(Cani et al., 2007).  
Some argue that even living bacteria could pass the intestinal barrier and enter into the 
organism. Using green fluorescent protein (GFP) labeled Escherichia coli (E. coli), it has been 
shown that E. coli GFP accumulated after gavage in mucosa in HFD-fed mice. Bacteria are co-
localized with DC in intestinal lamina propria and probably disseminated inside DC towards 
mesenteric adipose tissue and mesenteric lymph nodes (MLN) via blood (Amar et al., 2011). 
However, these observations could rather be bacterial fragments or only GFP tracker, 
translocated into the circulation than living bacteria. 
Another indicator of intestinal hyperpermeability in metabolic disease are increased 
levels of Ig directed against microbiota. HFD-fed mice exhibit increased IgG against E.coli in 
plasma (Mohammed et al., 2012) 
Data on intestinal permeability in genetically obese mice are conflicting. Stenman et al. 
evaluated intestinal permeability in Ussing chambers using FD4 and did not find any 
modification in ob/ob vs WT (Stenman et al., 2013). However, Johnson described increased 
intestinal permeability to FD4 in vivo and ex vivo in Ussing chambers in ob/ob mice. 
Transepithelial conductance (paracellular permeability) was not different in comparison to WT 
(Johnson et al., 2015). Another study confirms these observations: Ye et al. observed increased 
intestinal permeability to FD4 in vivo in ob/ob mice in comparison to WT (Ye et al., 2018). 
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Data on intestinal hyperpermeability in metabolic disorders in human are similar to 
observations in mouse models. Increased intestinal permeability measured in vivo by 
lactulose/mannitol absorption is positively correlate with HOMA index (measure of insulin 
resistance) in obese patients (Teixeira et al., 2012). Additionally, LPS is elevated in plasma of 
apparently healthy men at risk of becoming obese and diabetic. Elevated level of LPS is 
correlated with energy intake (Amar et al., 2008). Furthermore, IgG against E.coli is increased 
in obese patients (Mohammed et al., 2012). 
Dysfunction of the intestinal barrier and translocation of bacterial products could be at 
the origin of inflammation at local or systemic levels. 
6. Low-grade inflammation in metabolic disorders 
As already mentioned, it became clear that inflammation is a key feature of obesity and 
T2D (Hotamisligil, 2006; Pickup and Crook, 1998). However, one has to redefine the term of 
inflammation. Initially inflammation was described by using the following four characteristics: 
calor, rubor, tumor and dolor (fever, redness, swelling and pain) (Larsen and Henson, 1983). 
Then, metabolic disorders are characterized by a low-grade inflammation which triggers insulin 
resistance (Duncan et al., 2003; Pradhan et al., 2001; Shoelson et al., 2006). Low-grade 
inflammation is a state of chronic, but low-grade, secretion of inflammatory mediators, as for 
example cytokines. Indeed, levels of inflammatory mediators in low-grade inflammation are 
only slightly increased in comparison to healthy state. 
The pro-inflammatory cytokine TNF-α plays also a role in the development of insulin 
resistance. Indeed, TNF-α increases lipolysis in adipocytes of rats (Green et al., 1994) and 
human (Zhang et al., 2002), thus increasing circulation fatty acids which is detrimental for 
insulin sensitivity. TNF-α neutralization has been shown to ameliorate insulin sensitivity in 
obese fa/fa rats (mutation in the gene for leptin receptor) (Hotamisligil et al., 1993). The excess 
of pro-inflammatory cytokines impairs cellular insulin signaling by increasing serine 
phosphorylation of insulin receptor substrate-1 (IRS-1) and thus contributes to insulin 
resistance and T2D (Feinstein et al., 1993; Hotamisligil et al., 1996). IL-6 provokes 
hypertriglyceridemia in vivo by stimulating lipolysis and hepatic triglyceride secretion in rats 
(Nonogaki et al., 1995). 
Immune cells are also important for triggering of diseases. Innate and adaptive immune 
cells contribute to disease. During obesity and T2D, macrophages and lymphocytes infiltrate 
the adipose tissue and the liver. The accumulation of these immune cells is directly proportional 
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to measures of adiposity (adipocyte size, BMI) in mice and humans (Hotamisligil, 2006; 
Weisberg et al., 2003).  
In mice, which had HFD-induced metabolic disorders and in ob/ob mice increased 
numbers of macrophages and CD8+ T lymphocytes were observed in the stromal fraction of 
epididymal fat pads in comparison to control mice under normal diet. In contrast, CD4+ T 
lymphocytes and Treg were significantly decreased (Nishimura et al., 2009). Additionally, mice 
under HFD, had increased secretion of IFN-γ. Kinetic analysis of adipose tissue infiltration 
following diet-induced insulin resistance have shown that infiltration by CD8 T cells preceded 
the accumulation of macrophages. CD8+ T cell elimination reduced macrophage infiltration and 
adipose tissue inflammation and ameliorated metabolic parameters (Nishimura et al., 2009). 
In epidemiological and case-control studies in human, it has been shown that pro-
inflammatory cytokines and biomarkers, like C-reactive protein (CRP) and IL-6, are increased 
in metabolic disorders (Duncan et al., 2003; Pradhan et al., 2001). Additionally, macrophages 
have been shown to accumulate in adipose tissue of obese patients (Weisberg et al., 2003). 
7. Type 1 diabetes mellitus 
Type 1 diabetes mellitus (T1D) is an autoimmune disorder with genetic predisposing 
factor accounting for more than 90% and hence in contrast to most of metabolic disorders, not 
due to inappropriate lifestyle. However, every person with genetic predisposition for T1D does 
not develop T1D suggesting not only a role for genetic but also environment. T1D is 
characterized by blood hyperglycemia due to a loss of insulin. Indeed, pancreatic β-cells are 
destructed by autoreactive T cells. A role of intestinal hyperpermeability in the development 
and/or course of disease is questioned. 
During my PhD, Dr. Sandrine Ménard and myself were invited by Dr. Julien Diana, 
guest editor of the Journal of Frontiers in Immunology, to write a review about the intestinal 
barrier and stress in the case of autoimmune disorders: “Psychological Stress, Intestinal Barrier 
Dysfunctions and Autoimmune Disorders” submitted in May 2019 and at the moment under 
review. We also discuss the role of intestinal microbiota, intestinal permeability and immune 
response in the case of T1D. Parts of this review are reused in the following chapter; the review 
article itself is inserted at the end of chapter III.  
  
44 
 
CHAPTER III  
STRESS 
Stress, firstly described in 1936 by Selye, is defined as a real (physical) or perceived 
(psychological) threat to homoeostasis, to which the organism has to react by an adaptive 
response (Selye, 1936). 
Lifetime window, length and frequency of exposure to stress play a pivotal role in 
consequences of stress on the individual pathophysiology. Indeed, acute and chronic stress 
exposure could occur in early life in a still maturating organism or at adulthood in mature 
organism. Traumatic experiences can lead to so called post-traumatic stress disorder (PTSD), a 
condition in which a person is suffering from anxiety, depression and flashbacks long after the 
traumatic experience (Kessler et al., 2005). Persisting stress or inadequate response can lead to 
harmful maladaptive reactions depending on the kind of stress. 
The stress response is orchestrated by hypothalamo-pituitary-adrenal axis (HPA) and 
sympathetic nervous system (SNS). The neuroendocrine and autonomous response is mediated 
by hormones as epinephrine, norepinephrine, CRF, ACTH, glucocorticoids (cortisol in human 
and corticosterone in rodents) (Charmandari et al., 2005; Smith and Vale, 2006).  
1. The HPA axis 
The Hypothalamo-Pituitary-Adrenal axis consists of three organs (hypothalamus, 
hypophysis (or pituitary gland) and adrenal glands) and the hormones CRF, ACTH and 
glucocorticoids. In response to stress, corticotropin releasing factor (CRF) is released by the 
paraventricular nucleus of hypothalamus into blood vessels leading to the anterior pituitary 
gland. Here, CRF is binding to corticotrop cells, which release in response adrenocorticotropic 
hormone (ACTH) into systemic circulation. Via the blood stream, ACTH is attaining its 
principal target the adrenal cortex. ACTH stimulates the synthesis and release of 
glucocorticoids (cortisol in human; corticosterone in rodents). Glucocorticoids act at numerous 
sites via its intracellular glucocorticoid receptor (GR). The HPA response is finely regulated by 
retrocontrol: Glucocorticoid can bind to receptors in hippocampus, hypothalamus, hypophysis 
via its GR and downregulate CRF and ACTH release (Figure 19) (Smith and Vale, 2006). 
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Figure 19 The hypothalamus-pituitary-adrenal axis. The hypothalamus is releasing CRF which reaches 
anterior pituitary gland stimulating the release of ACTH. ACTH acts on adrenal gland stimulating release of 
glucocorticoids. Glucocorticoids have various functions on diverse target tissues and can regulate via negative 
feedback CRF and ACTH release. CRF corticotropin releasing factor, ACTH Adrenocorticotropic hormone, 
AVP arginine vasopressin, V vasopressin, GR glucocorticoid receptor (Thomson and Craighead, 2008). 
2. Immunomodulatory effect of glucocorticoids 
A special attention has been paid to glucocorticoid in stress response and immune 
regulation. Endogenous glucocorticoids, part of the endocrine stress response, have ubiquitous 
functions in development, metabolism and inflammation. In general, glucocorticoids have been 
described to dampen immune response all along the inflammation process (for review (Cain 
and Cidlowski, 2017)). Glucocorticoids attenuate signaling pathways of many pattern 
recognition receptors (Beaulieu and Morand, 2011; Miyata et al., 2015), diminish leukocyte 
transmigration by reducing adhesion molecules (Atsuta et al., 1999). Glucocorticoids also 
decrease the production of chemoattractants (Mukaida et al., 1994), program macrophages to 
anti-inflammatory M2c subtype (high expression of scavenger receptors and secretion of anti-
inflammatory cytokines) (Martinez et al., 2008) and decrease T cell response (Gillis et al., 
1979a, 1979b) preferentially Th1 and Th17 by promoting Th2 and Treg (Elenkov, 2004; 
Liberman et al., 2007). Due to their immunosuppressive effects, glucocorticoids have been used 
to treat various immune related disorders like autoimmune disorders (AD). 
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The literature of the past 60 years focused on immunosuppressive properties of 
glucocorticoids but glucocorticoids can also enhance inflammation and immunity (for review 
(Cain and Cidlowski, 2017)). Part of the explanation of conflicting effects of glucocorticoid on 
immune response might reside in the diversity of glucocorticoid-receptors in different tissues, 
the presence or absence of 11βHSD, an enzyme inactivating cortisol as well as the time of 
glucocorticoid exposure (before or after tissue injury/inflammation) (Frank et al., 2010) and the 
dose (Lim et al., 2007). As an example, in humans, childhood maltreatment is associated with 
modified methylation of the glucocorticoid receptor gene NR3C1 in adults in brain and in 
leucocytes (McGowan et al., 2009; Melas et al., 2013; Perroud et al., 2011). All those factors 
might explain that stressful events inducing glucocorticoids release play a role in AD 
occurrence that can be treated by exogenous glucocorticoids.  
3. Effect of stress on intestinal barrier 
Stress is playing a role in the course of gastro-intestinal disorders like irritable bowel 
syndrome (IBS) (Hislop, 1979; Lowman et al., 1987; Videlock et al., 2009) and inflammatory 
bowel diseases (IBD) (Sgambato et al., 2017). IBS is a very interesting model to study the 
consequences of stress on intestinal barrier. Indeed, the occurrence of stressful events is 
considered as a contributing factor triggering and/or maintaining IBS (Mayer et al., 2001; 
Wood, 2011), suggesting that dysfunctional interactions in the brain-gut axis contribute to the 
pathophysiology of the disease (Bonaz and Bernstein, 2013) and as such justifying it’s new 
classification as disorder of the brain-gut interaction (Drossman, 2016).  
Stress comes along with microbiota modifications, intestinal and systemic inflammation 
and modified intestinal permeability in rodent and human. It is difficult to decipher if stress 
directly influences microbiota or if the observed effects are a consequence of modified immune 
response or intestinal physiology. These actors are tightly linked and regulate one another. 
3.1 Stress affects microbiota composition 
Neonatal maternal separation induced microbiota dysbiosis in mice (Riba et al., 2017). 
Limited nesting stress altered microbiota in rat pups (Moussaoui et al., 2017). In adults, chronic 
water avoidance stress increased susceptibility to indomethacin induced hyperpermeability in 
mice and the effect is transferable via fecal microbiota transfer (Yoshikawa et al., 2017). Germ 
free (GF) mice have exaggerated HPA stress response after restraint stress (Sudo et al., 2004) 
showing the role of microbiota in the regulation of stress response. Mice exposed to social 
disruption stress have increased circulating IL-6 and MCP-1 levels, these effects were totally 
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abolished by antibiotic mixture (ampicillin, vancomycin, neomycin sulfate, and metronidazole), 
showing the importance of microbiota in the induction of stress effects (Bailey et al., 2011). 
However, one cannot exclude an effect induced directly by the antibiotic treatment on the 
physiology of the intestine, and not by microbiota. 
In humans, decreased total abundance of Actinobacteria, Lentisphaerae, and 
Verrucomicrobia is associated with PTSD in south Africans individuals (Hemmings et al., 
2017). Microbiota dysbiosis has been described in IBS patients (for review (Collins, 2014)). 
3.2 Stress affects intestinal permeability 
In preclinical model and epidemiological studies, stress has been associated with an 
increase of intestinal permeability. Chronic water avoidance stress increases intestinal 
permeability and decreases tight junction protein expression in colon of adult rat (Zheng et al., 
2013) and overall intestinal permeability in mice (Cameron, 2005). Chronic neonatal maternal 
separation, a model of early life stress, also increases intestinal permeability in rat (Barreau et 
al., 2004; Moussaoui et al., 2017; Øines et al., 2012) and male mice (Riba et al., 2018) but not 
female. Maternal separation applied just for one time (acute stress) increases intestinal 
permeability in rats, which has been shown being mediated by stress hormones glucocorticoids. 
Indeed, using GR inhibitor there were no increase in intestinal permeability after acute maternal 
separation (Moussaoui et al., 2014). Combination of different stressors (subacute (isolation, 
limited movement) and chronic crowding stress) also decreased tight junction mRNA 
expression in rats (Lauffer et al., 2016). In a mouse model of social disruption, a social stressor, 
bacterial RNA (Lactobacillus spp.) is increased in spleen, which indicates translocation of at 
least bacterial fragments (Lafuse et al., 2017). 
In human, acute psychological stress like public speaking has also been shown to induce 
intestinal hyperpermeability (Vanuytsel et al., 2014). Intestinal hyperpermeability has also been 
described in IBS patients, but only in IBS-diarrhea predominant patients (Bischoff et al., 2014). 
The stress hormone cortisol (human) and corticosterone (mice) have been shown to mediate 
stress increased intestinal hyperpermeability as administration of the GR agonist 
dexamethasone mimicks the intestinal hyperpermeability (Moussaoui et al., 2014; Zheng et al., 
2013).  
3.3 Stress modifies intestinal immune system 
Chronic neonatal maternal separation in rats increases cytokine expression, 
myeloperoxidase activity and mast cell numbers in colonic tissue and exacerbate TNBS-
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induced colitis (Barreau et al., 2004). Neonatal maternal separation in mice increased TNFα 
expression by intestinal tissue in young adult (Riba et al., 2017). Acute restraint stress augments 
histamine release by mast cells (Eutamene et al., 2003). Acute acoustic stress increased 
intestinal IL-17 and IL-22 expression in mice (Miranda and Roux, 2017).  
In human, stress aggravates IBD symptoms including higher release of pro-
inflammatory effectors (Sgambato et al., 2017). In IBS, an increased state of activation of 
immune cells has been described even though this observation is under debate (Barbara et al., 
2011).  
3.4 Stress alters systemic immune response 
Not only the intestinal immune system is influenced by psychological stress. There is 
also evidence for modified systemic immune response without direct proof that inflammatory 
immune cells were activated in gastrointestinal tract. Neonatal maternal deprived rats have 
increased cytokine expression in liver and spleen (Barreau et al., 2004). Humoral immune 
response against microbiota is increased in neonatal maternal deprived mice (Riba et al., 2018). 
Social disruption stress in mice increases bacterial translocation and induces circulating IL-6 
and MCP-1 (Bailey et al., 2011; Lafuse et al., 2017). 
Eutamene et al. showed that acute stress-induced increase of histamine content in mast 
cells of rats was mediated by IL-1β and CRF. Injection of both individually mimics stress-
induced effects and inhibition of IL-1β blocked stress-induced mast cell changes (Eutamene et 
al., 2003). These findings are highlighting the close relationship and interaction between HPA, 
intestinal and systemic immune response. 
Stress is associated with an increase in pro-inflammatory response as described in PTSD 
patients (de Oliveira et al., 2018). A meta-analysis of several studies showed that IL-6, TNFα 
and IL-1β secretion were increased in response to acute stress in human (Marsland et al., 2017). 
Childhood victimization is associated with elevated CRP levels in young adult (Baldwin et al., 
2017; Slopen et al., 2015).  
3.5 Visceral sensitivity 
Stress has also been described to induce visceral sensitivity. “Hypersensitivity refers to 
increased sensation of stimuli. In practice, this is appraised by measurement of threshold 
volumes or pressures for first sensation or pain. Alternatively, it refers to the increased scores 
of symptoms (including pain) in response to standard stimuli. Hyperalgesia refers to increased 
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pain sensation in response to a certain stimulus. Allodynia refers to the appreciation that a 
stimulus, which was previously not perceived as being painful, becomes painful.” (Camilleri et 
al., 2001).  
Acute water avoidance stress (1h) induces transient visceral hyperalgesia, this effect was 
mediated by GR (Myers and Greenwood-Van Meerveld, 2012). Partial restraint stress (2h) 
induces hypersensitivity in response to rectal distension in rats (Gué et al., 1997). Chronic 
maternal separation leads to visceral hypersensitivity in young adult male and female mice 
(Riba et al., 2018, 2017). In studies with rodents, it has been shown, that the modified pain 
perception by stress is due to modifications of the HPA. Indeed, the effects have been shown to 
be mediated by GR (Myers and Greenwood-Van Meerveld, 2012) and could be mimicked by 
CRF injection (Gué et al., 1997) but also inflammation could influence pain perception since 
mast cell numbers, IL-1β and IFNγ are increased by chronic water avoidance stress (Bradesi et 
al., 2005; Gué et al., 1997).  
In human, IBS patients are often suffering from increased visceral sensitivity (Ludidi et 
al., 2012; van der Veek et al., 2008). Stressful life events and early childhood adverse 
experiences are described to aggravate pain in IBS patients (Lampe et al., 2003). 
4. Effects of stress on glucose metabolism 
Glucocorticoids have a direct influence on metabolism. Indeed, in acute stressful 
situations stress hormones stimulate catabolic processes in order to maintain life. Glucose and 
free fatty acids are distributed to muscles in order to prepare a “fight or flight” response. 
However, acute and chronic stress do not have the same impact on metabolism. Whereas acute 
stress leads to feeding suppression and body weight loss, chronic stress is associated with food 
overconsumption and body weight gain (Rabasa and Dickson, 2016). Stress has also an impact 
on insulin sensitivity. Acute chronic stress in mice induced by inescapable food shocks led 
rapidly to insulin resistance (Li et al., 2013). In human, psychosocial stress –related variables 
were associated with hyperglycemia, hyperinsulinemia and increased plasminogen activator 
inhibitor-1 antigen comprising the IRS, even after adjusting for BMI (Räikkönen et al., 1996). 
 
In this chapter, I discussed the effect of stress on intestinal barrier and glucose 
metabolism. There is also tremendous data about a link between stress and autoimmune 
disorders. During my PhD, Dr. Sandrine Ménard and myself were invited by Dr. Julien Diana, 
guest editor of the Journal of Frontiers in Immunology, to write a review about the intestinal 
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barrier and stress in the case of autoimmune disorders: “Psychological Stress, Intestinal Barrier 
Dysfunctions and Autoimmune Disorders” submitted in May 2019 and at the moment under 
review.
Submitted in May 2019 to Frontiers in Immunology 
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Abstract 9 
Autoimmune disorders (AD) are multifactorial diseases involving, genetic, epigenetic and 10 
environmental factors characterized by an inappropriate immune response toward self-antigens. In the 11 
past decades there has been a continuous rise in the incidence of AD which cannot be explained by 12 
genetic factors alone. Influence of psychological stress on the development or the course of 13 
autoimmune disorder is debated for a long time. Indeed, based on epidemiological studies, stress has 14 
been suggested to precede AD occurrence and to exacerbate symptoms. Furthermore, compiling data 15 
showed that most of AD are associated with gastro-intestinal symptoms i.e. microbiota dysbiosis, 16 
intestinal hyperpermeability and intestinal inflammation. Interestingly, social stress (acute or chronic, 17 
in adult or in neonate) is a well described intestinal disrupting factor. Taken together those observations 18 
questioned a potential role of stress-induced defect of intestinal barrier in the onset and/or the course 19 
of AD. 20 
In this review, we aim to present evidences supporting a role of stress-induced intestinal barrier 21 
disruption in the onset and/or the course of AD. We will mainly focus on auto-immune Type 1 22 
Diabetes, Multiple Sclerosis and Systemic Lupus Erythematous, AD for which we could find sufficient 23 
circumstantial data to support this hypothesis. 24 
1 Introduction 25 
Autoimmune disorders (AD) are multifactorial diseases involving, genetic, epigenetic and 26 
environmental factors. In the past decades there has been a continuous rise in the incidence of AD 27 
which cannot be explained by genetic factors alone. Changes in our lifestyle including, diet, hygiene, 28 
exposure to social adversity or pollutants have been suggested to be risk factors for AD. AD are 29 
associated with defect of intestinal barrier and besides nutrition, one other environmental factor well 30 
described to impair intestinal barrier is psychological stress. The aim of this review is to compile 31 
evidences highlighting a relationship between stress, intestinal barrier disruption and occurrence of 32 
AD. Even though, there are no striking studies linking stress-induced intestinal barrier defect to AD 33 
onset, our goal is to combine evidences based on a review of the literature and offer a new field of 34 
research and perspectives on AD. We will focus on three of the most studied AD: auto-immune type 1 35 
diabetes (T1D), systemic lupus erythematous (SLE) and multiple sclerosis (MS). 36 
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This review is based on epidemiological and pre-clinical studies. Numerous excellent and recent 37 
reviews treating either AD and stress or stress and intestinal barrier will be quote to support this 38 
hypothesis. 39 
2 Stress  40 
Stress, firstly described in 1936 by Selye, is defined as a real (physical) or perceived (psychological) 41 
threat to homoeostasis, to which the organism has to react by an adaptive response (1).   42 
Life time window, length and frequency of exposure to stress play a pivotal role in consequences of 43 
stress on the individual pathophysiology. Indeed, acute and chronic stress exposure could occur in early 44 
life in a still maturating organism or at adulthood in mature organism. Traumatic experiences can lead 45 
to so called post-traumatic stress disorder (PTSD), a condition in which a person is suffering from 46 
anxiety, depression and flashbacks long after the traumatic experience (2). Persisting stress or 47 
inadequate response can lead to harmful maladaptive reactions depending on the kind of stress that will 48 
be discussed below. 49 
The stress response is orchestrated by hypothalamic pituitary adrenal axis (HPA) and sympathetic 50 
nervous system (SNS). The neuroendocrine and autonomous response is mediated by hormones as 51 
epinephrine, norepinephrine, CRH, ACTH, glucocorticoids (cortisol in human and corticosterone in 52 
rodents) (3,4). A special attention has been paid to glucocorticoid in stress response and immune 53 
regulation. Endogenous glucocorticoids, part of the endocrine stress response, have ubiquitous 54 
functions in development, metabolism and inflammation. In general, glucocorticoids have been 55 
described to dampen immune response all along the inflammation process (for review (5)): they 56 
attenuate signaling pathways of many pattern recognition receptors (6,7), diminish leukocyte 57 
transmigration by reducing adhesion molecules (8), decreasing the production of chemoattractants (9), 58 
program macrophages to anti-inflammatory M2c subtype (high expression of scavenger receptors and 59 
secretion of anti-inflammatory cytokines) (10), decrease T cell response (11,12) preferentially Th1 and 60 
Th17 by promoting Th2 and Treg (13,14). Due to their immunosuppressive effects, glucocorticoids 61 
have been used to treat various immune related disorders like AD. 62 
The literature of the past 60 years focused on immunosuppressive properties of glucocorticoids but 63 
glucocorticoids can also enhance inflammation and immunity (for review (5)). We will not go into the 64 
details of conflicting effects of glucocorticoid on immune response but part of the explanation might 65 
reside in the diversity of glucocorticoid-receptors in different tissues, the presence or absence of 66 
11βHSD, an enzyme inactivating cortisol as well as the time of glucocorticoid exposure (before or after 67 
tissue injury/inflammation) (15) and the dose (16). All those factors might explain that stressful events 68 
inducing glucocorticoids release play a role in AD occurrence that can be treated by exogenous 69 
glucocorticoids. As an example, in humans, childhood maltreatment is associated with modified 70 
methylation of the glucocorticoid receptor gene NR3C1 in adults in brain and in leucocytes (17–19). 71 
3 Role of stress in AD (for rev (20)) 72 
The onset of at least 50% of autoimmune disorders has been attributed to unknown trigger factors. 73 
Many retrospective studies observed that that most of patients suffering from AD report uncommon 74 
emotional stress before disease onset (21). This is obviously a vicious cycle as AD diseases causes 75 
stress in patients (22,23). This review will focus on three of the most studied AD that will provide 76 
sufficient evidence to support the hypothesis of a role of stress-induced intestinal barrier defect on AD 77 
onset i.e. T1D, SLE and MS. Type 1 Diabetes (T1D) is an organ specific AD characterized by 78 
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autoimmune response against host pancreatic β-cells leading to a defect of insulin production by 79 
pancreas (24). Systemic lupus erythematosus (SLE) is an AD characterized by severe and persistent 80 
inflammation that leads to tissue damage in multiple organs (25,26). Multiple sclerosis (MS) is a 81 
chronic inflammatory disease of the central nervous system with a pathogenesis characterized by a 82 
breakdown of the blood-brain barrier and demyelination of the central nervous system by infiltrating 83 
auto-reactive T cells (27,28). The most widely used preclinical MS model is Experimental 84 
Autoimmune Encephalomyelitis (EAE). 85 
A potential association between stressful events and T1D has been highlighted already longtime ago 86 
when Thomas Willis links, in the 17th century, T1D onset to prolonged sorrow (29). Early life stress 87 
seems to be of particular risk for T1D development (30,31). This is in accordance with literature 88 
highlighting neonatal maturation of pancreas as critical and vulnerable to stressors (32). Stress in adult 89 
has been described to increase incidence of SLE (33) and is able to exacerbate SLE symptoms (physical 90 
pain, sleep disturbances and unemployment) (34). Around 70% of MS patients reported unusual 91 
amount of stress before the onset of the disease (35,36). 92 
Those epidemiological studies suggest that stress could be involved in both triggering or exacerbating 93 
AD. Whether it is dependent on the kind of stress or AD involved is unknown and it would be 94 
interesting to conduct both retrospective epidemiological studies and preclinical studies to better 95 
document the role of stress in AD. However, some interventional studies suggest that stress 96 
management could benefit to AD patients. Indeed, escitalopram (antidepressant) decreases the risk of 97 
MS relapsing in women (37). Diazepam (tranquilizer) decreases EAE incidence and histological signs 98 
associated with this disease in a mice model (38). A meta-analysis of ten randomized controlled trials 99 
in children and adolescents showed that supportive or counseling therapy, cognitive behavioral therapy 100 
and family system therapy reduce glycosylated hemoglobin and as such improve diabetes control (39). 101 
Interestingly, in 11 studies in adults no beneficial effect of stress management could be observed on 102 
T1D (39). 103 
4 Consequences of stress on intestinal barrier and systemic immune response 104 
Stress can affect various physiological process. Already Selye observed and others confirmed that the 105 
gastrointestinal tract and the immune system are among particularly responsive to stress no matter the 106 
origin of the stress (1). 107 
4.1 Actors of intestinal barrier and function 108 
Intestinal epithelium is the mammalian organism’s biggest surface in contact with the environment. 109 
Therefore, intestinal barrier function is highly diverse and well developed. The intestinal barrier have 110 
to fulfill conflicting functions. Indeed, intestinal barrier allows the transport of nutrient but at the same 111 
time filters and defends the organism from harmful luminal content (pathogens, toxins…). Among the 112 
main actors of intestinal barrier we can quote, intestinal microbiota, intestinal epithelium and immune 113 
response (innate and adaptive). All those actors are in close relationship and regulate one another (for 114 
review (40)). Not only intestinal microbiota participates in the protection against pathogens 115 
colonization but also contributes to maturation of intestinal epithelium and immune system and 116 
provides various nutritional compounds (41). The intestinal epithelium is formed by distinct cell types 117 
distributed along the crypt–villus axis. Although they all derived from a common stem cell progenitor 118 
located in the crypts, their morphology and roles differ (for review (42)). The intestinal epithelium is 119 
renewed every five days and this constant renewing confers high plasticity and protection to the 120 
intestinal barrier since defective cells are removed rapidly (43). Intestinal permeability is the ability of 121 
intestinal epithelium to allow the selective entrance of luminal antigens into the organism (44). Another 122 
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actor of the intestinal barrier is the intestinal immune system (Gut associated lymphoid tissue – GALT) 123 
harbored in the lamina propria and the Peyers patches (PP). GALT comprises the PPs, the appendix 124 
and isolated lymphoid follicles (ILFs), which are considered inductive sites for mucosal B and T cells. 125 
The humoral response in the intestine can be divided in four stages: predominant IgA induction in 126 
mucosal B cells, recirculation of IgA plasma blasts and homing into the intestinal mucosa, terminal B 127 
cell differentiation to plasma cells with local IgA production and export of IgA through the intestinal 128 
epithelial layer (for review (45)). Most intestinal T cells mature in peripheral lymphoid organs. These 129 
cells gain the expression of intestinal homing receptors to migrate to the intestine. Intestinal 130 
lymphocytes are continuously exposed to food and microbial antigens. These lymphocytes help 131 
maintaining the integrity of the intestinal barrier and immune homeostasis. Due to their close location 132 
to luminal antigens they have both regulatory and effector capabilities, including the prevention of 133 
pathogenic invasion and maintenance of tolerance to prevent extensive tissue damage (for review (46)). 134 
Innate lymphoid cells (ILCs) are lymphocytes that do not express the type of diversified antigen 135 
receptors expressed on T cells and B cells. ILCs are largely tissue-resident cells participating in tissue 136 
homeostasis (for review (47)). A defective intestinal barrier will lead to inappropriate intestinal but 137 
also systemic immune response leading to gastrointestinal disorders but also to extra intestinal diseases 138 
like autoimmune diseases (48–50).  139 
Intestinal barrier homeostasis is highly regulated and a defect in microbiota composition could lead to 140 
intestinal hyperpermeability and intestinal inflammation. Intestinal inflammation will not only 141 
contribute to intestinal hyperpermeability (51) but will also favor microbiota colonization by 142 
pathobionts (52).  143 
4.2 Psychological stress impairs intestinal barrier 144 
Stress is playing a role in the course of gastro-intestinal disorders like irritable bowel syndrome (IBS) 145 
(53–55) and inflammatory bowel disease (IBD) (56). IBS is a very interesting model to study the 146 
consequences of stress on intestinal barrier. Indeed, the occurrence of stressful events is considered as 147 
a contributing factor triggering and/or maintaining IBS (57,58), suggesting that dysfunctional 148 
interactions in the brain-gut axis contribute to the pathophysiology of the disease (59) and as such 149 
justifying it’s new classification as disorder of the brain-gut interaction (60). In this review, we will 150 
focus on the consequences of psychological stress on intestinal barrier and its consequences on 151 
systemic immune response. 152 
4.2.1 Microbiota dysbiosis 153 
Stress is modifying microbiota in animal and human. Neonatal maternal separation induced microbiota 154 
dysbiosis in mice at different ages (61,62). Limited nesting stress altered microbiota in rat pups (63). 155 
In adults, chronic water avoidance stress increased susceptibility to indomethacin induced 156 
hyperpermeability in mice and the effect is transferable via fecal microbiota transfer (64). Germ free 157 
(GF) mice have exaggerated HPA stress response after restraint stress (65) showing the role of 158 
microbiota in the regulation of stress response. Mice exposed to social disruption stress have increased 159 
circulating IL-6 and MCP-1 levels, these effects were totally abolished by antibiotic treatment showing 160 
the importance of microbiota in the induction of stress effects (66). 161 
In humans, decreased total abundance of Actinobacteria, Lentisphaerae, and Verrucomicrobia is 162 
associated with PTSD in south Africans individuals (67). Microbiota dysbiosis has been described in 163 
IBS patients (for review (68)). 164 
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4.2.2 Stress is associated with intestinal hyperpermeability 165 
In preclinical model and epidemiological studies stress has been associated with an increase of 166 
intestinal permeability. Chronic water avoidance stress increases intestinal permeability and decreases 167 
tight junction protein expression in colon of adult rat (69) and overall intestinal permeability in mice 168 
(70). Chronic neonatal maternal separation, a model of early life stress, also increases intestinal 169 
permeability in rat (63,71,72) and mice (73). Maternal separation applied just for one time (acute stress) 170 
increases intestinal permeability in rats (74). Combination of different stressors (subacute (isolation, 171 
limited movement) and chronic crowding stress) also decreased tight junction mRNA expression in 172 
rats (75). In a mouse model of social disruption, a social stressor, bacterial RNA (Lactobacillus spp.) 173 
is increased in spleen, which indicates bacterial translocation (76). 174 
In human, acute psychological stress like public speaking has also been shown to induce intestinal 175 
hyperpermeability (77). Intestinal hyperpermeability has also been described in IBS patients (78). The 176 
stress hormone cortisol (human) and corticosterone (mice) have been shown to mediate stress increased 177 
intestinal hyperpermeability as administration of the GR agonist dexamethasone mimicks the intestinal 178 
hyperpermeability (69,74).  179 
4.2.3 Stress exacerbates Intestinal and systemic inflammation  180 
Chronic neonatal maternal separation in rats increases cytokine expression, myeloperoxidase activity 181 
and mast cell numbers in colonic tissue and exacerbate TNBS-induced colitis (71). Neonatal maternal 182 
separation in mice increased TNFα expression by intestinal tissue in young adult (61) and LPS-183 
stimulated TNFα secretion of isolated lamina propria immune cells in ageing (62). Acute restraint 184 
stress augments histamine release by mast cells (79). Acute acoustic stress increased intestinal IL-17 185 
and IL-22 expression in mice (80).  186 
In human, stress aggravates IBD symptoms including higher release of pro-inflammatory effectors 187 
(56). In IBS, an increased state of activation of immune cells has been described even though this 188 
observation is under debate (81).  189 
Not only the intestinal immune system is influenced by psychological stress. There is also evidence for 190 
modified systemic immune response without direct proof that inflammatory immune cells were 191 
activated in gastrointestinal tract. Neonatal maternal deprived rats have increased cytokine expression 192 
in liver and spleen (71). Humoral immune response against microbiota is increased in neonatal 193 
maternal deprived mice (62,73). Social disruption stress in mice increases bacterial translocation and 194 
induces circulating IL-6 and MCP-1 (66,76). 195 
Stress is associated with an increase in pro-inflammatory response as described in PTSD patients (82). 196 
A meta-analysis of several studies showed that IL-6, TNFα and IL-1β secretion were increased in 197 
response to acute stress in human (83). Childhood victimization is associated with elevated CRP levels 198 
in young adult (84,85).  199 
5 Defect of intestinal barrier in AD (for review (86)) 200 
We provided evidence that stress might play a role in onset or course of AD and review the well-201 
documented deleterious role of stress in intestinal barrier functions. We will now summarize the data 202 
regarding the defect of intestinal barrier in AD. Indeed, the observed defect of intestinal barrier in AD 203 
is an interesting lead that largely contribute to the rise of the hypothesis suggesting a contribution of 204 
stress induced intestinal barrier defect in AD.  205 
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5.1 Microbiota in AD 206 
Microbiota is known to contribute to intestinal mucosal permeability, induction of innate defenses and 207 
as such represent a risk factor for AD (87,88). A growing body of evidence suggests that intestinal 208 
microbiota can modify the incidence and/or severity of immune-mediated extra-intestinal diseases 209 
(89). Aberrant microbiota has been described in patients suffering from type 1 diabetes (T1D) (90) 210 
systemic lupus erythematous (SLE) (88) and multiple sclerosis (MS) (91). Knowledge regarding 211 
microbiota dysbiosis in AD patients and animal models will be summarized here and interventional 212 
studies helping to understand the role of microbiota in those diseases will be discussed at the end of 213 
the paragraph. 214 
Increased microbial diversity and decreased level of butyrate producing Clostridia have been found in 215 
microbiota of pediatric T1D patients (92)(93). In the BABYDIET cohort, alteration in the composition 216 
of mucin degrading bacteria, with increased Bacteroïdes and decreased abundance of Akkermansia, 217 
associate with the risk of early development of islet auto-antibodies (94). Thus, changes in microbial 218 
diversity and differences in relative abundance, highlight that gut microbiota and associated increased 219 
gut permeability may contribute to disease onset or its progression. A reduction of microbial diversity 220 
is more pronounced before the time of diabetes onset (95). Fecal transplantation of NOD diabetic 221 
microbiota in NOD resistant mice resulted in insulitis induction revealing a diabetogenic gut microbial 222 
community (96,97). Antibiotic treatment accelerates disease development (98,99) suggesting a 223 
protective role of microbiota colonization in T1D. 224 
The presence of a disrupted or altered microbiota in relapsing remitting MS patient compared to 225 
healthy control has been observed (100–103) with no consensus on the involvement of a particular 226 
bacterial species. In contrast another study comparing 16S RNA profiles of feces from MS and healthy 227 
patients did not show any differences (101). Demyelination initiates after colonization with feces of 228 
specific pathogen free mice (104). Microbiota depletion by non-absorbable antibiotics ameliorates the 229 
development of EAE by reducing the number of mesenteric Th17 cells (105). GF mice present 230 
attenuated symptom in both spontaneous and induced EAE models (104,106) suggesting a deleterious 231 
role of microbiota colonization in MS. Furthermore, microbiota shapes and predicts the course 232 
(chronic-progressive or relapse remitting) of EAE in a mice model (107). 233 
Only few studies on human SLE microbiome in small cohorts reported microbial dysbiosis (108–110) 234 
confirmed by pre-clinical studies in mice models (110). A study performed in a larger and diversified 235 
cohort of SLE patient showed that the severity of disease is associated with more severe microbiota 236 
dysbiosis (111). 237 
5.1.1 Interventional studies. What do they tell us? 238 
Here, we will focus on direct supplementation by living bacteria like probiotic and fecal microbiota 239 
transplantation (FMT) treatment but not indirect interventions like prebiotics or nutritional compounds 240 
produced by bacteria, as short chain fatty acids for example, that may involve indirect effects. Once 241 
AD are diagnosed, the production of antibody against self-antigen will remain and will still damage 242 
tissues but this process could be delayed or reduced. Probiotics are living microorganisms which confer 243 
a health benefit to the host (112). Probiotics are known to have beneficial effects on intestinal barrier 244 
(113,114) and anti-inflammatory properties (115–119) and as such represent an interesting tool to 245 
delay, reduce or even prevent AD.  246 
Animal studies suggest beneficial effects of probiotics supplementation on EAE via a stimulation of 247 
IL-10 production (106,120–124). Clinical studies showed that a mixture of probiotics improved 248 
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expanded disability status score and decreased inflammatory markers (125). Regarding T1D, probiotic 249 
treatment delays the onset of T1D in an experimental rat model and improves intestinal barrier (126). 250 
Probiotics also protects NOD mice from T1D by reducing intestinal inflammation (127). In humans, it 251 
was demonstrated in the TEDDY (The Environmental Determinants of Diabetes in the Young) cohort 252 
that early probiotic supplementation was associated with a decreased risk of islet autoimmunity 253 
compared to late or missing supplementation (128). In animal models for lupus nephritis, probiotic 254 
administration lowers inflammatory response in kidney and intestine in female and castrated males but 255 
not in non-castrated males (129). 256 
FMT with microbiota from different diabetes resistant mouse strains delayed the onset of T1D in NOD 257 
diabetes prone mice (97). Few studies investigate to role of FMT on AD symptoms and most of the 258 
time the recommendation for FMT treatment was to target associated gastrointestinal troubles. 259 
Neurological symptoms were improved and disease progression was paused in three MS patients after 260 
FMT treatment for chronic constipation (130). Unfortunately, no data are available on intestinal barrier 261 
function of probiotics and FMT treatments in parallel of beneficial effects on AD. 262 
5.1.2 Mimicking  263 
Structural similarities between antigens from infectious agents and myelin proteins (molecular 264 
mimicry) can induce activation of naïve autoreactive T cells which will recognize peptides derived 265 
from both infectious agents and self-antigens. Cross reactivity could occur when important motifs are 266 
conserved and overall structures of TCR-peptide-MHC interaction are similar suggesting that cross 267 
reactivity may happen frequently (131). Myelin basic protein, the immunodominant autoantigen of 268 
MS, cross react with Epstein Barr Virus (EBV), influenza A virus, herpes simplex virus, human 269 
papilloma virus (132) or human herpesvirus-6 (133). Regarding EBV, MS patients seem to exhibit 270 
higher antibody titers against certain antigenic components of the virus than control subjects even 271 
before the onset of MS (134). Despite cross-reactivity, infectious agents can impair self-antigen 272 
tolerance by indirect activation (135). It has been showed that an integrase expressed by intestinal 273 
Bacteroides encodes a low-avidity mimotope of the pancreatic β cell autoantigens and as such might 274 
participate to T1D onset. Colonization of GF mice with Bacteroides promotes the recruitment of 275 
diabetogenic CD8+ T cells to the gut (136). 276 
5.2 Intestinal hyperpermeability in AD 277 
In AD, intestinal hyper-permeability has been described, resulting in an increased entry of luminal 278 
antigens derived from food and/or intestinal microbiota or pathogens. The resulting inflammation has 279 
been suggested to participate in AD onset and/or exacerbation. However, if intestinal 280 
hyperpermeability is a cause or a consequence of inflammation is under debate. Furthermore, if the 281 
microbiota dysbiosis is a cause or a consequence of intestinal hyperpermeability and inflammation is 282 
still unclear. 283 
Even though it is still unclear whether intestinal hyperpermeability is trigger or a consequence of T1D 284 
progression (137,138)(93) epidemiological and pre-clinical studies demonstrated that intestinal 285 
hypermeability occurs before disease onset (139,140). Reversion of intestinal hyperpermeability by 286 
treatment with a zonulin 1 (intestinal homolog of an Vibrio cholerae enterotoxin that reversibly 287 
increase intestinal permeability) inhibitor ameliorates T1D manifestation in rat model (141). Microbial 288 
translocation in pancreatic lymph nodes activates NOD2 and IL-17 production in pancreatic lymph 289 
nodes and pancreas contributes to T1D development (142).  290 
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Increased intestinal permeability precede EAE onset which worsen during disease progression (143). 291 
Intestinal hyper-permeability was associated with the increase of crypt depth and mucosa thickness in 292 
jejunum and ileum, as well as with an overexpression of zonulin 1 (143) as observed for T1D (141,144). 293 
Intestinal barrier defect and subsequent exposure to microbial products play an important role in the 294 
pathology of SLE (145,146). sCD14, lysozyme and CXCL16 are markers of antimicrobial response 295 
found increased in SLE subject attesting of a defect of intestinal barrier (147). 296 
5.3 Intestinal Inflammation 297 
T1D is associated with increased intestinal myeloperoxidase activity and goblet cell (producing mucus) 298 
density, supporting the idea that early intestinal inflammation might lead to intestinal 299 
hyperpermeability (148,149). Many studies suggest that increase of Th17 cells is involved in the 300 
pathogenesis of auto-immune diabetes. More IL-17 secreting cells were detected in recent-onset T1D 301 
and IL-17 seems to promote inflammatory response to β-cells (150,151). Th17 are increased in 302 
peripheral blood of children with T1D (151,152). In vitro IL-17 potentiate inflammatory and 303 
proapoptotic responses on human islets cells (151). Anti-IL-17 treatment reduced islet T cell infiltrates 304 
and GAD65 autoantibodies in NOD mice (153). Neutrophil extra cellular traps (NET) might contribute 305 
to the generation of AD by exposing autoantigen (154). The role of NET has been particularly studied 306 
in T1D. Indeed, degradation of NETs in the gut prevented immune infiltration of pancreatic islet 307 
preserving β-cell mass and systemic inflammation (155). 308 
In a mouse model of SLE developing severe nephritis, α4β7 expressing T cells were increased in Peyer 309 
patches and pro-inflammatory cytokines (IL-17, IL-22, IFNα and β) were much more expressed in 310 
distal ileum (156). Furthermore, intestinal monocytes/macrophages of SLE patients have an altered 311 
expression of type1 interferon stimulated genes, HLA-DR and Fcγ receptors (157,158). Monocytes 312 
isolated from plasma of SLE patients release higher pro-inflammatory cytokines in response to LPS 313 
compared to healthy patients (159). More generally, higher production of pro-inflammatory cytokines 314 
by monocytes/macrophages has been described in SLE patients (for review (160))  315 
In MS, elevated Th1 and Th17 pro-inflammatory responses were observed in lamina propria, Peyer’s 316 
patches and mesenteric lymph nodes (143). GF EAE animals produce lower levels of IFNγ and IL-17 317 
in intestine associated with higher number of Treg cells (104). GF animals monocolonized with 318 
segmented filamentous bacteria, known to induce IL-17 (161,162), develop EAE showing that 319 
microbiota can affect neurologic inflammation by induction of Th17 in intestinal lamina propria that 320 
recirculate to the brain causing inflammation (106). Autoreactive T cells could migrate in different 321 
organs, from gut to brain in the case of MS, to liver in the case of auto-immune cholestatic liver disease 322 
(163,164) or to kidney in the case of SLE (165). Interestingly, not only T cells seem to be involved in 323 
MS but also circulating ILC. Indeed, higher number of ILC has been observed in MS patients (166).  324 
6 Conclusion 325 
As a conclusion, compiling evidence highlights the importance of both intestinal barrier defect and 326 
stress in AD. Stress is well known to have long lasting deleterious consequences on intestinal barrier. 327 
A transversal research on AD and intestinal barrier function would be of great interest and would bring 328 
new understanding in the pathophysiology of AD. Identifying intestinal barrier as an actor of AD could 329 
bring new possibilities for therapeutic targets and especially preventing strategies toward the spreading 330 
epidemic of AD. Therapeutic strategies suggest that probiotics and FMT treatment might improve AD 331 
symptom but preventive strategies in at risk population still need to be explore. 332 
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β-cell mass is expanding, especially after weaning (Bonner-Weir et al., 2016). During the time 
of physiologic maturation, the organism is particularly sensitive to environmental influences 
(Figure 20). 
1. Allostatic load 
Over the past three decades, a body of epidemiologic evidences has shown that early-
life conditions influence patterns of growth, body composition, and later risk of non-
communicable diseases at adulthood. Among them there are type 2 diabetes (T2D), 
dyslipidemia, high blood pressure (for review (Gluckman, 2008; Weaver, 2009)) but also 
cancers (Kelly-Irving et al., 2013), autoimmune diseases like type 1 diabetes (T1D) (Virk et al., 
2015) or cognitive and behavioral disorders (Banqueri et al., 2016).  
Life course epidemiology proposes the concept of embodiment which is “how we, like 
any living organism, literally incorporate, biologically, the world in which we live, including 
our societal and ecological circumstances” (Krieger, 2005). Early life insults are incorporated, 
the allostatic load – which “is the cost of chronic exposure to fluctuating or heightened neural 
or neuroendocrine responses resulting from repeated or chronic environmental challenge that 
an individual reacts to as being particularly stressful” (McEwen and Stellar, 1993) - is 
increasing (Figure 21). 
 
Figure 21 Allostasis and allostatic load. Suitable adaptive response of the organism to a stressor leads to 
allostasis. In case of increased stressors and increased adaptive response without relieve allostatic load is 
increasing (Seaway, n.d.). 
2. Evidence for the DOHaD hypothesis 
Barker proposed in the late 80s the concept of developmental origins of health and 
disease (DOHaD) (Barker et al., 1989) in response to observations he made in the Hertfordshire 
cohort. Indeed he found that low birth weight was associated with impaired glucose tolerance 
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in adulthood (Hales et al., 1991). Since, DOHaD has been extended from fetal period to a period 
running from meiosis and gametogenesis to adolescence, with special emphasis on the first 
1000 days of life. Of interest is the health status in adulthood and even of those of the 
offspring’s. 
Studies about the consequences of the Dutch famine during World War II showed that 
adults, exposed to the famine in the second or third trimester in utero had lower glucose 
tolerance (Ravelli et al., 1998). Data on the Chinese famine in 1958 showed that adults exposed 
in utero had higher risk for T2D (Wang et al., 2016). There has also been established a link 
between intrauterine growth restriction and later dyslipidemia (Barker et al., 1993). Animal 
models allowed to confirm the observations from epidemiological studies. Uterine ligation is a 
model for idiopathic in utero growth restriction and leads to dyslipidemia and T2D (Lane et al., 
2001; Simmons et al., 2001).  
Even psychological diseases and IQ have been linked to early environment. Infants from 
mother with high cortisol levels during pregnancy had lower IQ than their siblings (LeWinn et 
al., 2009). In the cohorts of Chinese and Dutch famines, a more than doubled risk for developing 
schizophrenia has been observed for the exposed group (Hoek et al., 1996; St Clair et al., 2005). 
However, Serpeloni et al. reported that children, whose mother was exposed in prenatal and 
postnatal period to intimate partner violence, had less psychological disorders, as for example 
depression or anxiety, than children, which were only exposed in prenatal period to this stressor. 
They found epigenetic modifications on glucocorticoid receptor (NR3C1) and its repressor 
FKBP51 (FKBP5) and differentially methylated regions on DNA, which has previously been 
associated with increased resilience (Serpeloni et al., 2019). However, these modifications 
might have beneficial effects only in the special environment where they are living (high 
violence). Indeed, the genes implicated are responsible for social and emotional behavior 
(oxytocin). The authors argue, that decreased sensibility to violence is protective in this specific 
context but may be disadvantageous in a more societally accepted subcultures (Serpeloni et al., 
2019). 
Modifications of immune system by early life environment have also been described. In 
human, O’Conner et al found that maternal prenatal anxiety predicts lower adaptive immune 
response after hepatitis B vaccination (O’Connor et al., 2013). Prenatal exposure to xenobiotic, 
as for example tobacco, increased asthma risk in infants (Hylkema and Blacquiere, 2009). In 
an animal model, perinatal exposure to bisphenol A led to altered immune response in adult 
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mice, namely dampened intestinal and increased systemic immune response (Malaisé et al., 
2018, 2017).  
3. Mechanisms 
Mechanistic studies in the DOHaD domain are still sparse but underlying mechanisms, 
which has been proposed, are epigenetic modification of genome via DNA methylation and 
histone acetylation. The phenomenon of catch-up growth has been associated with 
endoplasmatic reticulum stress, which could trigger later deleterious metabolic outcomes. 
Metabolic adaption in response to nutritional stress in utero has been another proposition. In 
infants small for gestational age and in rodents with in utero growth restriction decreased lipid 
oxidation has been observed (Hoffman et al., 2017). A potent tool seems to be the allostatic 
load, which is measured by diverse biomarkers (Casavant et al., 2019; Thayer et al., 2016)  
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The model of maternal separation induced a large variety of outcomes. Indeed, there are 
studies interested in behavioral outcomes of early life stress (Gracia-Rubio et al., 2016). MS 
serves also as a model in the research on brain activity (Nishi et al., 2013) and depression 
(Vetulani, 2013). The model is also used to study the gut-brain axis (O’Mahony et al., 2011). 
We are interested in this model due to its effects on intestinal homeostasis. Indeed, MS 
is responsible for long lasting alterations of intestinal homeostasis on adult male and female 
rodents offspring (Barreau et al., 2004; Riba et al., 2018, 2017).  
Recent data from the host laboratory, who have been working with this model for some 
years, showed that MS induced in 50 days old (PND50) male mice an increase in intestinal 
permeability and visceral hypersensitivity. MS led to low-grade inflammation and microbiota 
dysbiosis. It also exacerbated immune response toward microbiota. Indeed, MS increased 
humoral response toward a commensal E. coli isolated from feces of the mouse strain used 
(Riba et al., 2018). MS induces already at PND50 a sexual dimorphic phenotype. In female 50-
days old mice, MS leads to visceral hypersensitivity, decreased lysozyme expression, blooming 
of E. coli, humoral immune response against microbiota and intestinal low-grade inflammation 
(Riba et al., 2017). 
We carried out separate studies for male and female mice, since sexual dimorphism was 
observed from PND50 on. We analyzed the long-term effects of MS on male and female mice 
separately. 
The impaired intestinal barrier functions and abnormal immune responses toward 
microbiota observed in male mice by the MS model at PND50 have also been observed in 
metabolic disorders. For example, obesity and/or T2D have been associated with increased 
intestinal permeability in mice (Brun et al., 2007; Cani et al., 2008), IgG response against 
specific E.coli (Mohammed et al., 2012), dysbiosis (Turnbaugh et al., 2006) and low-grade 
systemic inflammation (Osborn and Olefsky, 2012). However, in PND50 male mice, which 
underwent maternal separation, no metabolic disorder were observed. 
As metabolic disorders occur in aging individuals, we wondered if MS-induced low-
grade inflammation leads to metabolic disorders in aging male mice (PND350) under normal 
diet and if we could identify MS as a risk factor in metabolic disorders development.  
In our first study, we focused on the characterization of immunometabolism in aging 
male mice, which underwent MS in neonatal period. We aimed to analyze the long term 
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consequences of neonatal maternal separation on mice’ metabolism, as well as on intestinal 
barrier functions, immune responses toward microbiota, and low-grade inflammation. 
My work aims to provide experimental data to support a link between early life stress 
and development of metabolic disorders with aging. This project will highlight the neonatal 
period as a critical window for homeostasis establishment and early life adverse events like 
stress as a risk factor triggering metabolic disorders. 
In a second time, we aimed to assess the role of microbiota dysbiosis in the development 
of metabolic disorders in the MS model in male mice. We wondered if microbiota dysbiosis, 
observed in the model of maternal separation, could trigger the observed immunometabolic 
phenotype in male mice. Fecal microbiota transfer is the current gold standard to prove causal 
relationship, so we carried out fecal microbiota transfer into germ-free male mice. 
In a third project, we aimed to analyze long-term consequences of MS in female mice 
on allostatic load, namely intestinal barrier function, neuroendocrine functions and metabolism. 
Additionally, we were interested in immune response and wondered if MS could lead to 
autoimmune disorder in aging female mice. As previously discussed in the review article, there 
seems to be a link between stressful environment, intestinal barrier dysfunction and 
autoimmune disorders. 
In a last part of this PhD project, we were interested in a methodological question 
regarding the various methods used to measure intestinal permeability and their relevance. We 
set up a project to compare ex vivo and in vivo measurements of intestinal permeability in a 
model of autoimmune type 1 diabetes. Our aim is to initiate a discussion around the definitions 
of intestinal permeability and systemic exposure in order to clarify the concept of intestinal 
permeability. 
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The first part of my work has the objective to describe long-lasting effects of neonatal 
maternal separation (MS) on immune-metabolism in male mice.  
Previous data from our laboratory from Riba et al. showed that MS induced in 50 days 
old (PND50) male mice an increase in intestinal permeability and visceral hypersensitivity. MS 
led to low-grade inflammation and microbiota dysbiosis. It also exacerbated immune response 
toward microbiota. Indeed, MS increased humoral response toward a commensal E. coli 
isolated from feces of the mouse strain used (Riba et al., 2018). 
These features are also described in metabolic disorders like diabetes. However, at 
PND50 no metabolic disorder has been observed. A major risk factor for metabolic disorders 
is aging. Therefore, we wondered, if mice, which underwent neonatal maternal separation 
would develop metabolic disorder with aging. This hypothesis was additionally strengthen by 
epidemiological studies, which showed an association between early life adverse events and 
metabolic disorder, especially type 2 diabetes (Huang et al., 2015). 
This work has been published as an original article online on April 11, 2019, in print in 
August 2019 in the Journal “Brain, Behavior, and Immunity” and I signed as the first author. 
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A B S T R A C T
Early life stress is known to impair intestinal barrier through induction of intestinal hyperpermeability, low-
grade inflammation and microbiota dysbiosis in young adult rodents. Interestingly, those features are also ob-
served in metabolic disorders (obesity and type 2 diabetes) that appear with ageing. Based on the concept of
Developmental Origins of Health and Diseases, our study aimed to investigate whether early life stress can
trigger metabolic disorders in ageing mice.
Maternal separation (MS) is a well-established model of early life stress in rodent. In this study, MS increased
fasted blood glycemia, induced glucose intolerance and decreased insulin sensitivity in post-natal day 350 wild
type C3H/HeN male mice fed a standard diet without affecting body weight. MS also triggered fecal dysbiosis
favoring pathobionts and significantly decreased IL-17 and IL-22 secretion in response to anti-CD3/CD28 sti-
mulation in small intestine lamina propria. Finally, IL-17 secretion in response to anti-CD3/CD28 stimulation was
also diminished at systemic level (spleen).
For the first time, we demonstrate that early life stress is a risk factor for metabolic disorders development in
ageing wild type mice under normal diet.
1. Introduction
During the last century, the incidence of non-communicable dis-
eases, including metabolic disorders, is expanding in western countries
(Bach, 2002). The causes for this drastic increase are debated. The
concept of Developmental Origins of Health and Disease (DOHaD)
highlights the importance of early life period and raises the hypothesis
that chronic diseases could find their origins in perinatal environment
(Barker et al., 1989; Gluckman et al., 2016). In mice and humans, early
life is important for the development of the immune system, metabolic
switch, microbiota colonization (Tamburini et al., 2016) and the de-
velopment of life-long beneficial host-microbe homeostasis (Hornef and
Fulde, 2014). Adverse events can disturb these mechanisms of adap-
tation. Several observational epidemiological studies have shown an
association between adverse childhood experiences and metabolic dis-
eases in later life (Huang et al., 2015). This study aims to provide ex-
perimental data to support a link between early life stress and
development of metabolic disorders with ageing.
Metabolic disorders, such as obesity and type 2 diabetes are asso-
ciated with modification of intestinal barrier, microbiota dysbiosis and
low grade inflammation (Brun et al., 2007; Cani et al., 2008; Osborn
and Olefsky, 2012; Turnbaugh et al., 2006). In mice, several models
such as diet induced obesity (high-fat or western diets) or genetic
models (ob/ob and db/db, respectively deficient for leptin and leptin
receptor) are used to investigate obesity associated with hyperglycemia.
In those models, a defect of intestinal barrier as well as low-grade in-
flammation were observed, even before the onset of obesity and hy-
perglycemia (Araújo et al., 2017; Brun et al., 2007). Neonatal maternal
separation (MS) is a stress model widely used in rodents as a paradigm
of early life adverse events. We previously observed that, in male mice,
MS triggers long lasting alterations of intestinal homeostasis in young
adult offspring (post-natal-day (PND) 50) including a defect of in-
testinal barrier, microbiota dysbiosis and low-grade inflammation (Riba
et al., 2018). With ageing, intestinal permeability and low-grade
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inflammation are increasing in mice (Thevaranjan et al., 2017) and
human (Man et al., 2015). This might explain why chronic metabolic
diseases appear in the ageing population and suggest a potential role of
intestinal barrier defect itself in triggering and/or maintaining meta-
bolic disorders.
Here, we aimed at investigating in wild-type male mice the long-
term effects of neonatal MS on metabolism, intestinal barrier function,
as well as on microbiota composition, immune response toward mi-
crobiota, and low-grade inflammation in ageing mice fed a regular diet.
2. Material and methods
2.1. Mouse model
All experimental protocols were approved by local Animal Care Use
Committee (Comité d'Ethique de Pharmacologie-Toxicologie de
Toulouse – Midi-Pyrénées, France) registered as N°86 at the Ministry of
Research and Higher Education (N° 0029/SMVT), and conducted in
accordance with the European directive 2010/63/UE. Mice were kept
at a constant temperature (22 ± 1 °C) and maintained on a 12:12 h
light/dark cycle (lights on 7 h30 am) on Specific and Opportunistic
Pathogen Free (SOPF) conditions. Normal diet (Harlan2018, Envigo,
Gannat, France) and water were available ad libitum.
2.1.1. Maternal separation protocol
Nulliparous female C3H/HeN mice (Janvier Labs, Le Genest St Isle,
France) were used. Maternal separation (MS) was performed as pre-
viously described (Riba et al., 2018). Briefly, pups were separated from
their dam and the rest of the litter 3 hours per day. MS was repeated for
10 working days, week-end excluded, between post-natal-day 2 (PND2)
and PND15. Control pups were left with their dam. At weaning
(PND21), litters were mixed within the same group and housed by 5
mice per cage; only males were kept for this study as MS induced on
PND50 male mice a defect of intestinal barrier, microbiota dysbiosis
and low-grade inflammation (Riba et al., 2018), features also observed
in metabolic disorders. Four independent batches of experiments were
realized. Experiments were performed at PND350.
2.1.2. Oral glucose (OGTT) and intraperitoneal insulin tolerance test (ITT)
OGTT and ITT were performed in mice 6 h-fasted during day light.
For OGTT, mice were gavaged with 2mg glucose per g of bodyweight.
Blood glucose levels were monitored from the tip of the tail vein with a
glucose meter (Johnson & Johnson, Issy-les-Moulineaux, France) at
−30, 0 (glucose gavage), 15, 30, 60, 90 and 120min.
During ITT mice were injected with 0.75mU insulin (NovoRapid,
Novo Nordisk, Chartres, France) per g of bodyweight. Blood glucose
levels were measured up to 30min after injection.
For fasted blood glucose, mice were fasted 16-h overnight.
For plasma insulin, blood samples were harvested in fasted state
(6 h) and 15min after glucose stimulation per os (2 mg glucose per g of
bodyweight). Insulin was measured with commercial ELISA kit (Merck
Millipore, Saint Quentin en Yvelines, France).
2.2. Fecal microbiota composition analysis
Total microbial genomic DNA was obtained from stool samples
using the ZR Fecal DNA MiniprepTM (Zymo Research, Ozyme SAS,
Montigny-le-Bretonneux, France) and DNA quantity was determined
using a TECAN Fluorometer (Qubit® dsDNA HS Assay Kit, Molecular
Probes, Thermofisher Scientific, Montigny le Bretonneux). The micro-
bial 16S rRNA gene was amplified during the first PCR step with
adapter fusion primers targeting the V3 to V4 regions. Sequence reads
were quality controlled and treated first with the FROGS pipeline (Find
Rapidly OTU with Galaxy Solution) (Escudié et al., 2018) to obtain
OTUs and their respective taxonomic assignment thanks to Galaxy in-
stance (http://sigenae-worbench.toulouse.inra.fr). Rarefaction curves,
richness and diversity indexes of bacterial community, as well as or-
dinations were computed using the Phyloseq package (v 1.19.1) in
RStudio software (Mcmurdie and Holmes, 2012; McMurdie and
Holmes, 2013; R Development Core Team, 2011). Differences in
structure between groups were determined using Adonis (permuted p-
value was obtained by performing 9999 permutations). LDA effect size
was performed between two groups and plotted using LEfSe (Segata
et al., 2011). For further univariate differential abundances analysis,
closely-related taxa were agglomerated at the species rank, reducing the
taxon list to 73. A negative binomial fit model for count data was run on
all groups using the DESeq2 package (v 1.14.1) (Love et al., 2014;
McMurdie and Holmes, 2014). Tests were corrected for multiple in-
ferences using the Benjamini-Hochberg method to control the false
discovery rate (Hochberg and Benjamini, 1990). Complete methods and
accession numbers are available in the Supplementary methods.
2.3. Intestinal permeability in Ussing chambers
Intestinal permeability was assessed as previously described (Riba
et al., 2018). Briefly, jejunal and colonic fragments were mounted in
Ussing chambers (Physiologic Instruments, San Diego, CA, USA). Tis-
sues were bathed 2 h with oxygenated thermostated Kreb’s solution
(Sigma, Saint Quentin Fallavier, France). Fluorescein Sodium Salt
40 µg/ml (FSS 376 Da; Sigma) and Horse Radish Peroxidase 0.4mg/ml
(HRP 4 kDa; Sigma) were respectively added to mucosal compartment
as para- and trans-cellular markers of intestinal permeability.
Epithelial permeability to total HRP was determined by ELISA.
Briefly, 96-wells black plates (Greiner, Les Ulis, France) were coated
with 10 µg/ml mouse polyclonal to HRP (Abcam, Paris, France),
blocked with PBS-1% bovine serum albumin (BSA), incubated with
serosal compartments of Ussing chamber, detected with 10 µg/ml
Rabbit polyclonal anti HRP biotin (Abcam) and revealed with FITC-
conjugated streptavidin (BD, Paris, France). Fluorescence intensity was
measured 485 nm/525 nm using an automatic Infinite M200 microplate
reader (Tecan, Männedorf, Switzerland). Epithelial permeability to FSS
was determined by measuring the fluorescence intensity (FI) 485 nm/
525 nm using an automatic Infinite M200 microplate reader.
Permeability was calculated as the ratio of flux/concentration, and
expressed as cm/second.
2.4. Immune cells isolation
Splenocytes were isolated through a 70-µm nylon mesh and sus-
pended in PBS 1%-KO SR serum (Gibco, Thermofisher Scientific).
Isolated cells from Small Intestines (si) lamina propria (siLP) were
obtained as follow: si were washed in cold PBS, incubated in PBS 3mM
EDTA (Sigma), washed in warm PBS, digested with 100 U/mL of col-
lagenase (Sigma) in DMEM 20% FCS and finally purified on Percoll
(Sigma).
2.4.1. Fluorescence-Activated cell sorter analysis
Isolated cells from spleen and siLP were stained as follow (all an-
tibodies are listed in Table 1). Activated T-cells: CD4 (BD), CD44 (BD),
CD62L (BD); Regulatory T-cells: CD4 (BD), CD25 (BD), Foxp3
(ebioscience, Thermofisher Scientific); ILC3: CD127 (BD), RORγt (BD).
Th17/22 CD3 (BD), RORγt (BD), IL-17 (BD). MACSQuant® Analyzers
(Miltenyi Biotec SA, Paris, France) and VenturiOne® (AppliedCyto-
metry, Sheffield, Great Britain) software were respectively used for data
collection and analysis.
2.4.2. Primary cell culture
Isolated cells from spleen and siLP were seeded at 2×106 cells per
well in the presence or absence of a) 100 ng/mL Lipopolysaccharide
(LPS; Sigma) or b) 5 µg/mL hamster anti-mouse CD3 (BD) and hamster
anti-mouse CD28 (BD) coated wells. Supernatants were collected after
a) 24 h, b) 72 h.
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2.5. Cytokines measurement
Cytokines were measured in supernatant of primary cell culture, or
jejunal fragments suspended in RIPA buffer (0.5% deoxycholate, 0.1%
SDS and 1% Igepal in TBS) containing complete anti protease cocktail
(Sigma). Jejunal protein concentrations were measured using BCA up-
tima kit (Interchim, Montlucon, France). IL-17, TNFα, IL-10, IL-22,
TGFβ and IFNγ in supernatant or lysate of jejunal fragments were as-
sayed using commercial ELISA kits (R&D Systems, Lille, France).
2.6. Humoral response in feces and plasma
Plates were coated with 5 µg/ml of sheep anti-mouse IgA (Sigma) or
goat anti-mouse IgG (SouthernBiotech, Cliniscience, Nanterre, France),
incubated with plasma, detected with 1.5 µg/ml HRP-conjugated goat
anti-mouse IgA (Sigma) or goat anti-mouse IgG (SouthernBiotech), HRP
was revealed using TMB and the reaction was stopped with H2SO4
before reading at 450 nm using automatic Infinite M200 microplate
reader.
Immunoglobulin specificity against commensal E. coli
Maxisorp 96-wells plates were coated with 5 µg/ml of protein from
C3H/HeN isolated E. coli lysate (being used as representative bacteria
of the intestinal microbiota), incubated with plasma (10 µg/mL IgG),
and revealed as above-mentioned. Results were expressed as arbitrary
units (AU) per 10 µg/mL of IgG, in comparison with a standardized
immune serum. The E. coli lysate was prepared as previously described
(Riba et al., 2018).
2.7. Measurements in plasma
ELISA kits were used to monitor corticosterone (Immunodiagnostic
Systems, Pouilly-en-Auxois, France), GIP, GLP-1 (Merck Millipore),
Ghrelin (elabioscience, Clinisciences) and LPS-binding protein (LPB)
(Abnova, Cliniscience) in plasma. Plasma-cholesterol, LDL, HDL, tri-
glycerides, free fatty acids and calcium were analyzed by the Platform
GenoToul Anexplo, Toulouse, France.
2.8. Statistical analysis
Statistical analyses were performed using GraphPad Prism version
6.04 (GraphPad Software, La Jolla, CA, USA). Results for single com-
parisons were displayed as box plots [min to max] and analyzed using
Student’s unpaired t-test or Mann-Whitney test after prior Shapiro-Wilk
Normality test and F-Test to compare variances. Results in text were
described as MS mean ± SD vs. Control mean ± SD for normally
distributed samples and as median, [25%-quartile; 75%-quartile] in
other case. Multiple conditions in OGTT, ITT and cytokine measure-
ments were displayed either as kinetics with SEM or box plots [min to
max] and compared per family by Holm-Sidak posttest after a sig-
nificant repeated measures (RM) two-way ANOVA. Differences were
considered significant for P < 0.05.
3. Results
3.1. MS’s effects on glucose tolerance and insulin sensitivity
At post-natal-day 350 (PND350), MS did neither affect body weight
(Fig. 1A) or the perigonadal-adipose-tissue-weight (PGAT)-to-body-
weight-ratio (data not shown) nor feed intake (Fig. 1B). However, MS
mice had higher fasted blood glucose than the control mice (127.0mg/
dL ± 23.5 vs. 101.1 mg/dL ± 22.3, t13=2.175, p < 0.05, two tailed
t-test, Fig. 1C). During oral glucose tolerance test (OGTT), blood glu-
cose levels were higher in MS mice than in control (at 15min: 270mg/
dL ± 57, vs. 227mg/dL ± 57, p < 0.0001; at 30min: 211mg/
dL ± 47 vs. 178mg/dL ± 30, F1,49=6.668, RM-two-way ANOVA
followed by Holm-Sidak’s post test, p < 0.01, Fig. 1D). The Area Under
the Curve (AUC) during OGTT for MS mice were higher (21353mg/dL/
2h, [20460; 24068], vs. 20022mg/dL/2h, [18376; 21866],
t49=2.463, p < 0.05, two tailed t-test, Fig. 1E). MS did affect neither
fasted nor glucose-stimulated insulin secretion (Fig. 1F). Insulin toler-
ance test (ITT) suggests lower insulin sensitivity for MS mice. Slower
decrease of blood glucose (at 15min: 136.5 mg/dL ± 27.6, vs.
105.1 mg/dL ± 26.1, p < 0.01; at 30min: 97.9 mg/dL ± 24.5 vs.
69.7 mg/dL ± 15.6, F1,28=7.365, RM-two-way ANOVA followed by
Holm-Sidak’s post test, p < 0.01, Fig. 1G), resulted in significantly
higher Area Under the Curve (AUC) for MS mice (3997mg/dL/
30min ± 162,8 vs. 3306mg/dL/30min ± 139,2, t28=3.105, two
tailed t-test , p= 0.0043, Fig. 1H). In plasma, no difference in corti-
costerone (Fig. 2A), incretins (GIP, GLP-1) (Fig. 2B and C), cholesterol,
HDL, LDL, triglycerides or free fatty acids (FFA) (Fig. 2D–H) levels was
observed. However, MS significantly increased ghrelin in plasma
(0.61 ± 0.13, n= 10 vs. 0.50 ± 0.05, t18=2.496, two tailed t-test,
p= 0.0279, Fig. 2I) at PND350.
3.2. Effect of MS on fecal microbiota
Despite the bacterial community richness indicated by the α-di-
versity richness index showed no significant change between MS mice
and control group (230 OTUs ± 5.86, vs 244 ± 8.56; t14=1,409,
two-tailed t-test, n= 9) (Fig. 3A), β-diversity indices revealed altera-
tions in the taxonomic bacterial community structure in MS compared
to control mice. Indeed β-diversity determined using both unweighted
and weighted Unifrac distances was altered in response to early life
stress (F1,14=3,775; p=0.0002 and F1,14=2,71; p=0.043 respec-
tively) (Fig. 3B). As compared to weighted Unifrac distance, use of the
unweighted Unifrac distance revealed a more pronounced separation
between mice groups, suggesting that abundant OTUs in both groups
are phylogenetically close and that MS-induced alterations mainly af-
fect OTUs with lower abundance. These findings were confirmed by
OTUs prevalence visualization (Supplementary Fig. 1A) and by ex-
amination of differences at each taxonomic rank using LEfSe analysis
(Fig. 3C, Supplementary Fig. 1B). No appreciable differences at the
taxonomic level of phyla was indeed observed between MS mice and
control group. However, community composition of MS mice was in-
creased in both Betaproteobacteria and Gammaproteobacteria classes
within the Proteobacteria phylum, as well increased in Bacteroidaceae
and Enterococcaceae families within the Bacteroidetes and Firmicutes
phyla respectively. Reduced abundance in Rikenellaceae and additional
taxa mainly among Lachnospiraceae family was observed in MS mice as
Table 1
Antibodies.
Antibody Company Reference Working
concentration
Anti-CD3-FITC BD 553062 dil 1/200
Anti-CD3 BD 555273 5 µg/mL
Anti-CD4-PE BD 553730 dil 1/200
Anti-CD25-PE-Cy7 BD 552880 dil 1/100
Anti-CD28 BD 553295 5 µg/mL
Anti-CD44-APC-Cy7 BD 560568 dil 1/200
Anti-CD62L-PE-Cy7 BD 560516 dil 1/500
Anti-CD127-AF488 BD 561533 dil 1/50
Anti-FoxP3 PerCP-
Cy5.5
eBioscience 45-5773-82 dil 1/100
Anti-RORgT-A647 BD 562682 dil 1/100
Anti-IL17-PE BD 559502 dil 1/100
Anti-mouse-Ig Southern Biotech 1010-01 5 µg/mL
Anti-mouse-IgG-HRP Southern Biotech 1030-05 dil 1/8000
Anti-mouse-IgA Sigma M-1272 5 µg/mL
Anti-mouse-IgA-HRP Sigma A4789 1.5 µg/mL
Anti-HRP Abcam 34961 10 µg/mL
Anti-HRP-biotin Abcam 195239 1.6 µg/mL
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compared to control mice (Supplementary Fig. 1B). Once agglomerated
at the species rank, differential abundance analysis using DESeq size
factors revealed that taxa significantly enriched in MS mice were pa-
thobionts, i.e. Bacteroides vulgatus, Proteus mirabilis, Enterococcus fae-
calis, Escherichia coli, and unidentified species belonging to Para-
sutterella and Bacteroides genus, whereas one unclassified taxa
belonging to commensal Lachnospiraceae (among 11 additional dif-
ferent unclassified Clostidiales members at the OTUs level) was sig-
nificantly enriched in control mice (q-values < 0.05; Fig. 3D,
Supplementary Fig. 1C, Table 2). In sum, alterations in structure and
composition observed in fecal microbiota of MS mice at PND350 meet
the definition of dysbiosis proposed notably by Peterson and Round
(Petersen and Round, 2014), i.e. a disturbance in the microbiome
structure that may consist in a loss of beneficial microorganisms, and/
or expansion of pathobionts or harmful microorganisms.
3.3. Repercussions of MS on intestinal permeability
We then wondered if MS could have long lasting consequences on
intestinal barrier. First, translocation of intestinal bacterial fragments
was assessed indirectly by LPS Binding Protein (LBP) concentrations in
plasma (Abad-Fernández et al., 2013), without modification in MS mice
(Fig. 4A). Additionally, we addressed intestinal permeability ex-vivo in
Ussing chambers in jejunum (Fig. 4B–D) and colon (data not shown).
No difference for electrical resistance, para- (Fluorescein Sodium Salt,
FSS) and trans-cellular permeability (Horse Radish Peroxidase, HRP)
was observed between MS and control mice.
3.4. Effects of MS on intestinal immune system
Even though MS had no consequences on intestinal permeability,
we wondered if humoral immune response was altered. Fecal IgG
concentrations were decreased in MS mice compared to control mice
(0.1078 µg/mg fecal protein [0.0375; 0.1625] vs. 0.2018 µg/mg fecal
Fig. 1. MS induced oral glucose intolerance associated with a loss of insulin sensitivity at PND350. (A) Body weight (g), n= 24–28. (B) Feed intake (g)/animal/week,
n= 8–9, (C) 16-h fasted blood glucose levels (mg/dL), n= 7–8, unpaired t-test, *p < 0.05. (D) Oral glucose tolerance test, after 6-h fasting, gavage with 2mg
glucose/g bodyweight at 0, blood glucose (mg/dL) from −30min to 120min, n=23–28, RM-two-way-ANOVA, **p < 0.01, ****p < 0.0001. (E) Area under the
curve of blood glucose 0–120min (mg/dL/2h), n=23–28 Mann-Whitney test, *p < 0.05. (F) Plasma insulin (ng/mL) after 6-h fasting and 15min after oral glucose
stimulation (2mg glucose/g bodyweight). (G) Insulin tolerance test, after 6-h fasting, intraperitoneal injection of 0.75mU insulin/g bodyweight at 0, blood glucose
(mg/dL) from−30min to 30min, n= 13–17, RM- two-way-ANOVA, **p < 0.01. (H) Area under the curve of blood glucose 0–30min (mg/dL/30min), n= 13–17,
unpaired t-test, **p < 0.01.
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protein [0.1066; 0.3825], t82=3.044, two tailed t-test p= 0.0006,
Fig. 5A). However, fecal IgA content was not different (Fig. 4B). Plas-
matic IgG and IgA concentrations were similar between both groups
(Fig. 5C and D) whereas anti-E. coli IgG representing humoral response
toward commensal microbiota were significantly increased in plasma of
MS mice (673 AU/10 µg/ml IgG [362.7; 904.8], vs. 449.4 AU/10 µg/ml
IgG [274.6; 754.5], t80=2.145, two tailed t-test, p= 0.0362, Fig. 5E).
We analyzed cellular immune response in the siLP. Percentage of
Rorγt+ in CD3+ was not affected by MS (Fig. 6A). Innate Lymphoid
Cells 3 (ILC3: CD127+ RORγt+) (Fig. 6B) and regulatory T cells (Treg:
CD25+ Foxp3+ in CD4+) (data not shown) were not altered in MS
mice. Fluorescence intensity of IL-17 on Th17 cells (CD3+ RORγt+ IL-
17+) was significantly decreased for MS mice suggesting lower IL-17
production (3428 IF IL-17 ± 1567 vs. 7854 IF IL-17 ± 2599,
t5=2.836, two tailed t-test, p= 0.0364, Fig. 6C). Furthermore, IL-17
secretion in response to TCR stimulation (anti-CD3/28) (Fig. 6D) and
IL-17 in jejunal tissue (Fig. 6E) were decreased in MS mice (TCR sti-
mulation: 2191.3 pg/ml ± 1583 vs. 4753.8 pg/ml ± 3635,
F1,21=4.610, RM-two-way ANOVA followed by Holm-Sidak’s post test,
p < 0.01; jejunal tissue: 30.98 pg/mg ± 19.1 vs. 49.36 pg/mg ±
21.1, t20=2.145, two tailed t-test p= 0.0444). IFNγ-secretion was not
modified by MS (Fig. 6F). Nevertheless, IL-10 and IL-22-secretion in
response to TCR-stimulation was significantly decreased in isolated LP
cells from MS mice as observed for IL-17 (IL-22: 2013.4 pg/ml ± 800
vs. 4597.7 pg/ml ± 1115, F1,21=3.028, RM two-way ANOVA fol-
lowed by Holm-Sidak’s post test, p < 0.05 Fig. 6G and H; IL-10:
709.8 pg/ml ± 961 vs. 2045.1 pg/ml ± 2056, F1,15=2.969, RM-two-
way ANOVA followed by Holm-Sidak’s post test, p < 0.05). Ad-
ditionally, IL-10 concentrations were decreased in jejunum of MS mice
(82.82 pg/mg ± 45.8 vs. 138.7 pg/mg ± 33.6, t23=3.454, two tailed
t-test, p= 0.0022; Fig. 6I), whereas IL-22 were non-detectable and
TGFβ similar in both groups (data not shown). TGFβ-secretion in re-
sponse to TCR stimulation was not modified by MS (data not shown).
Finally, TNFα-secretion in response to LPS-stimulation was slightly but
significantly increased in cells from MS mice (32.25 pg/ml ± 32.06 vs.
11.54 pg/ml ± 13.02, F1,21=2.996, RM-two-way ANOVA followed by
Holm-Sidak’s post test, p < 0.05, Fig. 6J).
3.5. MS’s effects on systemic immune response
We next assessed the systemic consequences of MS. Activated T cells
(CD4+ CD44high CD62Llow) (Fig. 7A) and regulatory T cells (CD4+
CD25+ foxp3+) (Fig. 7B) populations in spleen were not modified by
MS. Regarding functionality, IFNγ and IL-10-secretion in response to
Fig. 2. Plasmatic measurements in MS and control mice at PND350. (A) Basal plasma corticosterone levels (ng/mL) at PND350, n= 19–27. (B) Plasma GIP (pg/mL),
n= 22–27. (C) Plasma GLP1 (pM) in anti-DPP4 treated plasma, n=15–23. (D) Plasma cholesterol (mmol/L), n=15. (E) Plasma LDL (mmol/L), n=15. (F) Plasma
HDL (mmol/L), n=15. (G) Plasma triglycerides (mmol/L), n=15. (H) Plasma free fatty (FFA) acids (mmol/L), n= 10. (I) Ghrelin (ng/mL), n= 10, unpaired t-test
with Welch’s Correction, *p < 0.05.
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TCR-stimulation were not modified by MS (Fig. 7C and D). However, IL-
17 secretion was diminished in response to TCR-stimulation
(4249.81 pg/ml ± 1902.5 vs. 6590.09 pg/ml ± 4659.7,
F1,33=3.348, RM-two-way ANOVA followed by Holm-Sidak’s post test,
p < 0.05, Fig. 7E). TNFα-secretion in response to LPS-stimulation was
slightly but significantly increased in splenocytes of MS mice
(243.81 pg/ml ± 116.7, vs. 197.30 pg/ml ± 50.8, F1,46=4.293, RM-
two-way ANOVA followed by Holm-Sidak’s post test, p < 0.05,
Fig. 7F). Overall, MS-induced immunological perturbations followed
the same tendency at systemic and intestinal level.
4. Discussion
This study shows, for the first time, that early life stress is a risk
factor for glucose intolerance and loss of insulin sensitivity in ageing
wild-type mice under normal diet. In this model, glucose intolerance
was associated with microbiota dysbiosis, systemic response against
microbiota and decrease of IL-17 and IL-22 response in the intestine.
We previously observed that MS triggered features of Irritable
Bowel Syndrome (IBS) in young adult C3H/HeN male mice (PND50):
visceral hypersensitivity, intestinal hyperpermeability, low-grade
inflammation, defect of Paneth cells and microbiota dysbiosis (Riba
et al., 2018). As those features, apart of visceral hypersensitivity, are
also observed in metabolic disorders, we wondered if MS could trigger
metabolic disorders with ageing as metabolic disorders are ageing re-
lated diseases. This hypothesis was strengthened by epidemiological
study showing that both, stress and IBS, are positively correlated with
higher HbA1c (glycated hemoglobin) in patients suffering from type 2
diabetes (Badedi et al., 2016) indicating worse glycemic control. Fur-
thermore, epidemiological studies showed that IBS is related to meta-
bolic disorders independently of dietary patterns (Gulcan et al., 2009;
Guo et al., 2014). At PND350, MS induces glucose intolerance asso-
ciated with a loss of insulin sensitivity. Stress hormones (glucocorti-
coids) known to regulate metabolism (Schäcke et al., 2002) like corti-
costerone are not affected by MS at PND350 excluding a direct effect of
corticosterone on the observed metabolic phenotype.
Scattering evidences suggesting consequences of MS on metabolism
have already been published. MS alone did not induce glucose intol-
erance in 8-months-old Sprague-Dawley male rats, but diminished in-
sulin receptor expression in muscle and serum IGF-1 levels (Ghosh
et al., 2016). However, Sprague-Dawley rats submitted to MS combined
with post-weaning social isolation developed glucose intolerance at
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Fig. 3. MS induced fecal microbiota dysbiosis in favor of pathobionts. (A–E) 16S rRNA gene illumina Miseq sequences analysis, n= 7–9. (A) Chao-1 diversity index in
male PND350 mice. (B) Unweighted and weighted Unifrac Multidimentional Scaling (MDS) plot representing structural changes in bacterial community composition
in MS and control mice. (C) Circular cladogram generated from LEfSe analysis showing the most differentially abundant taxa enriched in microbiota from control
mice (red) or MS mice (green). LDA scores> 3 and significance alpha< 0.05 determined by Kruskal-Wallis test. (D) Classified differentially abundant taxa between
MS and control mice. Log2FoldChange (MS vs. Control)= log2(MS/Control) is plotted on the Y-axis. Phylum is indicated using color codes. Features were considered
significant if their adjusted post test p-value was<0.05. Key: a: Bacteroides vulgatus, b: Bacteroides spp., c: Odoribacter spp., d: Rikenellaceae RC9 gut group, e:
Enterococcus faecalis, f: Enterococcus spp., g: Lactococcus reuteri, h: Familly XIII UCG-006, j: Eubacterium xylanophilum, k: Peptococcus spp., l: Unlc. Ruminoclostridium 5,
m: Uncl. Ruminoclostridium 6, n: Unlc. Ruminococcus 1, o: Parasutterella spp., p: Bilophila spp., q: Escherichia coli, r: Escherichia shigella genus, s: Proteus mirabilis, t:
Proteus spp. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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PND180, involving increased corticosterone levels (Vargas et al., 2016)
reinforcing the idea that long-lasting perturbations of metabolic
homeostasis could enhance the risk for metabolic dysfunctions through
higher vulnerability to additional risk factors (Ghosh et al., 2016). Fi-
nally, shorter MS protocol (5 days, 90 minutes per day) increased body
weight as well as glucose and insulin response after arginine-stimula-
tion in male Sprague-Dawley rats aged between PND105 and PND133
(Gehrand et al., 2016).
Interestingly, in our study, the MS-induced glucose intolerance and
loss of insulin sensitivity were not associated with changes in body
weight. This is of particular interest as in human, type 2 diabetes are
not always associated with obesity (Carnethon, 2014; Zou et al., 2017).
Neither plasmatic markers mainly involved in metabolic disorders
(FFA, triglycerides, cholesterol, HDL, LDL) nor incretins, like GLP-1 and
GIP, were modified by MS at PND350. However, ghrelin, a satiety
hormone, was significantly increased in MS mice compared to control
without modification of food intake. In ob/ob mice loss of ghrelin
production significantly raised insulin secretion restoring peripheral
insulin sensitivity, thus improving glucose homeostasis (Sun et al.,
2006). So, in our model increase of ghrelin might contribute to the
glucose intolerance and the loss of insulin sensitivity.
MS consequences on metabolic disorders were associated with mi-
crobiota dysbiosis. Microbial signature at PND350 in response to MS
displayed similitudes with signature previously observed in patients
with type 2 diabetes, that was mainly characterized by a moderate
degree of enrichment in Bacteroidetes (mainly explained by a bloom in
Bacteroides genus) and Betaproteobacteria, associated with a decrease in
Clostridia within Firmicutes phylum (Larsen et al., 2010; Leite et al.,
2017; Pedersen et al., 2016). As previously observed in type 2 diabetic
patients, using a metagenome-wide association study (Qin et al., 2012),
microbiota dysbiosis in response to MS at PND350 was also mainly
driven by pathobionts like Bacteroides vulgatus, Enterococcus faecalis as
well as Enterobacteriaceae such as Proteus mirabilis and Escherichia coli
(Leite et al., 2017; Cuív et al., 2017; Seo et al., 2015). B. vulgatus and E.
coli are suspected to drive insulin resistance via branched-chained
amino acids (Leite et al., 2017; Pedersen et al., 2016). Interestingly, MS
increased Bacteroides spp. and especially the species B. vulgatus as ob-
served in type 2 diabetic patients, and directly associated with a loss of
insulin sensitivity (Leite et al., 2017; Pedersen et al., 2016).
The microbiota dysbiosis observed at PND350 is not associated with
intestinal permeability changes. Increased intestinal permeability is
positively correlated with HOMA index in obese patients and (Teixeira
et al., 2012) in high-fat diet (HFD) mice model (Cani et al., 2008).
Furthermore, intestinal hyperpermeability is pointed out as a factor
leading to endotoxemia that might contribute to low-grade inflamma-
tion and triggering metabolic disorders (Cani et al., 2007). A normal
intestinal permeability in our model could be due to the absence of
obesity. Indeed, intestinal hyperpermeability has been described in
complex metabolic disorder i.e. type 2 diabetes associated with obesity
in mice and human model but never in type 2 diabetes in lean in-
dividuals. In mouse model of HFD-induced intestinal hyperpermeability
associated with an increase of HOMA index, restoring intestinal per-
meability by fish oil treatment or resolvin D1 did not improve HOMA
index (Lam et al., 2015), suggesting that correcting intestinal perme-
ability is not sufficient to ameliorate metabolic status. Cells isolated
from small intestine and spleen of MS mice at PND350 secrete higher
TNFα concentration in response to LPS in vitro stimulation compared to
control mice. Interestingly, childhood victimization is correlated with
higher plasmatic CRP levels in young adult in human (Baldwin et al.,
2017). Until today, there is no consensus among scientists if low-grade
inflammation is cause or consequence of metabolic disorder. On one
hand, obesity leads to low-grade inflammation through the exceeding
production of inflammatory molecules by white adipose tissue (Gregor
and Hotamisligil, 2011) whereas, on the other hand, endotoxemia can
induce obesity and insulin resistance (Cani et al., 2007). MS also de-
creased IgG in feces adding evidence to impaired intestinal barrierTa
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despite no modification of intestinal permeability. This defect is also
reflected by higher TNFα in response to LPS in siLP and spleen, as well
as by higher anti-E. coli IgG in plasma. Interestingly, IgG against com-
mensal antigens were increased in diabetic patients (Mohammed et al.,
2012).
In our model, intestinal IL-17 and IL-22 and systemic IL-17 secre-
tions were impaired after TCR stimulation. The defect of IL-17 and IL-
22 secretion is not due to modification of populations, but rather to a
misfunction of Th17 and Th22 cells. The observed decrease of IL-17 and
IL-22 secretion is of particular interest since it was also observed in
Fig. 4. MS had no consequences on intestinal permeability. (A) LBP concentration in plasma (ng/mL) n= 9–10. (B–D) Ex vixo Ussing chambers experiment in
jejunum (B) Electrical resistance (Ω×cm2), n= 14–21. (C) Paracellular permeability to FSS (×10−7 cm/s), n= 14–19. (D) Transcellular permeability to HRP
(×10−8 cm/s), n= 7–11.
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Fig. 5. MS decreased fecal IgG and increased anti-E. coli IgG in plasma. (A) Fecal IgG content (µg/mg fecal protein), n= 38–46, Mann Whitney test, ***p < 0.001.
(B) Fecal IgA content (µg/mg fecal protein), n=41–50. (C) Plasma IgG concentration (µg/mL), n= 36–42. (D) Plasma IgA concentration (µg/mL), n=37–46. (E)
Plasmatic IgG against E. coli lysate (arbitrary units/10 µg/mL IgG), n=36–46, Mann Whitney test, *p < 0.05.
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other models of hyperglycemia induced by nutritional challenge and
genetically engineer. Indeed, HFD leading to obesity and type 2 dia-
betes are associated with a decrease of intestinal Th17 and Th22
populations (Garidou et al., 2015; Hong et al., 2017; Wang et al., 2014).
Furthermore, RORγt KO mice deficient for Th17/22 cells present a mild
glucose intolerance (Garidou et al., 2015). The direct or indirect
Fig. 6. MS impaired IL-17 and IL-22 secretion and increased TNFα in small intestine lamina propria (siLP). (A) Representatives dot plots of CD3+RORγt+ cells of siLP,
n= 3–4, unpaired t-test. (B) ILC3 in isolated siLP (RORγt+ in CD127+), n= 8–7. (C) Median fluorescence intensity of IL-17 on T helper 17 cell population
(CD3+RORγt+ cells) of siLP, n=3–4, unpaired t-test, *p < 0.05. (D, F–H) Cytokine secretion in siLP cell culture after 72 h without or with anti-CD3/CD28 (5 µg/
mL) stimulation. (D) IL-17, n=11–12. (F) IFNγ, n= 23. (H) IL-10, n=9–10. (G) IL-22, n=10–12, RM two-way ANOVA, *p < 0.05, **p < 0.01. (E, I) Cytokine
concentration (pg/mg protein) in jejunal tissue. (E) IL-17, n=11 (I) IL-10, n= 12–13, unpaired t-test, *p < 0.05, **p < 0.01. (J) TNFα secretion in siLP cell
culture after 16 h with or without LPS (100 ng/mL) stimulation, n=10–13, RM two-way ANOVA, * p < 0.05.
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increase of IL-22 moderates metabolic disorder induced by HFD (Wang
et al., 2014; Zou et al., 2017) and restores microbiota (Gulhane et al.,
2016; Zou et al., 2017) and intestinal barrier (Gulhane et al., 2016).
Taking together the results of this study show that MS in wild type
mice under normal diet induces glucose intolerance associated with a
loss of insulin sensitivity. Interestingly, glucose intolerance in MS
model is associated with a decrease of intestinal IL-17 and IL-22 se-
cretion as previously observed in studies of HFD-induced metabolic
disorders. Consequently, MS induce the same adverse effects as HFD,
without obesity and intestinal hyperpermeability. Finally, this study
highlights early life stress as a risk factor for metabolic disorders de-
velopment independently of nutritional challenge and early life period
as critical time window for appropriate establishment of immune
system and metabolism.
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SUPPLEMENTARY METHODS 
16S rRNA Amplification and Amplicon Sequencing 
The microbial 16S rRNA gene was amplified during the first PCR step with adapter fusion 
primers targeting the V3 to V4 regions (corresponding to a 460-bp region of Escherichia coli 
16S rRNA gene, GenBank number J01695). The forward PCR primer 5’CTT TCC CTA CAC 
GAC GCT CTT CCG ATC TAC GGR AGG CAG CAG3’ was a 43-nuclotide fusion primer 
consisting of the 28-nt illumina adapter (designed by bold font) and the 14-nt broad range 
bacterial primer 343F (Liu et al., 2007). The reverse PCR primer 5’GGA GTT CAG ACG 
TGT GCT CTT CCG ATC TTA CCA GGG TAT CTA ATC CT3’ was a 47-nuclotide fusion 
primer consisting of the 28-nt illumina adapter (designed by bold font) and the 19-nt broad 
range bacterial primer 784R (Andersson et al., 2008).  
The PCR mix contained MTP Taq DNA polymerase (SIGMA, 0,05 U/µl), 200 µM of each 
DNTP (SIGMA, premix), and 0,5 µM of each primer. After initial denaturation at 94°C for 60 
sec in CFX-96 Thermal Cycler (Bio-Rad), 30 cycles were run with 60 sec denaturation at 94°C, 
60 sec annealing at 65°C and 60 sec at 72°C.Round ended with 10 min extension at 72°C. 
Pooled amplicon libraries were sequenced employing an Illumina MiSeq (2 x 250 bp) at the 
GeT-PlaGe platform in Toulouse (France). Amplification quality (length, quantity and 
specificity) was verified using the Agilent 2200 Tapestation system (High sensitivity D1000 
ScreenTape Assay) and AATI Fragment Analyser at the GeT (Genomic and Transcriptomic, 
TRIX and PlaGe) platforms in Toulouse. The quality of the run was checked internally using 
PhiX, and then each pair-end sequences were assigned to its sample with the help of the 
previously integrated index. 
Microbiome 16S Data Analysis 
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High quality filtered reads were further processed using FROGS pipeline (Find Rapidly OTU 
with Galaxy Solution (Escudié et al., 2017)) to obtain OTUs and their respective taxonomic 
assignment thanks to Galaxy instance (http://sigenae-worbench.toulouse.inra.fr): Initial 
FROGS pre-process step allowed to select overlapped reads with expected length without N. 
Swarm clustering method (Mahé et al., 2014) was applied by using a first run for denoising 
with a distance of 1 and then a second run for clustering with an aggregation maximal distance 
of 3 on the seeds of first Swarm. Putative chimera were removed using Vsearch combined to 
cross-validation (GitHub repository. Doi 10.5281/zenedo.15524).  
Cluster abundances were filtered at 0,005% (Bokulich et al., 2013) and/or had to be present at 
least in 2 samples, yielding to  316 clusters corresponding to 308625 final valid reads. Between 
13 339 and 22 656 valid sequences per sample were counted (no significant difference between 
groups was noticed; p=0.421, unpaired t test with equal SD). 100% of clusters were affiliated 
to OTU by using a silva128 16S reference database and a taxonomic multi-affiliation procedure 
(Blast+ (Camacho et al., 2009) with equal multi-hits). Since rarefaction has shown to result in 
high rates of false positive tests for differential abundance (McMurdie and Holmes, 2014), 
counts were not rarefied.  
OTU prevalence, rarefaction curves were plotted for each sample by using Phyloseq package 
(v 1.19.1, Figure 3, Supplementary Figure 1A). Within sample community, alpha diversity was 
assessed by Chao-1 index. Divergence in community composition between samples was 
qualitatively and quantitatively assessed by calculating both unweighted (an investigation into 
the presence and absence of taxa) and weighted (which takes relative abundances of taxa in 
account) Unifrac distance matrices. Unconstrained ordination was visualized using 
multidimensional scaling (MDS) and hierarchical clustering (complete linkage combined with 
Unifrac distance, Supplementary Figure 1A) and compared using Adonis test (9999 
permutations). 
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In order to determine features at each phylogenetic rank that characterize fecal microbiota of 
PND350 mice in response to maternal separation, LEfSe algorithm (Segata et al., 2011) was 
performed with an alpha value of 0.05 (Kruskall-Wallis non parametric pairwise comparisons) 
and a threshold on the logarithmic LDA score for discriminative features of 2.  
OTUs were agglomerated at the species rank  before univariate differential abundance of taxa 
was obtained using a negative binomial noise model for over dispersion as implemented in the 
R package DESeq2 (v 1.14.1) (Love et al., 2014; McMurdie and Holmes, 2014). Taxa were 
considered significantly differentially  
abundant between treatments if their adjusted p-value was below 0.05.  
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LEGENDS SUPPLEMENTARY FIGURES 
Supplementary Figure 1: MS induces gut dysbiosis in offspring at PND350. (A) Prevalence 
per OTUs in samples associated with hierarchical clustering based on the Unifrac distances 
with Ward linkage. (B) Histogram of the LDA scores computed for affiliated OTUs that were 
found differentially abundant between MS and control mice. The magnitude of the LEfSe scores 
higher than 3 and p < 0.05 are displayed. Differences are represented in the color of the most 
abundant class. (C) Relative abundance of taxa agglomerated at the species rank that were 
found differentially abundant using Deseq2 analysis, adjusted p-value < 0.05. 
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Additional data 
Lysozyme activity is resolved at PND350 
At PND50 MS induced in male mice intestinal barrier dysfunction, namely intestinal 
hyperpermeability, decreased fecal lysozyme activity and increased fecal IgA (Riba et al., 
2018). In my article (Ilchmann-Diounou et al., 2019) we showed, that intestinal permeability is 
restored at PND350. We wondered if lysozyme activity in PND350 mice is still modified. Feces 
were collected and frozen at -80°C. Activity of lysozyme against peptidoglycan was determined 
using the EnzChek® Lysozyme Assay Kit (Molecular probes, life technology). 
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Figure 23 Resolved parameters of intestinal barrier dysfunctions in maternal separated (MS) or control 
C3H/HeN mice at post-natal day (PND) 350 (A) Lysozyme (LZM) activity in fecal supernatant (U/µg fecal 
protein) of feces measured by ELISA. (B) fecal IgA concentration (µg/mg fecal protein) measured by ELISA. 
At PND350 fecal lysozyme activity in MS and control mice were similar. As a 
consequence, decreased lysozyme activity at PND50 is resolved in time (Figure 23A). Fecal 
IgA were similar between MS and control at PND350 (Figure 23B) but increased at PND50. 
These are arguments that intestinal barrier dysfunction resolves with time. One can hypothesize 
that, the effects of MS on immune-metabolism are due to a delay in intestinal barrier 
development. However, even though intestinal permeability and lysozyme activity are 
corrected, the intestinal immune system is not. Indeed, fecal IgG were diminished by MS at 
PND350 (Ilchmann-Diounou et al., 2019). Furthermore, intestinal low-grade inflammation is 
persisting TNFα secretion in response to LPS stimulation is increased and diminished IL-17 
and IL-22 in siLP show that intestinal immune system in MS mice is distinct from control. The 
delayed maturation of intestinal barrier namely delayed gut closure and delayed lysozyme 
activity could be responsible for a wrong priming of the immune system, leading to long-lasting 
intestinal and systemic low-grade inflammation. 
However, interventional studies are needed to prove this hypothesis. 
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Microbiota dysbiosis is different between PND50 and PND350 
We were interested in evolution of microbiota in our model over the time of the 
experiment. We wondered, if microbiota dysbiosis at PND50 is similar to microbiota dysbiosis 
at PND350. 
We confirmed that the bacterial signature associated with MS was specific of PND350 
mice since bacterial signature observed in PND50 mice was distinct from that of PND350 mice 
(Figure 24A) and not driven by pathobiont expansion (Figure 24B), unlike what we observed 
at PND350 (Ilchmann-Diounou et al., 2019). 
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Figure 24 Bacterial taxonomic patterns that characterize fecal microbiota of PND350 mice and PND50 
mice differ significantly. (A) PLS-DA score plots on the first three components (top panel: X-variates 1 and 2, 
bottom panel: X-variates 1 and 3) built from affiliated OTUs agglomerated at the species rank (74 taxa). Samples 
are classified into four classes: Control mice at PND50 (C-PND50), PND350 (C-PND350) and MS mice at 
PND50 (MS-PND50) or PND350 (MS-PND350). (B) Relative abundance of taxa agglomerated at the species 
rank in PND50 mice. Taxa displayed are not altered by MS at PND50 (adj-p >0.1) despite they were previously 
found differentially abundant using Deseq2 analysis in PND350 mice. (PLS-DA = Partial least square 
discriminant analysis; OUT = operational taxonomic unit)  
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SECOND RESULT: 
ROLE OF MICROBIOTA IN MS-INDUCED GLUCOSE INTOLERANCE  
IN AGING MICE 
 
Work in progress 
 
In collaboration with Olier, Maïwenn; Ilchmann-Diounou, Hanna; Lencina, Corinne; 
Guzylack-Piriou, Laurence; Balvay, Aurélie; Maudet, Claire; Foussier, Anne; Rabot, Sylvie; 
Ménard, Sandrine 
 
Microbiota dysbiosis is described to play a crucial role in the development of various 
non-communicable diseases, including metabolic disorders. The definition of dysbiosis 
proposed notably by Peterson and Round (Petersen and Round, 2014), is a disturbance in the 
microbiome structure that may consist in a loss of beneficial microorganisms, and/or expansion 
of pathobionts or harmful microorganisms.  
Since microbiota is modified in our model of neonatal maternal separation (MS), and a 
tremendous amount of articles showed that microbiota dysbiosis is sufficient to induce 
metabolic disorder in germ-free recipient mice (Bäckhed et al., 2004; Turnbaugh et al., 2006), 
we wondered, if the observed effects of MS are triggered by gut microbiota dysbiosis. Germ-
free mice are the recent gold standard to prof a causal relationship. 
We set up collaboration with the germ-free platform ANAXEM at Micalis and Sylvie 
Rabot of the team Food, Gut Microbiota, Brain and Metabolic Diseases (AMIPEM) at Micalis, 
INRA Jouy en Josas, to carry out fecal microbiota transfer (FMT) of PND350 MS and control 
fecal samples into germ-free (GF) mice. 
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INTRODUCTION 
Intestinal microbiota is an important factor to intestinal homeostasis but more largely 
contribute to the host’s wellbeing. Host and microbiota interact in a symbiotic relationship that 
benefits to both: host and microbiota (Bäckhed et al., 2005). Microbiota dysbiosis is described 
to play a crucial role in the development of various non-communicable diseases, including 
metabolic disorders. The definition of dysbiosis proposed notably by Peterson and Round 
(Petersen and Round, 2014), is a disturbance in the microbiome structure that may consist in a 
loss of beneficial microorganisms, and/or expansion of pathobionts or harmful microorganisms. 
The main issue remaining in microbiota study was to define the ‘healthy” microbiota. This was 
the aim of the first phase of the National Institutes of Health Human Microbiome Project (NIH 
HMP), which started in 2007 (Turnbaugh et al., 2007). Then, the second phase (integrative 
HMP, iHMP or HMP2) aimed to focus on the role of microbiota on the onset of diseases 
including type 2 diabetes (T2D) (Zhou et al., 2019). Before iHMP, obesity and diabetes, were 
described to be associated with gut dysbiosis (Ley et al., 2005; Qin et al., 2012). The strength 
of iHMP in T2D is the following of participants (healthy and pre-diabetics) for 4 years (Zhou 
et al., 2019). This allows to associate microbiome profile to insulin sensitivity status that 
confirm microbiota dysbiosis associated to T2D and might contribute to early detection of T2D 
(Zhou et al., 2019). Those epidemiological studies need to be completed by mechanistic 
experiments to validate causative associations.  
Neonatal maternal separation (MS) has been described to play a role in the development of 
metabolic diseases (Aya-Ramos et al., 2017; Ghosh et al., 2016; Ilchmann-Diounou et al., 
2019). Indeed, MS induces type 2 diabetes-like features in aging, namely fasted hyperglycemia, 
glucose intolerance and insulin resistance, associated with intestinal and systemic low-grade 
inflammation, decreased intestinal IL-17 secretion and increased humoral response against 
microbiota. This immune-metabolic phenotype was associated with fecal dysbiosis (Ilchmann-
Diounou et al., 2019).  
We aimed to address the role of microbiota in MS-induced glucose intolerance. Germ free 
mice raised under axenic condition represent an interesting tool to answer this question. So, we 
set up a fecal microbiota transfer from old mice which underwent or not MS in early life into 
adult germ-free mice. 
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MATERIAL & METHODS 
Mouse model 
The donor mice, conventional, Specific and Opportunistic Pathogen Free (SOPF), C3H/HeN 
male mice, aged post-natal day (PND350), were raised in INRA Toulouse mouse house 
facilities. They are issue of an anterior experiment, experimental protocol and maternal 
separation (MS) procedure were previously described (Ilchmann-Diounou et al., 2019). 
Experimental protocol were approved by local Animal Care Use Committee (Comité d'Ethique 
de Pharmacologie-Toxicologie de Toulouse - Midi-Pyrénées, France) registered as N°86 at the 
Ministry of Research and Higher Education (N° 0029/SMVT), and conducted in accordance 
with the European directive 2010/63/UE. MS and control mice were kept at a constant 
temperature (22 ± 1°C) and maintained on a 12:12 h light/dark cycle (lights on 7h30 am). 
Normal diet (Harlan2018, Envigo, Gannat, France) and water were available ad libitum.  
The germ-free C3H/HeN male were obtained locally from the germ-free rodent breeding 
facility of Anaxem (Germfree animal facilities of the Micalis Institute, France). They were 
housed in sterile Plexiglas isolators (Eurobioconcept, Paris, France). The germ-free status was 
monitored weekly by microscopic examination and aerobic and anaerobic cultures of freshly 
voided feces. All mice were kept in Macrolon cages (38 cm long, 22 cm wide, 21 cm high) 
containing sterile beddings made of wood shavings. They were given a free access to autoclaved 
tap water and a γ-irradiated (45 kGy) normal diet (Harlan2018, Envigo, Gannat, France).The 
isolators were maintained at 20–24°C and on a 12-h light/dark cycle (lights on at 07:30 a.m.). 
Experimental procedures were conformed to the European guidelines for the care and use of 
laboratory animals. They were carried out in accordance with the recommendations of and 
approved by (approvals #10724) the ethics committee of the INRA Research Center at Jouy-
en-Josas (ethics committee named Comethea, registered by the French Ministry in charge of 
Research since 2011/06/30 with reference number 45). 
Colonization of Germ Free mice 
Fecal homogenate of PND350 maternal separated (MS) and control mice were prepared as 
follows. A pool of feces collected from 14 mice was suspended at 1/100 in Ringer solution 
supplemented with 0.05% (w/v) L-cysteine (HCl) and 10% skimmed milk and frozen at -80°C 
prior to use. 
PND150 GF mice were orally inoculated with a 1:100 dilution of fecal homogenate from 
PND350 MS mice, PND350 control mice or vehicle (Ringer solution supplemented with 0.05% 
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(w/v) L-cysteine (HCl) and 10% skimmed milk). Sixteen weeks after colonization, mice were 
used for analysis. Mice that received fecal homogenate from PND350 MS mice are named 
GFMS; from PND350 control mice are named GFC whereas mice receiving the vehicle are 
named GFM (Milk added to Ringer solution) mice. All mice had same age at analysis (150 days 
+ 16 weeks = 262 days). 
Fecal microbiota composition analysis 
Total microbial genomic DNA was obtained from stool samples using the ZR Fecal DNA 
MiniprepTM (Zymo Research, Ozyme SAS, Montigny-le-Bretonneux, France) and DNA 
quantity was determined using a TECAN Fluorometer (Qubit® dsDNA HS Assay Kit, 
Molecular Probes, Thermofisher Scientific, Montigny le Bretonneux).  
16S rRNA Amplification and Amplicon Sequencing 
The microbial 16S rRNA gene was amplified during the first PCR step with adapter fusion 
primers targeting the V3 to V4 regions (corresponding to a 460-bp region of Escherichia coli 
16S rRNA gene, GenBank number J01695). The forward PCR primer 5’CTT TCC CTA CAC 
GAC GCT CTT CCG ATC TAC GGR AGG CAG CAG3’ was a 43-nuclotide fusion primer 
consisting of the 28-nt illumina adapter (designed by bold font) and the 14-nt broad range 
bacterial primer 343F (Liu et al., 2007). The reverse PCR primer 5’GGA GTT CAG ACG 
TGT GCT CTT CCG ATC TTA CCA GGG TAT CTA ATC CT3’ was a 47-nuclotide fusion 
primer consisting of the 28-nt illumina adapter (designed by bold font) and the 19-nt broad 
range bacterial primer 784R (Andersson et al., 2008).  
The PCR mix contained MTP Taq DNA polymerase (SIGMA, 0,05 U/µl), 200 µM of each 
DNTP (SIGMA, premix), and 0,5 µM of each primer. After initial denaturation at 94°C for 60 
sec in CFX-96 Thermal Cycler (Bio-Rad), 30 cycles were run with 60 sec denaturation at 94°C, 
60 sec annealing at 65°C and 60 sec at 72°C.Round ended with 10 min extension at 72°C. 
Pooled amplicon libraries were sequenced employing an Illumina MiSeq (2 x 250 bp) at the 
GeT-PlaGe platform in Toulouse (France). Amplification quality (length, quantity and 
specificity) was verified using the Agilent 2200 Tapestation system (High sensitivity D1000 
ScreenTape Assay) and AATI Fragment Analyser at the GeT (Genomic and Transcriptomic, 
TRIX and PlaGe) platforms in Toulouse. The quality of the run was checked internally using 
PhiX, and then each pair-end sequences were assigned to its sample with the help of the 
previously integrated index. 
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Microbiome 16S Data Analysis 
High quality filtered reads were further processed using FROGS pipeline (Find Rapidly 
OTU with Galaxy Solution (Escudié et al., 2018)) to obtain OTUs and their respective 
taxonomic assignment thanks to Galaxy instance (http://sigenae-worbench.toulouse.inra.fr): 
Initial FROGS pre-process step allowed to select overlapped reads with expected length without 
N. Swarm clustering method (Mahé et al., 2014) was applied by using a first run for denoising 
with a distance of 1 and then a second run for clustering with an aggregation maximal distance 
of 3 on the seeds of first Swarm. Putative chimera were removed using Vsearch combined to 
cross-validation (GitHub repository. Doi 10.5281/zenedo.15524). Cluster abundances were 
filtered at 0,005% (Bokulich et al., 2013) and/or had to be present at least in 2 samples. 100% 
of clusters were affiliated to OTU by using a silva128 16S reference database and a taxonomic 
multi-affiliation procedure (Blast+ (Camacho et al., 2009) with equal multi-hits). Diversity 
indexes of bacterial community, as well as ordinations were computed using the Phyloseq 
package (v 1.19.1) in RStudio software (Mcmurdie and Holmes, 2012; McMurdie and Holmes, 
2013; R Development Core Team, 2011). Divergence in community composition between 
samples was assessed by calculating unweighted (an investigation into the presence and absence 
of taxa) Unifrac distance matrice. Unconstrained ordination was visualized using 
multidimensional scaling (MDS) and compared using Adonis test (9999 permutations). 
Oral glucose tolerance test (OGTT)  
OGTT were performed in mice after 16 h-fasted during night. For OGTT, mice were 
gavaged with 2 mg glucose per g of bodyweight. Blood glucose levels were monitored from 
the tip of the tail vein with a glucose meter (Johnson & Johnson, Issy-les-Moulineaux, France) 
at -30, 0 (glucose gavage), 15, 30, 60, 90 and 120 min.  
For fasted blood glucose, mice were fasted 16-h overnight.  
Intestinal permeability in Ussing chambers 
Intestinal permeability was assessed in jejunal fragments on Ussing chambers. Briefly, 
jejunal fragments were mounted in Ussing chambers (Physiologic Instruments, San Diego, CA, 
USA). Tissues were bathed 2h with oxygenated thermostated Kreb’s solution (Sigma, Saint 
Quentin Fallavier, France). Fluorescein Sodium Salt 40 µg/ml (FSS 376Da; Sigma) was added 
to mucosal compartment as para-cellular marker of intestinal permeability.  
Fluorescence intensity was measured 485nm/525nm using an automatic Infinite M200 
microplate reader (Tecan, Männedorf, Switzerland). Epithelial permeability to FSS was 
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determined by measuring the fluorescence intensity (FI) 485 nm/525 nm using an automatic 
Infinite M200 microplate reader. Permeability was calculated as the ratio of flux/concentration, 
and expressed as cm/second. 
Immune cells isolation 
Splenocytes were isolated through a 70-µm nylon mesh and suspended in PBS 1%-KO SR 
serum (Gibco, Thermofisher Scientific).  
Isolated cells from Small Intestines (si) lamina propria (siLP) were obtained as follow: si 
were washed in cold PBS, incubated in PBS 3 mM EDTA (Sigma), washed in warm PBS, 
digested with 100 U/mL of collagenase (Sigma) in DMEM 20% FCS and finally purified on 
Percoll (Sigma). 
Primary cell culture  
Isolated cells from spleen and siLP were seeded at 2x106 cells per well in the presence or 
absence of 5 µg/mL hamster anti-mouse CD3 (BD) and hamster anti-mouse CD28 (BD) coated 
wells. Supernatants were collected after 72h.  
Cytokines measurement 
Cytokines were measured in supernatant of primary cell culture, or jejunal fragments 
suspended in RIPA buffer (0.5% deoxycholate, 0.1% SDS and 1% Igepal in TBS) containing 
complete anti protease cocktail (Sigma). Jejunal protein concentrations were measured using 
BCA uptima kit (Interchim, Montlucon, France). IL-17, IFNγ, and IL-22 in supernatant or 
lysate of jejunal fragments were assayed using commercial ELISA kits (R&D Systems, Lille, 
France).  
Humoral response in feces and plasma 
Plates were coated with 5 µg/ml of sheep anti-mouse IgA (Sigma) or goat anti-mouse IgG 
(SouthernBiotech, Cliniscience, Nanterre, France), incubated with plasma, detected with 1.5 
µg/ml HRP-conjugated goat anti-mouse IgA (Sigma) or goat anti-mouse IgG 
(SouthernBiotech). HRP was revealed using TMB and the reaction was stopped with H2SO4 
before reading at 450 nm using automatic Infinite M200 microplate reader.  
Immunoglobulin specificity against commensal E. coli  
Maxisorp 96-wells plates were coated with 5 µg/ml of protein from C3H/HeN isolated 
E. coli lysate (being used as representative bacteria of the intestinal microbiota), incubated with 
plasma (10 µg/mL IgG or 30 µg/mL IgA), and revealed as above-mentioned. Results were 
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expressed as arbitrary units (AU) per 10 µg/mL of IgG or AU per µg/mL IgA, in comparison 
with a standardized immune serum. The E. coli lysate was prepared as previously described 
(Riba et al., 2018). 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 6.04 (GraphPad 
Software, La Jolla, CA, USA). Results for single comparisons were displayed as box plots [min 
to max] and analyzed using either one-way ANOVA, following Dunnett’s multiple comparison 
test (parametric) or Kruskal-Wallis test, following Dunn’s multiple comparison test (non-
parametric) in case of different standard deviations (Brown-Forsythe test). Multiple conditions 
in OGTT and cytokine measurements were displayed either as kinetics with SEM or box plots 
[min to max] and compared per family by Tukey multiple comparison posttest after a significant 
repeated measures (RM) two-way ANOVA. Differences were considered significant for 
P<0.05. 
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RESULTS 
Colonization led to distinct microbiota in GFC and GFMS mice 
We confirmed by 16S rRNA gene sequencing that inoculation of GF mice with microbiota 
from MS (IMS) or control (IMT) mice lead 16 weeks after colonization to recipient mice with 
distinct microbiota (GFC and GFMS) (Figure 1). Indeed, GFM group was distant from GFC 
and GFMS along axis 1 in multidimensional scaling (MDS) of Unifrac distances. GFC and 
GFMS groups could be separated along axis 2. Microbiota of recipient GFC is similar to 
inoculum coming from control donor mice and microbiota of recipient GFMS is similar to 
inoculum coming from MS donor mice. 
 
Figure 1 First two axes of a multidimensional scaling (MDS) of UniFrac distances from 16S rRNA gene 
sequencing of GFM (green), GFC (blue) and GFMS (red); inoculum of MS mice (IMS-brown), inoculum of 
control mice (IC-black). 
Fecal microbiota transfer of MS donor failed to induce glucose intolerance in recipient 
In order to test our hypothesis involving a role of MS microbiota driving glucose intolerance 
in aging mice (Ilchmann-Diounou et al., 2019), we looked at glucose metabolism in mice 
receiving either microbiota from MS (GFMS) or control mice (GFC) or the vehicle (GFM). 
Fecal microbiota transfer (FMT) of MS microbiota in recipient mice (GFMS) did not, after 16 
weeks, increase fasted blood glucose compared to FMT of control microbiota (GFC) (Figure 
2A). Glucose intolerance, as measured during oral glucose tolerance test (OGTT), was not 
induced by FMT of MS microbiota (Figure 2B-C). However, FMT of microbiota from MS and 
control mice induced glucose intolerance compared to mice receiving the vehicle (Figure 2B-
C). In summary, FMT of MS mice was not sufficient to transfer MS metabolic phenotype 
observed at PND350. 
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Figure 2 (A) 16h-fasted blood glycemia. (B) Oral glucose tolerance test in 16h-fasted mice, blood glucose 
(mg/dL), two-way ANOVA, **p<0.01 GFC in comparison to GFM, # p<0.05 GFMS in comparison to GFM. (C) 
Area under the curve (mg/dL/2h), one-way ANOVA, same letter = no statistical difference, different letters = 
significant differences.  
Fecal microbiota transfer of MS donor failed to decrease IL-17 secretion in small intestine 
lamina propria 
In our previous study, MS-induced glucose intolerance was associated with a decrease of 
IL-17 secretion in small intestine lamina propria (siLP). Even though FMT of MS microbiota 
in GFMS was not sufficient to induced glucose intolerance, we wonder if it could lead to the 
defect of IL-17 secretion in siLP. FMT of MS microbiota in GFMS did not decrease IL-17 
concentration in jejunum nor IL-17 secretion in response to T cell receptor (TcR) stimulation 
in siLP cells (Figure 3A-B) compared to GFC or GFM.  
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Figure 3 (A) IL-17 concentration (pg/mg protein) in lysate of small intestine (SI). (B) Primary cell culture of 
small intestine lamina propria (siLP). IL-17 concentration in cell culture supernatant (pg/mL) after 72h incubation 
without or with anti-CD3/CD28 stimulation. 
In summary, our FMT protocol allowed to colonize GF recipient mice with MS (GFMS) and 
control microbiota (GFC) that are similar to inoculum from donor mice and as such led to 
different microbiota between GFMS and GFC. However, FMT of MS microbiota in GFMS , 
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even after 16 weeks, was not sufficient to reproduce MS-induces phenotype, namely fasted 
hyperglycemia, glucose intolerance and defect of IL-17 secretion in small intestine.  
We choose to make the most of this work by exploiting the results in a different way. Indeed, 
we took advantage of the obtained results to study the long-term effects of colonization (after 
16 weeks) of GF adult mice with microbiota of aging (PND350) control mice on different 
parameters, notably intestinal permeability, intestinal and systemic immune response and 
glucose metabolism. Indeed, at our knowledge, colonization effects are principally measured in 
a short time window after colonization. We analyzed intestinal barrier, immune response and 
metabolism 16 weeks after colonization. 
In the following part, results are presented and compared between GF, recipient (previous 
GFC) and donor mice (previous control). 
 
What are the long-term effects of fecal microbiota transfer in adult germ-free mice? 
 
Fecal microbiota of recipient mice differ from donor and inoculum. 
Figure 4 shows that inoculated microbiota of donor mice were distinct to recipient 
microbiota. The groups are separated along axis 2, but not axis 1 in multidimensional scaling 
(MDS) of Jaccard distances. Inoculum do not differentiate from donor microbiota, since it could 
not be separated by Jaccard distances. GF fecal 16S rRNA sequencing confirmed that GF mice 
are different from donor and recipient (separated along axis 1).  
 
Figure 4 First two axes of a multidimensional scaling (MDS) of Jaccard distances from 16S rRNA gene 
sequencing of donors (conventional mice), recipients (germ-free mice colonized with the inoculum: inoc) and 
germ-free mice. 
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Microbiota colonization of GF mice is not sufficient to achieve intestinal barrier 
maturation observed in donor mice 
Intestinal paracellular permeability to FSS is lower in donor mice compared to GF mice. 
(Figure 5A). Colonization (recipient mice) decreased slightly but not significantly intestinal 
paracellular permeability compared to GF mice but do not reach the same levels as donor mice. 
Concentration of secretory immunogloblulin A (sIgA) in feces is higher in donor mice 
compared to GF mice (Figure 5B). Colonization (recipient mice) did not significantly increase 
sIgA in feces compared to GF mice. Compared to donor mice, recipient mice had lower IgA. 
Lipocalin-2 concentration in feces is higher in donor mice compared to GF mice (Figure 5C). 
Colonization (recipient mice) did not increase lipocalin-2 concentration in feces compared to 
GF mice. Compared to donor mice, recipient mice had lower lipocalin 2.  
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Figure 5 (A) Paracellular jejunal permeability to FSS (10-7 cm/s), assessed in Ussing chambers. (B) secretory 
IgA in fecal supernatant (sIgA) (ng/µg fecal protein). (C) Lipocalin-2 (lcn2) (pg/µg fecal protein) in fecal 
supernatant, Kruskal-Wallis test, same letter = no statistical difference, different letters = significant differences. 
Microbiota colonization induces systemic humoral immune response 
IgA and IgG concentrations in plasma were higher in donor mice compared to GF mice 
(Figure 6A-B). Colonization (recipient mice) significantly increased IgA but not IgG compared 
to GF mice. Compared to donor mice, recipient mice had lower IgG and IgA concentration in 
plasma.  
Humoral response (IgA and IgG) directed against microbiota (E.coli lysate as a 
representative of bacterial luminal antigens) were higher in donor mice compared to GF mice 
(Figure 6 C-D). Colonization (recipient mice) slightly but not significantly increased anti-E. 
coli IgG and IgA compared to GF mice. Compared to donor mice, recipient mice had decreased 
anti-E. coli IgG and IgA in plasma. 
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Figure 6 Plasmatic humoral immune response. A IgG (µg/mL). B IgA (µg/mL). C anti-E.coli IgG (AU/10 
µg/mL IgG). D anti-E.coli IgA (AU/µg/mL IgA). Kruskal-Wallis test., same letter = no statistical difference, 
different letters = significant differences. 
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Microbiota colonization triggers IL-17 secretion in response to TcR stimulation in siLP 
IL-17 secretion by siLP cells in response to TcR stimulation is higher in donor mice 
compared to GF mice (Figure 7A). Similar secretions of IL-22 and IFNγ by siLP cells in 
response to TcR stimulation were observed between donor and GF mice (Figure 7B-C). 
Colonization (recipient mice) significantly increased IL-17 secretion in response to TcR 
stimulation in siLP compared to GF. Compared to donor mice, recipient mice had identical IL-
17 secretion in response to TcR stimulation in siLP. 
There were no differences for IL-17 (Figure 7A), IL-22 (Figure 7B) and IFNγ (Figure 7C) 
secretion in basal state between the three groups. 
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Figure 7 Primary cell culture of small intestine lamina propria (siLP). Cytokine concentrations in cell culture 
supernatant (pg/mL) after 72h incubation without or with anti-CD3/CD28 stimulation. (A) IL-17. (B) IL-22. 
(C) IFNγ. Two-way ANOVA, same letter = no statistical difference, different letter = significant differences. 
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Microbiota colonization triggers IL-17 secretion in response to TcR stimulation in spleen 
On systemic level, IL-17 secretion by splenocytes in response to TcR stimulation is higher 
in donor mice compared to GF mice (Figure 8A). Similar secretions of IL-22 and IFNγ by 
splenocytes in response to TcR stimulation were observed between donor and GF mice (Figure 
8B-C). Colonization (recipient mice) significantly increased IL-17 secretion in response to TcR 
stimulation in splenocytes compared to GF. However, recipient mice did not reach the same IL-
17 concentrations than donor, so recipient mice had lower IL17 secretion in response to TcR 
stimulation in spleen compared to donor mice  
In basal conditions, IL-22 secretion is lower in donor compared to GF and recipient mice 
(Figure 8B). 
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Figure 8 Primary cell culture of splenocytes. Cytokine concentrations in cell culture supernatant (pg/mL) after 
72h incubation without or with E.coli lysate or anti-CD3/CD28 stimulation. (A) IL-17. (B) IL-22. (C) IFNγ. Two-
way ANOVA, same letter = no statistical difference, different letters = significant differences. 
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Microbiota colonization induced glucose intolerance compared to GF and donor 
Body weight was higher in donor mice compared to GF and recipient (Figure 9A). 
Interestingly, fasted blood glucose was lower in donor mice compared to GF and recipient mice 
(Figure 9B). Glucose tolerance during OGTT was better in donor and GF mice compared to 
recipient mice as observed through the kinetic and AUC (Figure 9C-D). Indeed, 16 weeks 
colonization induced glucose intolerance in recipient mice compared to GF and donor. 
G F
R e
c i
p i
e n
t
D o
n
o
r
0
5 0
1 0 0
1 5 0
2 0 0
g
ly
c
e
m
ia
 
(m
g
/d
L
) a a b
-3 0 0 3 0 6 0 9 0 1 2 0
1 0 0
1 5 0
2 0 0
2 5 0
T im e  (m in )
B
lo
o
d
 
g
lu
c
o
s
e
 
(m
g
/d
L
) G F
R e c ip ie n t
D o n o r
**
#  #
**
G F
R e
c i
p i
e n
t
D o
n
o
r
0
1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
A
U
C
 
(m
g
/d
L
/2
h
)
a
b
a
G F
R e
c i
p i
e n
t
D o
n
o
r
2 5
3 0
3 5
4 0
4 5
5 0
5 5
b
o
d
y 
w
e
ig
h
t 
(g
) a a
b
A B
C
*  R e c ip ie n t v s  D o n o r
#  R e c ip ie n t v s  G F
D
 
Figure 9 (A) Body weight (g). (B) 16h-fasted blood glucose (mg/dL). (C) Oral glucose tolerance test in 16h-
fasted mice, blood glucose (mg/dL), two-way ANOVA, **p<0.01 recipient vs donor, ## p<0.01 recipient vs GF. 
(D) Area under the curve (AUC) (mg/dL/2h), one-way ANOVA, same letter = no statistical difference, different 
letters = significant differences. 
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DISCUSSION 
In this study, we aimed to address the role of microbiota in MS-induced glucose intolerance 
and associated defect of IL-17 secretion in siLP and spleen (Ilchmann-Diounou et al., 2019). 
We performed fecal microbiota transfer (FMT) from maternal separated (MS) and control at 
PND350 into germ-free (GF) adult mice and demonstrated that 16 weeks after FMT, MS 
microbiota did not induce glucose intolerance nor IL-17 secretion defect compared to control 
microbiota even though microbiota was different between mice receiving microbiota inoculum 
from control or MS mice.  
Our experiment showed that microbiota was not sufficient to induce the MS PND350 
phenotype. Microbiota dysbiosis was observed at earlier time point in the MS model (PND50) 
and was associated with intestinal barrier modification (lower anti-microbial peptides, intestinal 
hyperpermeability, low grade inflammation) without disturbed glucose metabolic phenotype 
(Riba et al., 2018). At PND350 in MS mice, antimicrobial peptides and intestinal permeability 
returned to the control level and only intestinal inflammation and microbiota dysbiosis 
remained. Microbiota is evolving in the course of time in the MS model (cf. III. Part Results. 
First Result, Additional Data). Therefore, we wonder if the microbiota at PND350 could be a 
consequence of earlier defect and if the causative microbiota could be the dysbiotic microbiota 
observed in MS mice a PND50. The next step will be to perform FMT with microbiota of MS 
mice at PND50. If microbiota from MS PND50 mice fails to induce glucose intolerance 
associated with decrease of IL-17 secretion in siLP and spleen it would be interesting to 
combine dysbiotic microbiota and impaired intestinal barrier i.e. transfer microbiota from 
control and MS mice on GF mice submitted or not to MS. Indeed, a weakened intestinal barrier 
associated with low-grade inflammation may be necessary to enable dysbiotic MS microbiota 
to modify host immune-metabolism. Indeed, de Palma et al. showed that microbiota transfer 
was not sufficient to induce MS-caused behavioral modifications in GF mice (De Palma et al., 
2015). This experiment will also be an opportunity to address the consequences of MS on 
intestinal barrier and immune response in GF conditions. Indeed, MS has been widely used in 
rodent to address the long lasting consequences of early life stress on intestinal homeostasis (at 
PND50 irritable bowel syndrome model) but the contribution of microbiota in those outcomes 
has never been tested. 
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Even though we could not reach our primary objective, we took advantage of this work and 
analyzed the effect of FMT on adult GF mice in order to compare intestinal physiology as well 
as systemic immune response and glucose metabolism between donor, recipient and GF mice.  
With our work, we showed that, 16 weeks after colonization, recipient mice failed to reach 
the same level of maturation that donor mice, regarding intestinal barrier, immune response and 
metabolic status.  
First, microbiota from recipient mice is different from donor microbiota, even if inoculum 
was a good representative of donor microbiota. This result could be explained by the 
conservation of the inoculum or the frequency of the inoculum administration. FMT could be 
performed by co-housing, frozen inoculum without prior preparation or frozen inoculum with 
cryoprotectant (milk in our case). Inoculation could be performed twice a week for several 
weeks or in one shot, what we did. Further analysis of the bacteria involved in the distinction 
between donor and recipient are needed to provide explanations and also to reconcile the data 
on microbiota and consequence of colonization on host maturation.  
Adult GF mice present defect in immune response, social behavior, nutrient absorption and 
metabolism (Desbonnet et al., 2014). 
 
Indeed, in a second part, we showed that colonization only induced partial maturation of host 
functions. We demonstrated that intestinal permeability is lower in donor mice compared to GF 
and recipient mice are in-between. Data on intestinal permeability in GF mice are conflicting. 
An increase of transcelluar intestinal permeability to HRP has been described (Heyman et al., 
1986) in conventionally raised mice compared to GF. Thevaranjan et al. report no modifications 
of in vivo measured intestinal permeability in GF vs conventionally raised or colonized mice 
(Thevaranjan et al., 2017). It is interesting to note that colonization decreased permeability of 
another barrier: the Blood Brain Barrier (Braniste et al., 2014). We then looked at IgA and 
lipocalin production by the intestine. Donor mice have higher concentration of sIgA and 
lipocalin compared to GF and recipient mice. It has already been published that GF mice have 
weakened intestinal barrier, namely immature immune system (Falk et al., 1998; Macpherson 
and Harris, 2004) and impair sIgA secretion (Moreau et al., 1978). However, it has been 
demonstrated that colonization of GF with complex microbiota induced the same IgA response 
that the one observed in conventionally raised mice (Lécuyer et al., 2014). The discrepancy 
between those results and our results could be explain by the method used to measured IgA, 
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elispot in siLP (Lécuyer et al., 2014) and ELISA on feces for us. Furthermore, inoculum was 
prepared out of fresh microbiota and gavaged twice. They analyzed mice 8 weeks after 
colonization whereas we analyzed them 16 weeks after colonization. In a recent article Le Roy 
et al. demonstrated that stabilization of microbiota is reached 9 weeks after colonization and as 
such host parameters could be unstable before (Le roy front in microbial 2019). Regarding 
cellular intestinal immune response, GF mice are described to have thinner siLP (Round and 
Mazmanian, 2009) and a great deficit in gut associated lymphoid tissue which can be restored 
by colonization (Falk et al., 1998; Macpherson and Harris, 2004). In our study, donor produced 
higher IL-17 in response to TcR stimulation compared to GF and colonization completed 
restore IL-17 secretion in recipient mice. Indeed, it has been well described that GF mice have 
decreased Th17 in small intestine which can be stimulated by colonization and more 
particularly by Segmented Filamentous Bacteria (Gaboriau-Routhiau et al., 2009; Ivanov et al., 
2008). Interestingly, regarding IL-17 response, the same observation has been made at systemic 
level (spleen). 
Donor mice had higher Ig in plasma compared to GF and colonization slightly increased IgA 
response but not IgG. Humoral response toward microbiota was higher in donor mice compared 
to GF and colonization failed to induce such response. 
GF mice body weight is lower compared to donor mice and colonization failed to increase 
GF body weight so recipient mice are lighter compared to donor mice even after 16 weeks of 
colonization. It has been published that GF mice are lighter than conventionally raised mice 
(Thevaranjan et al., 2017) but colonization has been published to increase adipose mass 
(Bäckhed et al., 2004). Colonization induced glucose intolerance in recipient mice compared to 
GF and donor mice. However, it has been described that GF have better glucose tolerance than 
specific pathogen free (SPF) mice (Wostmann et al., 1983) but in our study we did not observed 
any difference between GF and donor mice regarding glucose tolerance. Microbiota 
colonization induces both inflammation and glucose intolerance in a dynamic pathway. Indeed, 
Molinaro et al. showed that colonization induced early transient inflammation associated with 
glucose intolerance and after 4 weeks the inflammation disappear but glucose intolerance 
remained (Molinaro et al., 2017). However, in this study conventionally raised mice were 
glucose intolerant compared to GF mice whereas we did not observed any differences in our 
model. This result is surprising, as aging is a major risk factor for the development of T2D, in 
both human and animal studies (Almaça et al., 2014; Meneilly and Tessier, 2001). Their 
protection from metabolic disorders are principally due to increased fatty acid metabolism, 
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caused by increased AMP-activated protein kinase (AMPK, a key regulator of metabolism) 
activity and elevated levels of Fiaf (fasting-induced adipose factor, a regulator of fatty acid 
metabolism) (Bäckhed et al., 2007). Beside the already mentioned difference in protocol used 
for inoculation of microbiota. The age of the receiver mice is of importance as well as the age 
of the microbiota from the donor mice.  
Microbiota of PND350 mice were transferred in GF mice aged of PND150 that might be too 
old. There is more and more evidence for a window of opportunity in early life (Dupont et al., 
2016; Ménard et al., 2008; Renz et al., 2017). The first days of life are a highly dynamic period 
in the development of intestinal barrier (Stockinger et al., 2011). Age of recipient is important 
for the establishment of transferred microbiota. Indeed, experiments of microbiota transfer into 
GF and SPF of different age, showed that microbiota of mice, which has been transplanted at 
the age of three weeks (GF or SPF) clustered more closely with inoculum than those which 
were 8-weeks old at transplantation (Le Roy et al., 2019). Furthermore, it has been 
demonstrated that colonizing with old microbiota do not lead to the same outcome than 
colonizing with young microbiota (Thevaranjan et al., 2017) May be the differences in our 
model are at least partially explained by the use of old microbiota used to colonize old GF mice. 
Additionally, age is also a crucial factor for immune priming. Al Nabhani et al. identified a 
unique time window where a so-called “weaning reaction” takes place. Indeed, microbiota 
changes in the timeframe of weaning provoke robust but transient immune reaction, which is 
crucial for later protection to immune-related pathologies (Al Nabhani et al., 2019).  
 
In summary, this study gave us the opportunity to observe the effect of late FMT in adultGF 
mice on intestinal barrier and immune system maturation. This study gives interesting 
perspectives to better understand the role of microbiota in maturing the host, the importance of 
microbiota used to colonize and the time of colonization. It lso provides information relative to 
the close relationship and regulation between intestinal barrier, immune response and glucose 
metabolism.  
 
PERSPECTIVES 
The established collaborations gave us the opportunity to continue the project in order to 
question the role of microbiota in the MS model. In ongoing experiments, we apply MS in GF 
mice, studying intestinal barrier. We wonder, what are the effects of MS in GF conditions. 
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Furthermore, we are planning to proceed to FMT experiments, inoculating MS or control 
microbiota in young GF mice, which underwent or not MS prior to FMT. We hope that these 
experiments put light on the role of microbiota in the MS phenotype.  
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As a third part of my PhD project, we were interested in the long-term effects of neonatal 
maternal separation (MS) on the female litter. We chose to analyze and present female data 
separately from male data, since we observed from early time point a sexual dimorphism in our 
model. Indeed, female and male data in early adulthood (PND50) were published in two 
different articles due to sexual dimorphism. Indeed, in male mice MS increased intestinal 
permeability and led to intestinal low-grade inflammation (Riba et al., 2018), whereas in female 
mice, MS induced, intestinal E. coli overgrowth, - (Riba et al., 2017)) . Nevertheless, some 
observations were similar between male and female mice that underwent MS, as for example 
intestinal hypersensitivity, diminished intestinal lysozyme activity and elevated humoral 
immune response against microbiota. 
We wondered what are the long-term consequences of MS in female aging mice on 
allostatic load, namely intestinal barrier function, neuroendocrine functions and metabolism. 
Additionally, we were interested in immune response and wondered if MS could lead to 
autoimmune disorder in aging female mice. As previously discussed in the review article, there 
seems to be a link between stressful environment, intestinal barrier dysfunction and 
autoimmune disorders. 
This work is still ongoing within the framework of a collaboration with Prof Jamileh 
Movassat, Biology and Pathology of the Endocrine Pancreas at BFA, Université Paris Diderot, 
Paris and in collaboration with Dr Julien Diana, Innate and Adaptive Immune Pathways in 
Autoimmunity and Autoinflammation at INEM, Inserm, Paris.  
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ABSTRACT 
The incidence of metabolic disorders is increasing worldwide. Besides diet and life style 
habits, epidemiological studies highlighted an association between stress and the increase 
incidence of non-communicable diseases (NCD) including metabolic disorders, inflammatory 
and autoimmune diseases. Based on the concept of Developmental Origins of Health and 
Diseases (DOHaD) our study aimed to investigate whether early life stress can trigger NCD 
and associated key feature i.e. low-grade inflammation. 
Maternal separation (MS) is an established model of early life stress in rodent. C3H/HeN 
mice pups were separated from their dam and the rest of the litter 3 hours per day during 10 
days starting at post-natal day 2 (PND2). All experiments were carried out in female offspring 
aged of PND350 on standard diet. 
MS had an impact on intestinal immune system at PND350 but not on intestinal 
permeability. Secretion of IL-17 and IL-22 by small intestine Lamina Propria (siLP) cells in 
response to Tcell receptor (TcR) stimulation was increased by MS as well as TNFα secretion 
with and without LPS stimulation. Additionally, MS led to low-grade inflammation: IFNγ-
secretion by splenocytes in response to TcR stimulation was increased. MS decreased body 
weight and induced glucose intolerance, measured during oral glucose tolerance test (OGTT). 
MS did not induce a loss of insulin sensitivity measured by intraperitoneal insulin tolerance test 
(ITT). Instead, MS decreased plasma insulin secretion in response to glucose stimulation. 
Furthermore, ratio of β-cell surface to pancreas surface was slightly decreased in MS mice and 
this ratio positively correlates with insulin secretion induced by glucose.  
For the first time, this study showed that early life stress induces glucose intolerance 
associated with a loss of insulin secretion in mice non-genetically predisposed to metabolic 
disorders or type 1 diabetes and fed with standard diet. Interestingly, glucose intolerance is 
associated with local and systemic low-grade inflammation but not with intestinal 
hyperpermeability.  
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INTRODUCTION 
The early life period is crucial for the development and maturation of metabolism, immune 
system, intestinal barrier and a life-long beneficial host-microbiota interaction (Stockinger et 
al., 2011). The concept of Developmental Origins of Health and Disease (DOHaD) highlights 
the importance of early life period and raises the hypothesis that chronic diseases could find 
their origins in perinatal environment (Barker et al., 1989; Gluckman et al., 2016). Apart of 
genetics and life style, early life environment could leave a silent imprinting in child’s 
physiology, which possibly erupt later in pathology. This imprinting is also called allostatic 
load and usually measured through neuroendocrine, metabolic, inflammatory and 
cardiovascular markers (Edes & Crews, 2017). 
Early life psychological stress is one of multiple factors of interest. Epidemiological studies 
have shown an association between early life stress and increased circulation inflammatory 
markers in young adults (Baldwin et al., 2017). Neonatal maternal separation (MS) is a stress 
model widely used in rodents as a paradigm of early life adverse events. We previously 
observed that, in female mice, MS triggers lasting alterations of intestinal homeostasis in young 
adult offspring (post-natal-day (PND) 50) including defect of Paneth cells and low-grade 
inflammation (Riba et al., 2017).  
In this study, we aimed to investigate in aging wild-type mice under standard diet the long-
term effects (PND350) of neonatal MS on mice’s allostatic load: intestinal barrier function, 
low-grade inflammation, neuroendocrine functions, as well as glucose metabolism. 
131 
 
EXPERIMENTAL PROCEDURES 
Mouse model 
All experimental protocols were approved by local Animal Care Use Committee (Comité 
d'Ethique de Pharmacologie-Toxicologie de Toulouse - Midi-Pyrénées, France) registered as 
N°86 at the Ministry of Research and Higher Education (N° 0029/SMVT), and conducted in 
accordance with the European directive 2010/63/UE. Mice were kept at a constant temperature 
(22 ± 1°C) and maintained on a 12:12 h light/dark cycle (lights on 7h30 am) on Specific and 
Opportunistic Pathogen Free (SOPF) conditions. Normal diet (Harlan2018, Envigo, Gannat, 
France) and water were available ad libitum.  
Maternal Separation protocol 
Nulliparous female C3H/HeN mice (Janvier Labs, Le Genest St Isle, France) were used. 
Maternal separation (MS) was performed as previously described (7). Briefly, pups were 
separated from their dam and the rest of the litter 3 hours per day. MS was repeated for 10 
working days, weekend excluded, between post-natal-day 2 (PND2) and PND15. Control pups 
were left with their dam. At weaning (PND21), litters were mixed within the same group; only 
females were kept for this study. Four independent batches of experiments were realized. 
Experiments were performed at PND350.  
Oral glucose (OGTT) and intraperitoneal insulin tolerance test (ITT) 
OGTT and ITT were performed in mice 6 h-fasted during day light. For OGTT, mice were 
gavaged with 2 mg glucose per g of bodyweight. Blood glucose levels were monitored from 
the tip of the tail vein with a glucose meter (Johnson & Johnson, Issy-les-Moulineaux, France) 
at -30, 0 (glucose gavage), 15, 30, 60, 90 and 120 min. 
For plasma insulin, blood samples were harvested in fasted state (6h) and 15 min after 
glucose stimulation per os (2 mg glucose per g of bodyweight). Insulin was measured with 
commercial ELISA kit (Merck Millipore, Saint Quentin en Yvelines, France). 
During ITT mice were injected with 0.75 mU insulin (NovoRapid, Novo Nordisk, Chartres, 
France) per g of bodyweight. Blood glucose levels were measured up to 30 min after injection.  
For fasted blood glucose, mice were fasted 16-h overnight.  
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Lysozyme activity in fecal content 
Activity of lysozyme against the peptidoglycan was determined in feces suspended in 
phosphate-buffered saline using the EnzChek Lysozyme Assay Kit (Molecular probes, Life 
Technology, St Aubin, France). 
Intestinal permeability in Ussing chambers 
Intestinal permeability was assessed as previously described (Riba et al., 2018). Briefly, 
jejunal and colonic fragments were mounted in Ussing chambers (Physiologic Instruments, San 
Diego, CA, USA). Tissues were bathed 2h with oxygenated thermostated Kreb’s solution 
(Sigma, Saint Quentin Fallavier, France). Fluorescein Sodium Salt 40 µg/ml (FSS 376 Da; 
Sigma) and Horse Radish Peroxidase 0.4 mg/ml (HRP 4 kDa; Sigma) were respectively added 
to mucosal compartment as para- and trans-cellular markers of intestinal permeability.  
Intestinal permeability to total HRP was determined by ELISA. Briefly, 96-wells black 
plates (Greiner, Les Ulis, France) were coated with 10 µg/ml mouse polyclonal to HRP (Abcam, 
Paris, France), blocked with PBS-1% bovine serum albumin (BSA), incubated with serosal 
compartments of Ussing chamber, detected with 10µg/ml Rabbit polyclonal anti HRP biotin 
(Abcam) and revealed with FITC-conjugated streptavidin (BD, Paris, France). Fluorescence 
intensity was measured 485 nm/525 nm using an automatic Infinite M200 microplate reader 
(Tecan, Männedorf, Switzerland). Intestinal permeability to FSS was determined by measuring 
the fluorescence intensity (FI) 485 nm/525 nm using an automatic Infinite M200 microplate 
reader. Permeability was calculated as the ratio of flux/concentration, and expressed as 
cm/second. 
Immune cells isolation 
Splenocytes were isolated through a 70-µm nylon mesh and suspended in PBS 1%-KO SR 
serum (Gibco, Thermofisher Scientific).  
Isolated cells from small intestines (si) lamina propria (siLP) were obtained as follow: si 
were washed in cold PBS, incubated in PBS 3 mM EDTA (Sigma), washed in warm PBS, 
digested with 100 U/mL of collagenase (Sigma) in DMEM 20% FCS and finally purified on 
Percoll (Sigma). 
Fluorescence-Activated Cell Sorter Analysis 
Isolated cells from spleen and siLP were stained as follow. Activated T-cells: CD4 (BD), 
CD44 (BD), CD62L (BD); Regulatory T-cells: CD4 (BD), CD25 (BD), Foxp3 (ebioscience, 
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Thermofisher Scientific); ILC3: CD127 (BD), RORγt (BD). Th17/22 CD3 (BD), RORγt (BD). 
MACSQuant® Analyzers (Miltenyi Biotec SA, Paris, France) and VenturiOne 
(AppliedCytometry, Sheffield, Great Britain) software were respectively used for data 
collection and analysis. 
Primary cell culture  
Isolated cells from spleen and siLP were seeded at 2x106 cells per well in the presence or 
absence of a) 100 ng/mL Lipopolysaccharide (LPS; Sigma), b) 1 µg/mL of protein from 
commensal E. coli lysate or c) 5µg/mL hamster anti-mouse CD3 (BD) and hamster anti-mouse 
CD28 (BD) coated wells. Supernatants were collected after a) 24h, b/c) 72h.  
Cytokines measurement 
Cytokines were measured in supernatant of primary cell culture, or jejunal fragments 
suspended in RIPA buffer (0.5% deoxycholate, 0.1% SDS and 1% Igepal in TBS) containing 
complete anti protease cocktail (Sigma). Jejunal protein concentrations were measured using 
BCA uptima kit (Interchim, Montlucon, France). IL-17, TNFα, IL-10, IL-22, TGFβ and IFNγ 
in supernatant or lysate of jejunal fragments were assayed using commercial ELISA kits (R&D 
Systems, Lille, France).  
Humoral response in feces and plasma 
Plates were coated with 5µg/ml of sheep anti-mouse IgA (Sigma) or goat anti-mouse IgG 
(SouthernBiotech, Cliniscience, Nanterre, France), incubated with plasma, detected with 1.5 
µg/ml HRP-conjugated goat anti-mouse IgA (Sigma) or goat anti-mouse IgG 
(SouthernBiotech), HRP was revealed using TMB and the reaction was stopped with H2SO4 
2N before reading at 450nm using automatic Infinite M200 microplate reader.  
Measurements in plasma 
ELISA kits were used to monitor corticosterone (Immunodiagnostic Systems, Pouilly-en-
Auxois, France), GIP and GLP-1 (Merck Millipore, Saint Quentin en Yvelines, France). 
Plasma-cholesterol, LDL, HDL, triglycerides, free fatty acids and calcium were analyzed by 
the Platform GenoToul Anexplo, Toulouse, France.  
Staining and counting of β-cells 
Pancreas were fixed over night in Formol-4%, rinsed in ethanol-70% and included in 
paraffin. Entire pancreas were cut in 5 µm slices, representative slices across the organ were 
mounted on slides, first stained with anti-insulin-guinea pig (Abcam) and anti-glucagon-rabbit 
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(Europroximia), second incubated with anti-guinea pig-HRP (Abcam) and anti-rabbit-HRP 
(Jackson), third revealed with diamino-benzidine (Vectorlabs). Surfaces counts were realized 
using Microvision HistoLab 10.5. Ratio of total insulin-positive-surface to total pancreas-
surface was calculated. 
Statistical analysis 
Statistical analysis were performed using GraphPad Prism version 6.04 (GraphPad Software, 
La Jolla, CA, USA). Results for single comparisons were displayed as box plots [min to max] 
and analyzed using unpaired t-test or Mann-Whitney test after prior Shapiro-Wilk Normality 
test and F-Test to compare variances. Multiple groups were displayed either as kinetics with 
SEM or box plots [min to max] and compared per family by Bonferroni posttest after a 
significant two-way ANOVA. Differences were considered significant for P<0.05. 
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RESULTS 
MS had no effect on fecal lysozyme nor intestinal permeability. 
Since maternal separation is a model of intestinal irritable bowel syndrome at PND50, we 
wondered if the intestinal barrier is disturbed in our model at long term. First, lysozyme activity 
in feces of PND350 mice was not different (Figure 1A). Second, translocation of intestinal 
bacterial fragments was assessed indirectly by LPS Binding Protein (LBP) concentrations in 
plasma, without modification in MS mice (Figure 1B). Additionally, we addressed intestinal 
permeability ex-vivo in Ussing chambers in jejunum (Figure 1C-E) and colon (data not shown). 
No difference for electrical resistance, para- (Fluorescein Sodium Salt, FSS) and trans-cellular 
permeability (Horse Radish Peroxidase, HRP) was observed between MS and control mice. 
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Figure 1 MS did not affect fecal lyzozyme nor intestinal permeability. (A) Lysozyme (LZM) activity in fecal 
content (U LZM/ µg protein). (B) LPS-binding protein (LBP) in plasma (ng/mL). (C-E) Jejunal permeability as 
assessed in Ussing chambers. (C) Paracellular permeability of jejunum to FSS (x10-7 cm/s). (D) Electrical 
resistance of jejunal tissue (Ωxcm2). (E) Transcellular permeability of jejunum to total HRP (x10-8 cm/s). 
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MS increased cellular response in siLP 
We analyzed intestinal immune response. First, fecal IgG and IgA were similar between both 
groups (Figure 2A-B).  
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Figure 2 MS had no effect on fecal Ig. (A) Fecal IgA content (µg/mg fecal protein). (B) Fecal IgG content 
(µg/mg fecal protein). 
Second, we looked at the cellular immune response in the small intestine lamina propria 
(siLP). Percentage of Rorγt+ in CD3+ (Th17/22 cells) was not affected by MS (Figure 3A). 
Innate Lymphoid Cells 3 (ILC3: CD127+ RORγt+) (Figure 3B) and regulatory T cells (Treg: 
CD25+ Foxp3+ in CD4+) (Figure 3C) were not altered in MS mice either. TNFα-secretion in 
basal state and in response to LPS-stimulation was significantly increased in siLP cells from 
MS mice (Figure 3D). IFNγ-secretion was not modified by MS (Figure 3E). Nevertheless, IL-
17 and IL-22-secretion in response to TcR-stimulation (anti CD3/CD28) was significantly 
increased in isolated siLP cells from MS mice (Figure 3F-G). We observed the same tendency 
for basal state and E. coli lysate stimulation. IL-10 and TGFβ-secretion were not modified by 
MS (data not shown).  
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Figure 3 MS increased IL-17, IL-22 and TNFα secretions in small intestine lamina propria (siLP). (A) 
Representatives dot plots of CD3+RORγt+ cells of siLP. (B) ILC3 in isolated siLP (RORγt+ CD127+) (C) regulatory 
T cells in siLP (CD25+Foxp3+ in CD4+) (D) TNFα secretion in siLP cell culture after 24h with or without LPS 
(100 ng/mL) stimulation, two-way ANOVA, * p < 0.05. (E)-(G) Cytokine secretion in siLP cell culture after 72h 
without, with E. coli lysate (1 µg/mL) or anti-CD3/CD28 (5 µg/mL) stimulation. (E) IFNγ. (F) IL-17. (G) IL-22, 
two-way ANOVA, ** p < 0.01, * p < 0.0001. 
MS had no consequences on humoral response in plasma 
We next assessed the systemic consequences of MS. We looked at plasmatic IgG and IgA 
concentrations, which were similar between both groups (Figure 4A, B).  
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Figure 4 MS did not affect circulating IgA and IgG. (A) Plasmatic IgA (µg/mL). (B) Plasmatic IgG (µg/mL). 
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We further analyzed systemic immune response by isolation of splenocytes. Activated T 
cells (CD4+ CD44high CD62Llow) (Figure 5A) and regulatory T cells (CD4+ CD25+ foxp3+) 
(Figure 5B) populations in spleen were not modified by MS. Regarding functionality, TNFα-
secretion in response to LPS-stimulation was not different between both groups (Figure 5C). 
IFNγ-secretion in response to TcR-stimulation was significantly higher in MS mice (Figure 
5D). However, Il-17 and IL-22 secretion in response to TcR-stimulation were not modified by 
MS (Figure 5E, F).  
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Figure 5 MS increased IFNγ-secretion in spleen. (A) Representative dot plots of activated T cell population 
in spleen (CD44high CD62Llow in CD4+). (B) Representative dot plots of regulatory T cell population in spleen 
(CD25+ Foxp3+ in CD4+). (C) TNFα secretion in primary cell culture of splenocytes after 24h with or without LPS 
(100 ng/mL) stimulation (D-F) Cytokine secretion in primary cell culture of splenocytes after 72h without, with 
E.coli lysate (1 µg/mL) or anti-CD3/CD28 (5 µg/mL) stimulation. (D) IFNγ. (E) IL-17. (F) IL-22, two-way 
ANOVA, * p < 0.05. 
MS impaired glucose tolerance associated with a decrease of insulin secretion 
Regarding glucose metabolism phenotype, at PND350, MS mice had slightly but 
significantly lower body weight than control mice (Figure 6A) without modification of food 
intake (data not shown). During oral glucose tolerance test (OGTT), blood glucose levels were 
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higher in MS mice than in control (Figure 6B) resulting in significantly higher Area Under the 
Curve (AUC) for MS mice (Figure 6C). Insulin tolerance test (ITT) was not different between 
groups (Figure 6D, E). Insulin secretion after glucose stimulation (+15 min) justified for 
bodyweight was significantly decreased in MS mice compared to control (Figure 6F).  
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Figure 6 MS induced oral glucose intolerance associated with a loss of insulin secretion. (A) Body weight 
(g), unpaired t-test, * p<0.05. (B) Oral glucose tolerance test, after 6-h fasting, gavage with 2 mg glucose/g 
bodyweight at 0, blood glucose (mg/dL) from -30 min to 120 min, two-way-ANOVA, ** p < 0.01, **** 
p < 0.0001. (C) Area under the curve (AUC) of blood glucose 0-120 min (mg/dL/2h), unpaired t-test. (D) Insulin 
tolerance test, after 6-h fasting, intraperitoneal injection of 0.75 mU insulin/g bodyweight at 0, blood glucose 
(mg/dL) from -30 min to 30 min. (E) Area under the curve of blood glucose 0-30 min (mg/dL/30min). (F) Insulin 
secretion in 6h-fasted state and after glucose stimulation (2 mg glucose/g bodyweight) justified for body weight, 
two-way-ANOVA, ** p < 0.01. 
MS did not affect plasmatic marker of stress or metabolism 
No differences in plasmatic markers of metabolism like cholesterol, HDL, LDL, 
triglycerides or free fatty acids were observed (Figure 7A-E). There were no differences in 
plasma corticosterone (Figure 7F) and incretins (GIP, GLP-1, Figure 7G-H).  
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Figure 7 MS did not induce changes in metabolic plasmatic markers. (A) Free fatty acids (FFA) (mmol/L). 
(B) Triglycerides (mmol/L). (C) Cholesterol (mmol/L). (D) High-density lipoprotein (HDL) (mmol/L). (E) Low-
density lipoprotein (LDL) (mmol/L). (F) Corticosterone (ng/mL). (G) Glucagon like peptide-1 (GLP-1) (pM). (H) 
Glucose insulinotropic peptide (GIP) (pg/mL). 
MS decreased β-cell surface in pancreas 
Because of the observed decrease of insulin secretion in response to glucose stimulation, we 
wondered if in our model pancreas β-cells producing insulin were affected. We assessed β-cell 
surface in pancreas by immunohistochemistry. The ratio of β-cell surface to total pancreas 
surface was slightly but not significantly decreased for MS mice compared to control (Figure 
8A). We wondered if we could find a correlation between β-cell surface/ pancreas surface and 
insulin secretion in response to glucose stimulation. Indeed, these two factors are positively 
correlated and values of MS mice tend to be inferior to control (Figure 8B). 
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Figure 8 MS leads to diminished β-cell surface. (A) total β-cell surface/total pancreas surface (B) positive 
correlation between β-cell surface/pancreas surface and insulin secretion/bodyweight. 
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DISCUSSION 
We here show that maternal separation (MS) has a long-lasting impact on allostatic load. 
MS exacerbates IL-17 and IL-22 intestinal immune response as well as intestinal and systemic 
low-grade inflammation at PND350 in C3H/HeN female mice. MS leads also to glucose 
intolerance associated with a lower stimulation of insulin secretion by glucose and a slight 
decrease of ratio β-cell surface / pancreas surface. These results mimic type 1 diabetes features 
even though we are in non-genetically predisposed mice. 
As previously shown, at PND50 MS induces intestinal barrier dysfunction: defect of Paneth 
cells and intestinal low-grade inflammation (Riba et al., 2017). Interestingly, at PND350 we do 
not observe anymore the decrease of fecal lysozyme activity but intestinal low-grade 
inflammation is persisting. Intestinal permeability was never affect in female by MS (PND50 
nor PND350). In our model of MS at PND350 in female, MS induced glucose intolerance and 
defect of insulin secretion associated with increased intestinal and systemic IL-17 secretion in 
response to TcR stimulation. Furthermore, IL22 secretion in response to TcR stimulation was 
also increased in siLP of MS mice. The increased secretion of IL-17 and IL-22 is not due to 
modification of populations, but rather to a hyperfunction of Th17 and Th22. Interestingly, 
Th22 and Th17 levels were significantly elevated in patients of T1D (Xu et al., 2014). 
Stress hormones (glucocorticoids) known to regulate metabolism (Schäcke et al., 2002) and 
immune function (Cain & Cidlowski, 2017) like corticosterone are not affected by MS at 
PND350 excluding a direct effect of corticosterone on the observed metabolic and immune 
phenotype. 
Interestingly, in our study, the MS-induced glucose intolerance and loss of insulin secretion 
were associated with slight but significantly lower body weight. Neither plasmatic markers 
mainly involved in metabolic disorders (FFA, triglycerides, cholesterol, HDL, LDL) nor 
incretins, like GLP-1 and GIP, were modified by MS at PND350. 
Pancreas is immature at birth and weaning is necessary for the maturation of β cells 
producing insulin (Stolovich-Rain et al., 2015). Early life period is as such a critical window 
for pancreas maturation and scattering evidences suggest that stress might impair appropriate 
pancreas maturation. There is a slight correlation between bereavement and type 1 diabetes 
incidence after 11 years of age (Virk et al., 2015). β-cell mass is influenced by early life 
environment. Adverse nutritional status in utero and early life can impact β-cell development 
(Portha et al., 2011). 
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Taking together the results of this study show that MS in wild type mice under normal diet 
leaves a long-lasting imprinting on allostatic load. MS induces glucose intolerance associated 
with a loss of insulin secretion in response to glucose stimulation. Finally, this study highlights 
early life stress as a risk factor for glucose metabolism development independently of 
nutritional challenge and the early life period as critical time window for establishment of 
appropriate establishment of immune system and metabolism. 
 
PERSPECTIVES 
This work is still in progress and two aspects are under investigation: 
1. Diabetes incidence in NOD/ShiltJ mice  
We aim to perform MS in mice genetically prone to type 1 diabetes (T1D): NOD/ShiltJ mice 
and identify MS as a potential risk factor for autoimmune T1D. This perspective is of particular 
interest, since it will strengthen the hypothesis defended in our review presented in the 
introduction section “Psychological Stress, Intestinal Barrier Dysfunctions and Autoimmune 
Disorders” 
Male mice, which are more resistant to T1D development, will be kept to be able to 
appreciate both incidence and gravity of diabetes with and without MS. This experiment will 
be performed within the framework of a collaboration with Dr Julien Diana, INSERM, Institut 
Necker Enfant Malades, Paris. 
2. Role of CRAMP antimicrobial peptide in diabetes triggered by MS.  
Antimicrobial peptides are also playing a role in the development of diabetes in non-obese 
diabetic mice model. CRAMP an antimicrobial peptides expressed in pancreas islet cells is 
protective for development of type 1 diabetes in NOD mice (Sun et al., 2015). Interestingly, 
CRAMP is also expressed in small intestine of mice but only from birth to PND15 (Ménard et 
al., 2008), corresponding to the period of MS stress. CRAMP will be stained in the pancreas of 
C3H/HeN mice aged of PND350 submitted or not to MS and in intestine of NOD mice 
submitted or not to MS and aged of PND7 and PND15. This work will also be performed within 
the framework of a collaboration with Dr Julien Diana, INSERM, Institut Necker Enfant 
Malades, Paris. 
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FOURTH RESULT: 
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A fourth part of my PhD project had a methodological orientation. There are various 
methods to evaluate intestinal permeability. We set up a project to compare in vivo and ex vivo 
measurements in a model of autoimmune type 1 diabetes, the NOD/ShiltJ mouse strain. 
Our aim is to initiate a discussion around the definitions of intestinal permeability and 
systemic exposure in order to clarify the concept of intestinal permeability. 
This work has been realized in collaboration with Dr Colette Denis and Dr Marie Buléon 
from Renal Fibrosis Lab, I2MC, Inserm, Toulouse. 
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ABSTRACT 
Intestinal permeability (IP) is the ability of luminal antigens to pass intestinal epithelium. 
We aimed to compare IP measured by in vivo and ex vivo technics in a mouse model of type 1 
diabetes mellitus - the Non Obese Diabetic (NOD/ShiltJ). 
In vivo IP to FITC Dextran 4kDa (FD4) measured in blood during a 4h kinetic after gavage 
was higher in diabetic NOD mice compared to non-diabetic NOD mice. Surprisingly, ex vivo 
IP to FD4 in Ussing chambers were not different between groups neither in jejunum nor in 
colon. Diabetes-induced modifications of renal excretion, transit time, feces humidity and 
histology failed to explain this difference. However, diabetic mice had significantly longer 
intestine compared to non-diabetic mice and intestinal length positively correlated with in vivo 
IP. 
Our results demonstrate that depending on technic used to address IP, results can be different 
even if using the same marker. This difference could be explained by confounding factors 
affecting in vivo measurements whereas ex vivo IP is addressed in a controlled surface and thus 
correspond to the ability of luminal antigen to cross the intestinal epithelium. FD4 
concentrations measured in blood after gavage reflect systemic exposure to luminal content 
rather than IP stricto sensu. 
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INTRODUCTION 
There are multiple methods for the determination of intestinal permeability (IP) including in 
vivo and ex vivo measurements. First, in vivo methods are often used due to the simplicity of 
protocol and the absence for the need of complex device. Indeed, several non-metabolized 
molecules can be used to determine their passage across intestinal barrier in vivo in animal and 
human. The individual is receiving the molecule via the oral route and after a fixed time, blood 
or urine is collected and the marker is detected according to its properties (radioactivity, 
fluorescence, etc). Thanks to distinct chemical characteristics and degradation process by 
intestinal microbiota, different markers can be used to assess permeability of different intestinal 
segments 1. Another possibility to assess intestinal permeability is by dosing serological 
markers without any previous gavage, as for example zonulin-1 2 or endotoxin 3 that will 
represent respectively intestinal homolog of a Vibrio cholerae enterotoxin that reversibly 
increase IP and a marker of intestinal lipopolysaccharide translocation in the blood. However, 
the relevance of using those markers as indicators of IP is still under debate. Last, ex vivo 
experiments can be used to determine IP. Tight junctions (TJ) proteins, sealing the paracellular 
pathway, can be observed through microscopy or in protein extracts of tissues. Tremendous 
amount of tight junctions proteins have been described and various mechanisms of 
compensation identified 4. Analysis of TJ proteins represents an interesting complement to 
identify the mechanisms involved when intestinal flux are modified but their analyze alone can 
not lead to any conclusion regarding the physiological process of IP. Ussing chambers are a 
well-established ex vivo method to analyze permeability of different tissues 5. However, they 
are more invasive, since biopsies are necessary. Looking at the functionality of a tissue, as in 
Ussing chambers, is of great advantage since it is performed in a controlled surface avoiding 
the confounding factors involved in in vivo experiment per gavage i.e. intestinal transit, renal 
excretion, intestinal length. 
Increased intestinal permeability has been highlighted as a cause or a consequence in 
intestinal but also extra-intestinal disorders. A condition in which increased intestinal 
permeability is documented is type 1 diabetes (T1D) - an autoimmune disorder characterized 
by hyperglycemia involving pancreatic islet cells antibodies and destruction of β-cells 
producing insulin. Intestinal hyperpermeability is observed in human patients but also in 
rodents models (NOD mice, BioBreeding Diabetes Prone rats) even before the onset of the 
disease 6–8. These facts nourished the debate if intestinal hyperpermeability is triggering the 
onset of T1D by increasing the translocation of luminal antigen that might contribute to 
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destruction process of insulin producing cells. However, until today no consensus is found. To 
our knowledge, all studies investigating IP in T1D (human and animal models) have been 
performed in vivo. In our laboratory, we investigate IP principally through two different 
methods: in vivo by FITC-Dextran 4 kDa measurement in plasma 4h after oral gavage and ex 
vivo in Ussing chambers. We aimed to further characterize the defect of intestinal permeability 
in a mouse model of T1D - the Non Obese Diabetic Strain (NOD) - using both in vivo and ex 
vivo methods. 
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RESULTS 
Results of intestinal permeability measurements in vivo and ex vivo by FD4 are conflicting 
Consistently with literature, passage of FD4 through the intestinal barrier into the plasma 
had a tendency to be increased in NOD mice with overt diabetes compared to non-diabetic (ND) 
NOD mice four hours after FD4 gavage (1.370 µg/mL ± 0.17 vs 0.919 ± 0.12, p=0.0809, Figure 
1A). However, intestinal permeability assessed in Ussing chambers did not show any increased 
permeability for FD4, neither in small intestine (SI) (jejunum) nor in colon (Figure 1B). We 
wondered if differences are due to modification in the kinetic of passage from intestinal lumen 
to blood. Kinetic of fluorescence intensity (FI) during in vivo intestinal permeability assessment 
were monitored by repeated blood collection during 4h post FD4 gavage. FI in blood of diabetic 
NOD mice was increased all along the experiment and a significant difference is observed 1h 
after gavage (11.975 µg/mL ± 3.61 vs 3.340 ± 0.81, p<0.01, Figure 1C). The area under the 
curve (AUC) of FI during 4h was increased for diabetic NOD mice in comparison to non-
diabetic mice (1882 ± 556.8 vs 670.4 ± 167.3, p=0.0499, Figure 1D). 
Urinary FD4 excretion is higher in diabetic NOD mice 
In order to decipher the origin of the difference of in vivo and ex vivo measurements, we 
questioned a potential defect of FD4 excretion in urine of diabetic compared to non-diabetic 
(ND) mice. To do so, intestinal pathway was bypass using intravenous injection of FD4. 
Diabetic NOD mice had elevated excreted quantity of urine after 1 and 2 hours (Figure 2A) 
with similar FD4 concentrations in urine the first hour and lower FD4 concentration the second 
hour (Figure 2B). As a consequence, quantity of FD4 excreted in urine was higher in diabetics 
the first hour and similar the second one (Figure 2C). The consequence of this higher urinary 
excretion of FD4 by diabetic mice is lower FD4 concentration in plasma of diabetic mice 2h 
after intravenous injection (Figure 2D). 
Additionally we addressed fecal humidity and transit time, which both were similar between 
diabetic and non-diabetic NOD mice (Figure 3).  
Intestinal length is increased in diabetic NOD mice 
We wondered if the intestinal morphology was modified by diabetes in NOD mice compared 
to non-diabetic (ND) mice. Surprisingly at macroscopical level, small intestine (45.24 cm ± 
0.72 vs 41.53 ± 0.76, p=0.0009, Figure 4A) and colon (9.80 cm [8.50; 10.60] vs 8.75 [8.5; 9.43], 
p=0.0306, Figure 4B) of diabetic NOD mice were significantly longer than intestine of non-
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diabetic NOD mice, but we did not observed any further differences at microscopic level. We 
did not observe any particularity or abnormality by microscopic screening of duodenal, jejunal, 
ileal or colonic tissue. Villi length, crypt depths and intestinal circumference were measured 
and no differences were observed between diabetic and non-diabetic NOD mice (Figure 4C-F) 
Small intestine length is positively correlated with AUC of FD4 concentrations in blood 
Total intestinal length is correlated with the area under the curve of FD4 concentration during 
4h after gavage (Pearson correlation, r=0.6659, R2=0.4434, p=0.0253, Figure 5). 
Ex vivo paracellular intestinal permeability to FSS is decreased in diabetic mice 
In order to further characterize intestinal permeability, we used Fluorescein Sodium Salt 
(FSS) and Horse Radish Peroxidase (HRP) as specific para- and transcellular marker 
respectively in Ussing chambers. Paracellular permeability to FSS was significantly decreased 
in small intestine (jejunum) of diabetic mice compared to non-diabetic (ND) mice (44.859 
ng/cm2/2h ± 11.05 vs 217.96 ± 76.50, p<0.05, Figure 6A). Short circuit current (Isc) in colon 
was significantly increased in diabetic NOD mice compared to non-diabetic NOD mice (-
13.335 µAcm2 ± 1.59 vs -25.266 ± 6.39, p<0.05, Figure 6B). Transcellular permeability to HRP 
was not modified; neither in jejunal nor in colonic tissue (Figure 6C). Intact HRP as a measure 
of non-lysosomal transcellular pathway was not affected either (Figure 6D). 
Diabetic state is not associated with inflammatory profile 
We wondered if diabetes had an effect on inflammatory state in the intestine. We screened 
several cytokines (TNFα, Lipocalin-2, IL-10, IL-17 and IL-22) in lysate of colon and jejunum 
(small intestine: SI). As expected cytokine levels in colonic tissues were higher. IL-10, IL-17 
and IL-22 were non-detectable in lysate of SI tissue. There were no diabetes-induced 
modifications in cytokine concentrations (Figure 7). 
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DISCUSSION 
We here demonstrate that using the same marker FITC-Dextran 4 kDa (FD4) in vivo and ex 
vivo to measure IP can give different results in a type 1 diabetes model: the non-obese diabetic 
mice.  
In our study, we compared NOD diabetic vs non-diabetic mice. This is an advantage in 
comparison to other studies in which different mouse/rat strains were compared, for example 
NOD vs non-obese resistant (NOR) mice or BioBreeding diabetes-prone (BBDP) vs 
BioBreeding diabetes-resistant rats (BBDR) 8,9. 
We used FD4 to assess intestinal permeability in vivo. As most laboratories take plasma at 
4h after gavage, when FD4 had time to transit all along the intestinal tract 10, we choose to 
follow this method. We observed a tendency for an increase in FD4 concentration in plasma at 
4h after gavage in diabetic mice that is consistent with literature. Indeed, intestinal permeability 
has been described to be increased by auto-immune diabetes in rodents and in human 6–8,11. 
During ex vivo jejunal (representative of small intestine) and colonic permeability 
measurements in Ussing chambers we used the same marker i.e. FD4. Surprisingly, ex vivo FD4 
flux was not different between diabetic and non-diabetic NOD mice. This result suggests that 
the increased FD4 concentration in blood observed in vivo is not the result of increased FD4 
flux in jejunum and/or colon and as such excludes an increase of IP stricto sensu in auto-
immune diabetes. Indeed, the proper definition of IP is “the facility with which intestinal 
epithelium allows molecules to pass through by non-mediated passive diffusion” expressed in 
cm/sec 1 and as such need to take into account the exposed surface witch cannot be done in in 
vivo experiments. To decipher differences in kinetic of FD4 absorption in the mouse model, 
blood samples were taken at different time points during the 4h-period after FD4 gavage and 
FD4 concentrations measured. Although FD4-flux in Ussing chambers were similar in tissue 
of diabetic and non-diabetic mice, all along the in vivo experiment FD4 concentrations in blood 
were higher in diabetic compared to non-diabetic mice and significantly different at 1h after 
FD4 gavage. As a result, AUC of FD4 is higher in diabetic mice compared to non-diabetic mice. 
Those results highlight the interest to follow the kinetic of FD4 in blood rather than measuring 
FD4 concentration in plasma at a unique time point. Of note, Woting and Blaut observed that 
absorption kinetics is highly depend on mouse strain 12. 
We then wondered if urinary excretion of FD4 was modified. It is largely known that 
diabetes comes along with renal complications. Hyperglycemia leads to polyuria and 80% of 
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persons diagnosed with diabetes mellitus have lower urinary tract complications, as for example 
nephropathy that at the ultimate stage can lead to a defect of urinary excretion process and 
request dialysis intervention 13. However, our results showed that the quantity of FD4 excreted 
in urine of diabetic mice is higher the first hour and the same the second hour. This effect is 
mainly driven by increased volume of urine excreted by diabetic mice compared to non-diabetic 
rather than higher concentration of FD4 excreted. In those experiments of urinary excretion, 
bypassing intestinal pathway, higher quantity of FD4 excreted in diabetic mice is associated 
with lower FD4 in plasma 2H after gavage. Those results excluded a defect of renal excretion 
of FD4 in diabetic mice to explain higher FD4 concentration in plasma after FD4 oral gavage 
(in vivo permeability assessment). 
Transit time and feces humidity were not different between diabetic and non-diabetic mice. 
However, in literature enhanced intestinal transit, measured by charcoal progression after 20 
min in the intestinal tract, is described in NOD mice with long-term diabetes  (4-5 weeks) 14. In 
insulin-dependent diabetes mellitus patients both delayed and rapid intestinal transit has been 
documented 15. Nevertheless, since transit time was not modified in our study transit could not 
explain the increased FD4 concentration in blood. 
We looked in detail at intestinal morphology by histology. Surprisingly no aberrant 
structures indicating inflammation or epithelium modifications have been observed. Villi length 
and crypt depth were similar between diabetic and non-diabetic mice. Neu et al. observed 
increased mucosal crypt depth in BioBreeding diabetes-prone vs BioBreeding diabetes-resistant 
rats 9. However, as already pointed out at the beginning of the section discussion, they compared 
two different strains (BBDP vs BBDR) whereas in our study we compare same strain but 
different diabetic state. In streptozotocin-induced diabetic rats increased wall stiffness 16 and 
increased thickness of intestinal mucosa 17 have been observed. Circumference of ileum was 
increased and contraction force of intestinal smooth muscles were decreased in diabetic rats 18. 
Another study reported that colonic smooth muscle from RIP-I/hIFNβ diabetic mice had similar 
contractile responses with control mice 19. In human, 75% of diabetes mellitus patients (T1D 
and T2D) suffer from gastro-intestinal symptoms 20. Abnormal motility has been described in 
patients suffering from auto-immune diabetes with conflicting results, some report intestinal 
hypermotility 21 others hypomotility 22 . In our study, we do not observe any difference in 
circumference of small (duodenum, jejunum, ileum) and large intestine between diabetic and 
non-diabetic mice excluding a major role of tonus to explain our different results in in vivo and 
ex vivo measurements for FD4. 
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The most striking result of our study was the elongation of intestine in diabetic NOD mice. 
Interestingly, increased intestinal proliferation, intestinal weight and length have previously 
been described in streptozotocin- and alloxan-induced diabetes 23,24. The increase of intestinal 
length means an increase of absorptive surface that seems to be a main contributor to the 
observed higher FD4 concentration in plasma of diabetic mice compared to non-diabetic mice. 
We aimed to further characterize intestinal permeability in our model in Ussing chambers 
using FSS and HRP as respective markers of para- and trans-cellular permeability 25. Small 
inert molecules with a molecular weight below 600 Da can pass the epithelial barrier between 
cells via the tight junctions 26. Horse Radish Peroxidase (HRP) is a bigger molecule (44 kDa) 
which can pass the intestinal epithelial barrier by transcellular route via endocytosis. For that, 
it serves as a marker to measure transcellular permeability. Surprisingly, in jejunum, 
paracellular permeability to FSS was significantly decreased in diabetic mice whereas 
transcellular permeability to HRP was not modified (intact and total HRP). FD4 can be 
considered as a marker of transcellular permeability due to its molecular weight (4 kDa) and as 
it acts like HRP and not FSS.  
Short current circuit (Isc) was significantly increased in colon of diabetic mice and might 
reflect an increased Cl- secretion into the lumen triggering H2O flux in the lumen 27. However, 
we did not observe differences in fecal humidity and intestinal transit time excluding a major 
effect on water fluxes. 
In our model, diabetic state was not associated with intestinal inflammation. So we could 
exclude any direct effect of inflammation on modified intestinal morphology and permeability, 
since inflammation comes along with increased intestinal permeability 28 
During in vivo measurements FD4 concentrations are increased in diabetic mice as early as 
15 min after gavage that could involve gastric and duodenal permeability since FD4 is increased 
shortly after gavage and the FD4 bolus is still in the upper intestinal part, it would be interesting 
to assess additionally gastric and duodenal permeability. Indeed, in insulin-dependent diabetes 
patients abnormal duodenal chyme transport has been observed 29. Even though, the accurate 
characterization of IP in different fragments of small intestine is of interest, this is not the object 
of our study. Here our objective was to emphasize that ex vivo and in vivo measurement of FD4 
transport by intestine can lead to conflicting results and we used jejunum as a representative 
fragment of small intestine. 
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In summary, our work highlights that the assessment of intestinal permeability is complex 
and a lot of confounding factors have to be considered when setting up the experiment. On one 
side, in vivo experiments do not allow to control the absorptive surface, neither intestinal 
circumference nor intestinal length, are known in the experimental conditions. Furthermore, 
one has also to consider that in vivo intestinal permeability measurements are highly dynamic 
– depending on transit, excretion and could be fluctuating in time. One point plasma 
measurements are difficult to consider as representative. Overall, in vivo measurements are 
reflecting more likely the exposition of the organism to the luminal marker in circulation at one 
time point, rather than the intestinal permeability as such in its stricto sensu definition. On the 
other side, Ussing chamber allow to control surface. This allows the researcher to analyse 
different intestinal segments and to use different molecular markers. Ussing chambers allow to 
measure real permeability, which is “the facility with which intestinal epithelium allows 
molecules to pass through by non-mediated passive diffusion” expressed in cm/sec 1. However, 
tissues are outside of the organism and effects of innervation and blood circulation are depleted 
and additional observations and experiments are necessary to describe the physiologic 
importance of observed modifications ex vivo.  
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MATERIALS AND METHODS 
Mouse model 
All experimental protocols were approved by local Animal Care Use Committee (Comité 
d'Ethique de Pharmacologie-Toxicologie de Toulouse - Midi-Pyrénées, France) registered as 
N°86 at the Ministry of Research and Higher Education (N° 0029/SMVT), and conducted in 
accordance with the European directive 2010/63/UE. NOD Shilt/J strain (Charles River, 
France) were housed by five per cage. Female NOD mice were chosen for the experiment since 
they develop more rapidly diabetes than male NOD mice (Jackson Laboratory Physiologic Data 
Sheet). Mice were kept at a constant temperature (22 ± 1°C) and maintained on a 12:12 h 
light/dark cycle (lights on 8h00 am) on Specific and Opportunistic Pathogen Free (SOPF) 
conditions. Normal diet (Harlan2018, Envigo, Gannat, France) and water were available ad 
libitum. Blood glucose levels of NOD Shilt/J mice were monitored weekly from the tip of the 
tail vein with a glucose meter (AccuCheck, Roche, Mannheim, Germany). Mice with non-fasted 
glycaemia superior to 250 mg/dL were considered as diabetic according to Jackson Laboratory 
Physiologic Data Sheet. After one to four weeks posterior to diabetes diagnosis, diabetic mice 
and non-diabetic mice from same cage were attributed either to in vivo or ex vivo intestinal 
permeability assays. Three independent batches of animals were analyzed. 
Intestinal permeability in vivo – FITC-Dextran 4 kDa (FD4) 
Mice were fasted for 3h prior to intragastric gavage with FITC-Dextran 4kDa (750 µg/g 
bodyweight in tap water). Small blood samples were obtained at the tip of the tail vein via 
microheamatrocrit capillary tubes (Hirschmann, Eberstadt, Germany) before and 15 min, 30 
min, 60 min, 2h, 3h, 4h after gavage. At the end of the procedure mice were euthanized by 
dislocation and blood was harvested intracardiac for plasma. Blood samples were diluted 1/20 
and plasma 1/10 in NaCl 0,9%, and Fluorescent Intensity (FI) measured by excitation: 485 nm/ 
emission: 525 nm using an automatic Infinite M200 microplate reader. FI in blood was 
corrected by FI measured before gavage. 
Intestinal permeability ex vivo - Ussing chambers 
Intestinal permeability was assessed as previously described 25. Briefly, jejunal (as 
representative for small intestine: SI) and colonic fragments were mounted in Ussing chambers 
(Physiologic Instruments, San Diego, CA, USA). Tissues were bathed 2h with oxygenated 
thermostated Krebs solution (Sigma, Saint Quentin Fallavier, France). Horse Radish Peroxidase 
400 µg/ml (HRP 40 kDa; Sigma) and Fluorescein Sodium Salt 40 µg/ml (FSS 376Da; Sigma) 
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or FITC-Dextran 400 µg/mL (FD4 4 kDa, TdB, Sweden) were added to mucosal compartment. 
FSS and HRP were used as respective markers for para- and trans-cellular intestinal 
permeability.  
Intestinal permeability to total HRP was determined by ELISA. Briefly, 96-wells black 
plates (Greiner, Les Ulis, France) were coated with 10 µg/ml mouse polyclonal to HRP (Abcam, 
Paris, France), blocked with PBS-1% bovine serum albumin (BSA), incubated with serosal 
compartments of Ussing chamber, detected with 10 µg/ml Rabbit polyclonal anti HRP biotin 
(Abcam) and revealed with SPRD-conjugated streptavidin (BD, Paris, France). Fluorescence 
intensity was measured 485nm/525nm using an automatic Infinite M200 microplate reader 
(Tecan, Männedorf, Switzerland). Intestinal permeability to intact HRP was determined in 96-
wells black plates, adding TMB substrate to serosal compartments of Ussing chambers, and 
measuring the slope within 90 seconds at 37°C at 450 nm in automatic Infinite M200 microplate 
reader. Intestinal permeability to FSS and FD4 were determined by measuring FI 485 nm/525 
nm using an automatic Infinite M200 microplate reader. Results of Ussing chambers 
measurements are presented as flux, expressed as ng/2h/cm2. 
FD4 excretion in urine 
For analysis of FD4 excretion in urine, mice were anesthetized by a mixture of ketamine 100 
mg/kg of body weight and xylazine 10 mg/kg of body weight and maintained anesthetized by 
jugular catheter perfusion with 20mg/kg/h ketamine and a flow of 0.1ml/h. 10 mg FD4 was 
injected in jugular vein (100 mg/mL), arterial pressure was monitored in femoral artery. Urine 
was collected through a catheter inserted in bladder at 1h and 2h after FD4 injection. FD4 
concentration was measured by FI. After 2h mice were euthanized by cervical dislocation, 
blood was taken for measurements of FI in plasma. 
Histological analysis of intestinal morphology 
Intestinal fragments of duodenum, jejunum, ileum and colon were fixed in 4% formalin and 
included in paraffin. Paraffin sections were stained with Hematoxylin and Eosin (Eosine 
aqueuse 1% Labo modern, France). Tissue were screened for morphological abnormalities. 
Intestinal diameter, crypt depth and villi length were measured (Nis Element-Ar, Nikon System-
Elements-Advanced research, microscope Nikon Eclipse 90 i, France).  
Fecal humidity and Transit time 
Feces of diabetic and non-diabetic mice were collected and regrouped by condition, 
weighed, dried at 37°C for one week and weighed again. Lost weight was considered as water 
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content. In the morning, mice were isolated in clean cages without bedding material but tissue 
for 45 min without food. Afterwards feces were numbered. 
Cytokine measurements 
Cytokines were measured in jejunal (representative of small intestine: SI) or colonic 
fragments suspended in RIPA buffer (0.5% deoxycholate, 0.1% SDS and 1% Igepal in TBS) 
containing complete anti protease cocktail (Sigma). Jejunal and colonic protein concentrations 
were measured using BCA uptima kit (Interchim, Montlucon, France). TNFα, Lipocalin-2, IL-
10, IL-17 and IL-22 in lysate of jejunal or colonic fragments were assayed using commercial 
ELISA kits (R&D Systems, Lille, France) and expressed as pg/mg of protein. 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 6.04 (GraphPad 
Software, La Jolla, CA, USA). Results for single comparisons were displayed as box plots [min 
to max] and analyzed using Student’s unpaired t-test (two-tailed) or Mann-Whitney test (two-
tailed) after prior Shapiro-Wilk Normality test and F-Test to compare variances. Multiple 
measurements in time or in different tissues were displayed either as kinetics with SEM or box 
plots [min to max] compared per family by Holm-Sidak posttest after a significant two-way 
ANOVA. Differences were considered significant for P<0.05. Results in text were described as 
NOD diabetic mean ± SEM vs. NOD non-diabetic mean ± SEM for normally distributed 
samples and as median, [25%-quartile; 75%-quartile] in other case. 
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LEGENDS 
Figure 1 In vivo and ex vivo measurements of intestinal permeability to FITC-Dextran 4 kDa 
(FD4) give different results. (A) Plasmatic FD4 concentration 4h after gavage by 750 µg FD4/g 
bodyweight, unpaired students t-test, p=0.0809, n=4-5. (B) Jejunal (small intestine: SI) and 
colonic permeability to FD4 (400 µg/mL in serosal compartment) measured in Ussing 
chambers, n=4-5. (C) Kinetic of FD4 fluorescence in blood during 4h after gavage by 750 µg 
FD4/g bodyweight, repeated-measurement two-way ANOVA, ** p<0.01, n=5-6. (D) Area 
under the curve (AUC) of FD4 in blood during 4h after FD4 gavage, unpaired students t-test, 
p=0.0499, n=5-6. 
Figure 2 Urinary excretion of FITC-Dextran 4 kDa (FD4) is higher in diabetic NOD mice. 
FD4 (10 mg/mice) was injected in jugular vein in anesthetized mice (A) urinary volume (µL) 
measured 1h and 2h after intravenous injection of FD4 harvested in bladder during the 
experiment in anesthetized mice, n=2-3. (B) FD4 concentrations in urine (µg/mL), n=2-3. (C) 
Quantity of FD4 excreted as calculated from FD4 concentrations measured in urine multiplied 
by urine volume, n=2-3. (D) FD4 concentrations measured in plasma harvested 2h after FD4 
intravenous injection, n=2. 
Figure 3 Intestinal transit and humidity in feces are not affected by diabetes in NOD diabetic 
mice. (A) Intestinal transit, measured as number of feces/mice during 45 minutes, n=7-14. (B) 
Fecal humidity calculated as the ratio of fresh feces weight (one cage) and one week at 37°C 
dried feces weight, n=2. 
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Figure 4 Macroscopical and microscopical and characterization of small intestine and colon 
in diabetic vs non-diabetic NOD mice. (A) Small intestine length (cm), unpaired students t-test, 
p=0.0009, n=25-26. (B) Colon length (cm), Mann-Whitney test, p=0.0306, n=25-26. (C-D) 
representative cross sections of 4%-formalin, paraffin-embedded haematoxylin/eosin stained 
jejunal, objective 2x (E-F) and colonic tissue, objective 10x (C-D) tissue n=5. 
Figure 5 Total intestinal length (cm) is positively correlated with the area under the curve 
(AUC) of FD4 concentrations during the 4h after FD4 gavage, pearson correlation, r=0.6659, 
R2=0.4434, p=0.0253, n=11. 
Figure 6 Measurements of intestinal permeability in Ussing chambers in jejunum (small 
intestine: SI) and colonic tissue. (A) Paracellular flux (ng/cm2/2h) of Fluorescein Sodium Salt 
(FSS), 330 Da, 40 µg/mL in serosal compartment, two-way Anova, Sidaks multiple comparison 
post-test, *p<0.05, n=8-12. (B) Short circuit current (Isc, µA.cm2), two-way Anova, Sidaks 
multiple comparison post-test, *p<0.05, n=7-10. (C) transcellular flux (ng/cm2/2h) of total 
Horse Radish Peroxidase (HRP), 44 kDa, 400 µg/mL in serosal compartment, n=8-13. (D) 
transcellular flux (ng/cm2/2h) of intact Horse Radish Peroxidase (HRP), 44 kDa, 400 µg/mL in 
serosal compartment, n=6-8. 
Figure 7 Cytokine concentrations in colonic and jejunum (small intestine: SI) lysate were 
similar between diabetic and non-diabetic NOD mice. Cytokine concentrations in (pg/mg 
protein) (A) TNFα, n=5 and (B) Lipocalin-2, n=5 in jejunum (small intestine: SI) and colon. 
(C) IL-10, n=5 (D) IL-17, n=5 (E) IL-22, n=5, in colon. 
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Addtional Discussion 
The original article published by Thaiss and colleagues in 2018 in the journal Science 
is entitled “Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection”. 
The question if hyperglycemia is triggering intestinal barrier dysfunction (including intestinal 
hyperpermeability) is of great interest in our model. The authors are principally working with 
a model of type 1 diabetes induced by streptozotocin (STZ). One has to note that STZ is entering 
the cell via GLUT2 (Lenzen, 2008; Wang and Gleichmann, 1998), which is not only expressed 
in β cells of pancreas but also on intestinal epithelial cells. Thus, a direct effect of STZ on the 
observed intestinal barrier dysfunction cannot be excluded. Additionally, STZ is also used in 
gut cancer (Clamon et al., 1987; Welt et al., 2003), emphasizing its action on intestinal epithelial 
cells and thus an impact on intestine. STZ is also used as chemotherapeutic agent. A clastogenic 
effect of STZ on human colon cancer cell lines has been described (Bolzán and Bianchi, 2003). 
In their paper, Thaiss et al. describe that mice with a partial knock-out of GLUT2 on intestinal 
epithelial cells (GLUT2ΔIEC) were resistant to STZ-induced transcriptomic and tight junctional 
changes despite persisting hyperglycemia. They conclude that hyperglycemia is 
reprogramming via GLUT2 the intestinal transcriptome. However, these observations are more 
in favor for the hypothesis that STZ is affecting directly the intestinal epithelial cells. Indeed, 
disturbance of glucose transporters in the intestinal epithelial cell could lead to reorganization 
or even loss of cell polarization and an ectopic expression of SGLT1 to compensate the knock-
out. Perhaps glucose could also enter into the epithelial cell via SGLT1, a glucose transporter. 
(Kellett and Brot-Laroche, 2005).  
The authors use many different models to support their hypothesis. Indeed, they have 
data on STZ-induced hyperglycemia, db/db, ob/ob, Akita and HFD mice. It is important to note 
that in these models, hyperglycemia is linked with obesity and inflammation. It is difficult to 
disentangle the effects of these three phenomenon. Indeed, they are highly interwoven and 
influenced one by another. The authors present only data on immune system of STZ treated 
mice, but not of db/db, ob/ob, Akita and HFD mice, which would be interesting for the 
comprehension of increased pathogen load in all five models. Our work was carried out in non-
obese diabetic (NOD) mice. There is no interference with obesity. Additionally we showed that 
hyperglycemia was not associated with inflammation. So the NOD model would have been an 
interesting plus in the work of Thaiss et al. 
Even though, we were not convinced that this paper clearly demonstrated that 
hyperglycemia drives intestinal hyperpermeability the role of hyperglycemia on intestinal 
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permeability was of particular interest in our model of NOD diabetic mice. We set up the 
following experiment to confirm a potential role of high glucose on intestinal permeability in 
Ussing chambers. Intestinal permeability was assessed in Ussing chambers on small intestine 
and colon from NOD non-diabetic, diabetic, C57Bl6/J and Balbc/J mice in high-glucose (6 g/L) 
vs normal glucose (2 g/L) conditions. In jejunum (Figure 25) and colon (Figure 26), no 
increase FSS, FD4 and HRP fluxes after 2h bathing could be detected and electrical parameters 
were not affected neither. We had just 1 point for NOD mice in every condition, but did not 
observe increased passage of molecules in high-glucose conditions. So, we excluded a role of 
hyperglycemia in the increase of intestinal permeability measured in Ussing chambers.  
2
 g
/L
6
g
/L
2
 g
/L
6
g
/L
0
5 0 0
1 0 0 0
1 5 0 0
F
S
S
 (
n
g
/c
m
2
/2
h
)
2
 g
/L
6
g
/L
2
 g
/L
6
g
/L
0
5 0
1 0 0
1 5 0
R
 (

.c
m
²)
2
 g
/L
6
g
/L
2
 g
/L
6
g
/L
-2 0 0
-1 5 0
-1 0 0
-5 0
0
Is
c
 (
µ
A
*
c
m
2
)
2
 g
/L
6
g
/L
2
 g
/L
6
g
/L
0
1 0 0
2 0 0
3 0 0
H
R
P
 t
o
t 
(n
g
/c
m
2
/2
h
)
2
 g
/L
6
g
/L
2
 g
/L
6
g
/L
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
F
D
4
 (
n
g
/c
m
2
/2
h
)
C 5 7 /B l6
B a lb c
A B C
D E
 
Figure 25 Jejunal permeability measurements in Ussing chambers in C57/Bl6 and Balbc mice in low (2 g/L) 
and high-glucose (6g/L) Krebs medium. (A) FSS-flux (ng/cm2/2h). (B) Electrical resistance (R) (Ωxcm2). (C) 
Short circuit current ISC (µAxcm2). (D) HRP-flux (ng/cm2/2h). (E) FD4-flux (ng/cm2/2h). 
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Figure 26 Colonic permeability measurements in Ussing chambers in C57/Bl6 and Balbc mice in low (2 g/L) 
and high-glucose (6g/L) Krebs medium. (A) FSS-flux (ng/cm2/2h). (B) Electrical resistance (R) (Ωxcm2). (C) 
Short circuit current ISC (µAxcm2). (D) HRP-flux (ng/cm2/2h). (E) FD4-flux (ng/cm2/2h). 
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THE INTESTINE IS PLAYING A CRUCIAL ROLE IN HEALTH AND 
DISEASE 
Historically, MS model has been used with the objective to analyze its consequences on 
intestinal barrier function and as such is a reference as a rodent model of Irritable Bowel 
Syndrome (IBS). The interest in intestinal homeostasis gain a special attention during the last 
years. Indeed, intestinal homeostasis is impaired not only in intestinal disorders, but also in 
extra-intestinal disorders and we aimed to address this question during my PhD.  
The intestine is playing a central role in our life: it is the biggest body surface in contact 
with the outside, transporting about 30 000 tons of food and 50 000 liter of fluids during our 
life, harboring the biggest immune repertoire in our organism and due to the numerous neurons 
often called our second brain. 
The different projects of my PhD highlight the long-term consequences of stress on 
intestinal homeostasis and the development of diseases. Indeed, intestinal hyperpermeability is 
one of the first characteristics of MS-induced phenotype in young C3H/HeN male mice. 
Microbiota dysbiosis is observed in young MS male mice. The intestinal immune system is 
modified by MS in male and female mice from young age on, and remained different between 
MS and control throughout lifetime. Our observations on MS-induced effects in male and 
female young adult mice led us hence to the hypothesis that intestinal barrier dysfunction could 
be at the origin of later disease. Interventional studies are needed to confirm this. 
 
In male mice, intestinal hyperpermeability induced by MS appeared from early age on. 
Indeed, intestinal permeability was increased from early time point on (PND15). Riba et al. 
reported still increased intestinal permeability at PND50 and additionally decrease in lysozyme 
activity (Riba et al., 2018), which were both resolved later on (PND350) (Ilchmann-Diounou 
et al., 2019) (Figure 27).  
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Figure 27 Jejunal paracellular permeability to FSS (x10-7 cm/s) assessed in Ussing chambers in C3H/HeN 
male maternal separated (MS) and control mice at post-natal day (PND) 15, 50, 100, 150 and 350.  
The intestinal barrier in MS male mice is also weakened by diminished lysozyme 
content in Paneth cells and decreased fecal lysozyme activity at PND50 and intestinal low-
grade inflammation, namely increased TNFα and fecal IgA concentrations (Riba et al., 2018). 
The effects of MS on antimicrobial activity and on IgA concentrations were resolved in 
PND350 mice (cf. III. Part Results, First Result, Additional Data), whereas intestinal low-grade 
inflammation and increased IgG against commensal microbiota, which is an indicator for 
disturbed host-microbiota mutualism, are persisting in time (Ilchmann-Diounou et al., 2019). 
Metabolic disorder only appear at PND350. Additionally, microbiota dysbiosis is observed at 
PND50 and PND350, but evolving in time.  
The establishment of life-long beneficial host-microbiota interaction takes place in the 
early life (Stockinger et al., 2011). After birth, the host is massively colonized and encountering 
microbiota for the first time. A transient disturbed barrier can have long-lasting consequences 
due to the potent priming mechanisms on immunity during the highly shapeable neonatal 
period. Increased exposition to luminal antigens (from microbiota and food origins), due to 
weakened intestinal barrier, in this time frame can have an impact on later disease susceptibility. 
Al Nabhani et al. show that a transient but robust immune reaction during weaning period have 
long-term effects on the resistance to immunopathology in later life, notably colitis and allergy 
(Al Nabhani et al., 2019). However, MS does not predispose to colitis (IL-10 KO model) or 
enteric infection by Salmonella or Listeria (Riba et al., 2018). 
We hypothesize that intestinal barrier dysfunction, which precedes the onset of 
metabolic phenotype, is triggering metabolic disorder in our model.  
The role of intestinal barrier in metabolic disorder is highly discussed. Some consider 
intestinal barrier dysfunction as a consequence, other as a cause of metabolic disorder. Cani et 
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hyperpermeability was observed before the onset of disease in biobreeding diabetic prone 
(BBDP) rats (Meddings et al., 1999). Additionally, tight junction proteins were modified in 
BBDP (Neu et al., 2005). In epidemiological studies, different results have been observed. Bosi 
et al. demonstrated that intestinal hyperpermeability, as measured in vivo by lactulose/mannitol 
(L/M) test occurs before disease onset (Bosi et al., 2006), others found increased in vivo 
cellobiose/M intestinal permeability in established but uncomplicated T1D (Carratù et al., 
1999). While Kuitunen et al. did not observe increased intestinal permeability (L/M) in T1D 
patients (Kuitunen et al., 2002). Relatives of T1D patients had intermediate in vivo L/M 
intestinal permeability between T1D and control (Sapone et al., 2006). In rats, reversion of 
intestinal hyperpermeability by treatment with a zonulin 1 (intestinal homolog of an Vibrio 
cholerae enterotoxin that reversibly increase intestinal permeability) inhibitor ameliorates T1D 
manifestation in rat model (Watts et al., 2005). Our study, addressing intestinal permeability in 
T1D in non-obese diabetic (NOD) mice compared to non-diabetic NOD mice by in vivo and ex 
vivo measurements, showed important intestinal modifications during T1D in NOD/ShiltJ mice. 
In the NOD mice model, we observed increased in vivo intestinal permeability (FD4) but 
decreased ex vivo paracellular permeability associated with striking intestinal modifications 
only after the onset of diabetes. We excluded an ex vivo intestinal hyper-permeability expressed 
in cm/s in diabetic mice but agreed with a higher in vivo exposure to luminal content. 
Due to the proximity between pancreas and duodenum, bacterial translocation from the 
intestine via the pancreatic duct towards pancreas could be hypothesized. 40% of long-term 
T1D patients had periductal fibrosis (Meier et al., 2005), which could be an indicator for 
persisting duct inflammation, possibly induced by bacterial infection. Microbial translocation 
in pancreatic lymph nodes activates NOD2 and IL-17 production in pancreatic lymph nodes 
and pancreas contributes to T1D development (de Goffau et al., 2013). Indeed, Korsgren et al. 
instilled different bacteria into the pancreatic duct. This leads to consecutive islet inflammation 
and T1D. Different bacteria were tested, among them E. coli, which exhibits the most severe 
pancreatic inflammation in comparison to S. aureus, E. faecalis, α-Streptococcus (Korsgren et 
al., 2012). This is of particular interest since E. coli has been increased in fecal microbiota of 
PND50 female MS mice due to defect of AMP in Paneth cells of small intestine. AMP 
expression is not uniquely found in Paneth cells, also neutrophils and epithelial cells can express 
and secrete AMPs. It is interesting to consider that antimicrobial peptides expression has also 
been found in pancreas. Indeed, the AMP repertoire seems to be diverse in pancreas, however 
in human pancreas their expression is not yet fully known (Stenwall et al., 2019). The presence 
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of CRAMP in the pancreas has been shown to protect mice from autoimmune diabetes (Sun et 
al., 2015). Stenwall et al. analysed pancreas of healthy control and one T1D patient. They found 
differentially expressed AMP in healthy vs the patient. AMP were generally less present in the 
patient than in control, even in the inflamed parts of pancreas of the patients, where AMP 
expression was higher than in non-inflamed parts (Stenwall et al., 2019). It could be possible, 
that early life stress is not only decreasing intestinal AMP activity, but also AMP activity in 
pancreas leading to pancreatic inflammation, which could end up in destruction of insulin-
producing β-cells. To answer this question we plan to assess the presence of the AMP CRAMP 
in pancreas and small intestine of MS and control mice. Indeed, it is of particular interest that 
CRAMP is only expressed in small intestine from birth to PND15 corresponding to the 
timeframe of MS protocol. However, in our model in C3H/HeN mice the effect of MS on 
pancreas were modest so it would be also interesting to perform those analyses in a genetically 
predisposed mouse model. 
 
In conclusion, the work of my PhD project highlights the role of intestinal barrier 
dysfunction in extra-intestinal, namely metabolic and autoimmune, diseases. The challenging 
hypothesis of intestinal barrier dysfunction and bacterial translocation preceding disease onset 
and its causal role in the pathogenesis of those diseases still need to be assessed in interventional 
studies. 
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THE ROLE OF LOW-GRADE INFLAMMATION IN AGING - 
INFLAMMAGING 
During my PhD thesis, we showed that neonatal maternal separation (MS) leads to 
metabolic disorder in aging male mice. It is interesting to consider that metabolic disorder did 
not appear at an earlier time point. Indeed, “aging is a ubiquitous complex phenomenon that 
results from environmental, stochastic, genetic, and epigenetic events in different cell types and 
tissues and their interactions throughout life” (Franceschi and Campisi, 2014). Aging is 
characterized by decreased capacity to react to diverse stressors and as a consequence, gradually 
increasing pro-inflammatory status, a phenomenon called “inflammaging”. Chronic low-grade 
inflammation establishes (Franceschi et al., 2006), resilience decreases. These are risk factors 
to develop metabolic but also other non-communicable diseases (NCDs).  
There are multiple propositions for the origins of the inflammaging process in aging 
individuals (for review (Franceschi and Campisi, 2014)). Damaged macromolecules and cell 
debris (self) can accumulate due to inadequate elimination. Harmful metabolites, products and 
fragments from bacteria or other sources (non-self) leak inside the organism due to 
inappropriate barrier function. Indeed, intestinal barrier dysfunction have been described in 
aging (Man et al., 2015). Cellular senescence, which is arrest of cell proliferation, is also playing 
a role in aging. In elderly, there is increased activation of the coagulation system (Hager et al., 
1989) which can be considered as part of the immune system due to its strong interaction with 
the last, underlining a disturbed immune system in the elderly. Another parameter favoring 
inflammaging are the changes in the immune system, also called immune senescence. Indeed, 
there have been multiple observations on immune system in elderly. Some authors propose that 
the adaptive immune response undergoes great changes and declines, whereas the innate 
immune response seems to stay preserved and becomes more reactive (Franceschi et al., 2000). 
Thanks to previous work and my PhD project, we had the possibility to follow several 
markers of the immune system at different time points during our protocol in C3H/HeN male 
mice, namely in early life (PND7, PND15, PN21), in young adulthood (PND50) adult 
(PND100, PND150) and in aging (PND350). Due to experimental reasons, not all data are 
available for every time point. 
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Figure 30 Plasmatic immunoglobulin concentrations measured by ELISA in C3H/HeN male mice at post-
natal day (PND) 7, 15, 21, 50, 100, 150 and 350. (A) IgG (µg/mL). (B) IgA (ng/mL) 
In C3H/HeN mice, IgG and IgA plasmatic concentrations increase in time (Figure 30), 
whereas IgG increased sharply in aging mice (PND350, Figure 30A). Paganelli et al. observed 
similar phenomena in human. They studied a cohort, including males and females, in the age 
range from 23 years to 106 years. They showed that plasmatic IgG and IgA increased with 
aging (Paganelli et al., 2008). 
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Figure 31 Cytokine concentrations measured by ELISA in C3H/HeN male mice at post-natal day (PND) 7, 15, 
21, 50, 100, 150 and 350. (A) TNFα concentrations (pg/mg protein) in lysate of small intestine. (B) TGFβ 
secretion (pg/mL) in response to anti-CD3/CD28 (T cell receptor) stimulation in primary culture of splenocytes. 
Cytokine secretion during lifetime is visualized in Figure 31. We observed cytokine 
concentrations in SI. TNFα concentrations increased with aging (Figure 31A). These results 
are consistent with literature. Thevaranjan et al. identified increased TNFα as driving force for 
decreased killing capacity of macrophages from old vs young mice (Thevaranjan et al., 2017). 
In human, stimulated secretion of IL-6, IL-1β, TNFα was increased in PBMC of old (mean age 
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80.2) vs young (mean age 26.8) participants. There were no differences for IFNγ secretion 
(Fagiolo et al., 1993).  
We analyzed several cytokines of adaptive immune response at systemic level (spleen), 
as for example pro-inflammatory and anti-inflammatory, like TGFβ (Figure 31B). TGFβ 
secretion constantly decreased in time and reached lowest levels in aging mice. These are 
indications that adaptive immune response seems to decrease in aging. Indeed, the immune 
system in the young is characterized by strong Th2 response and secretion of the anti-
inflammatory cytokine TGFβ in order to favor entry of luminal antigens for immune priming 
and establishment of tolerance (Adkins et al., 2004). Even though in physiological conditions 
TGFβ seem to decrease with age, it is interesting to note that the opposite is observed in 
pathologies. In human, increased TGFβ is described in aging and in numerous age-related 
pathologies, as for example osteoarthritis (Krieglstein et al., 2012). In healthy state, TGFβ is 
necessary for maintenance of articulate cartilage, in the case of osteoarthritis decrease of TGFβ-
receptor expression and modified TGFβ signaling has been described (van Caam et al., 2016). 
These observations highlight that not only TGFβ concentration could be affected during aging 
but also underlying mechanisms. 
Aging is also associated with intestinal barrier dysfunctions. Indeed, with aging 
intestinal permeability increases and innate immune system is modified in mice (Thevaranjan 
et al., 2017) and human (Man et al., 2015). Intestinal IL-6 (Man et al., 2015) and TNFα 
(Thevaranjan et al., 2017) secretion are increased in aging subjects. Thevaranjan et al. showed 
that aging is associated with microbiota dysbiosis, which is triggering age-associated 
inflammation. However, both were interdependent, since microbiota dysbiosis could be 
reversed by treating increased TNFα (Thevaranjan et al., 2017). They concluded that “age-
associated inflammation and microbial dysbiosis drive intestinal permeability and translocation 
of bacterial components, further fueling inflammation and impairing cellular antibacterial 
function” (Thevaranjan et al., 2017). Those results are underlining the potent role of 
inflammation and intestinal barrier dysfunction in aging. 
Until here, I demonstrate the effects of aging on immune system and intestinal barrier 
in C3H/HeN mice. However, this does not explain why we observe differences between MS 
and control mice. Why do MS mice develop metabolic disorder with aging but not control? 
Franceschi et al. propose that inflammaging alone is not sufficient to induce age-related 
diseases. Low-grade inflammation in aging leads to higher susceptibility to disorders, the 
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authors called this “first hit”. However, to develop disease a “second hit” is necessary. 
According to Franceschi et al. this could be genetically predisposition (Franceschi et al., 2006), 
but I would extend the term “second hit” by defining it as an additional risk factor like MS. 
Indeed, MS mice experienced an important insult in early life – the separation from their 
dam, which led already in young mice to modifications of immune system and intestinal barrier. 
According to the theory of embodiment, this insult can leave an imprinting on the organism 
which lead later to higher disease susceptibility. The cost of the adaption to early life stress in 
MS male mice is reflected by early (PND50) development of low-grade inflammation (Riba et 
al., 2018). As young adult, MS mice already faced the symptoms of irritable bowel syndrome 
(Riba et al., 2018). These modifications can be resumed as wear and tear on the body – which 
try to find new homeostasis (Fava et al., 2019). In aging (PND350) male mice face higher low-
grade inflammation compared to control (Ilchmann-Diounou et al., 2019). Indeed, at PND350 
protective IL-17, IL-22 and IL-10 responses were decreased and pro-inflammatory TNFα 
secretion increased in SI.  
To conclude, our work confirmed that aging is associated with profound changes in the 
immune system and higher susceptibility to disease. Indeed, metabolic disorder only appear at 
PND350 in our model. 
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THE MODEL OF MATERNAL SEPARATION IS A USEFUL MODEL TO 
DECIPHER ETIOLOGY OF METABOLIC DISORDERS 
During my PhD thesis, we showed that neonatal maternal separation (MS) leads to 
metabolic disorder in aging (PND350) male mice without any dietary challenge. Metabolic 
disorder was characterized by fasted hyperglycemia, glucose intolerance and insulin resistance 
without obesity. Additionally, we observed microbiota dysbiosis, intestinal and systemic 
immune alterations and increased humoral immune response against microbiota (Ilchmann-
Diounou et al., 2019).  
Interestingly, low-grade inflammation was already observed in small intestine and 
spleen in our model at earlier time point (PND50) (Riba et al., 2018) and persists at PND350 
with increased LPS-induced TNFα secretion in siLP and spleen suggesting an imprinting of 
early life. Additionally, intestinal barrier dysfunction has been observed at PND50, namely 
decreased lysozyme activity, intestinal hyperpermeability and microbiota dysbiosis (Riba et al., 
2018).  
We hypothesize that weakened intestinal barrier at PND50 induces persistent low-grade 
inflammation that precedes metabolic disorder. Until today, there is no consensus among 
scientists if low-grade inflammation is cause or consequence of metabolic disorder.  
Arguments in favor of low-grade inflammation as a trigger are inflammaging process 
(treated in the previous chapter) and experiments with anti-inflammatory treatments in 
metabolic diseases. In 1957, Reid and colleagues demonstrated that aspirin (salicylates), an 
anti-inflammatory treatment decreased fasting blood glucose levels in overweight and lean 
diabetic patients (Reid, 1957). Later on, studies indentified IκB/NFκB axis as the molecular 
target of hypoglycemic effects of salicylates (Shoelson et al., 2003; Yuan et al., 2001).  
Our data suggest that defect of intestinal barrier functions (intestinal hyperpermeability 
and defect of Paneth cells associated with microbiota dysbiosis) and low-grade inflammation 
observed in PND50 male mice submitted to MS (Riba et al., 2018) precedes the onset of glucose 
intolerance and insulin resistance observed in PND350 mice. This observation is in accordance 
with studies suggesting that high-fat diet impairs intestinal barrier (intestinal hyperpermeability 
and defect of Paneth cells) and triggers low-grade inflammation before the onset of adverse 
metabolic consequences (for review, (Araújo et al., 2017)). Furthermore, in mouse model of 
HFD-induced intestinal hyperpermeability associated with an increase of HOMA index (a 
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measure for insulin resistance), restoring intestinal permeability by fish oil treatment or 
resolving D1 did not improve HOMA index (Lam et al., 2015), suggesting that correcting 
intestinal permeability is not sufficient to ameliorate metabolic status. One could hypothesize 
that, past intestinal hyperpermeability have been already responsible for the establishment of 
low-grade inflammation. Correcting hyperpermeability at late time point when metabolic 
disorder is established may be too late to correct immune modifications. In our model, we 
observe corrected intestinal permeability at PND350, however, metabolic disorder only 
appeared at this time point. MS increased humoral immune response against-E. coli in plasma 
from PND50 and this signature persists until PND350. Interestingly, IgG against specific 
bacterial antigens were increased in diabetic patients (Mohammed et al., 2012). 
These results are encouraging to set up an experimental model to decipher whether 
metabolic disorder are a consequence or a cause of an ongoing low-grade inflammation, a 
question still under debate in metabolic disorder and particularly in T2D. Indeed, since 
metabolism and inflammation are closely related and regulate one another (as previously 
discussed), in established metabolic disorder with inflammation it is difficult to discriminate 
which one – inflammation or metabolic disorder – precedes the other. The neonatal maternal 
separation paradigm seems an appropriate model in order to answer this question and to 
evaluate the mechanisms linking intestinal barrier, immune changes, low-grade inflammation 
and glucose metabolism disorders, which seem to appear in a distinct time frame in this model. 
Using the model of neonatal maternal separation to study metabolic disorder may contribute to 
a better understanding of the relationship between immunology, intestinal barrier (including 
microbiota) and metabolism. In the following, I am suggesting some interventional studies, 
which could be useful to respond to the question. 
Since metabolic disorder in our model appear late, it would be interesting to precipitate 
or accelerate the establishment of metabolic disorder, by a dietary challenge. Indeed, our results 
are obtained under normal diet. High-fat high-sugar diet (HFHSD) could be a useful tool, since 
it is described to induce rapidly metabolic disorder.  
In a first step, one has to validate that HFHSD induces exacerbated metabolic disorder 
in MS mice compared to control. Indeed, preliminary results in our laboratory showed that 
HFHSD induces in MS male mice greater weight gain compared to control under HFHSD diet 
(Figure 32). Besides, food intake were similar between control under HFHSD and MS under 
HFHSD. 
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Figure 32 Preliminary data Body weight (g) from maternal separated (MS) and control C3H/HeN male mice 
under high-fat high-sugar diet (HFHSD) or normal diet (ND) at post-natal day (PND) 50 (start of HFHSD) and 
1, 2, and 3 weeks after HFHSD. Asterisk is indicating statistic difference between MS mice under HFHSD and 
control mice under normal diet, two-way ANOVA, Sidak’s multiple comparison test, ** p<0.01, *** p<0.001, 
n=7-10 mice. 
In a second step, numerous interventional studies are possible to assess the role of 
- Intestinal barrier  
o Intestinal barrier correction (decrease of inflammation and intestinal 
hyperpermeability induced by MS) via pre- and probiotic treatment, before 
HFHSD challenge. 
o Intestinal permeability correction (decrease of intestinal hyperpermeability 
induced by MS) by ML-7, a MLCK-inhibitor (Moussaoui et al., 2014; Rincel 
et al., 2019) or zonulin inhibitor (Fasano, 2011), before HFHSD challenge 
- Immune response 
o Decrease of inflammation induced by MS by non-steroidal anti-
inflammatory treatment, before HFHSD challenge. 
We hope that by reducing inflammation and/or improving intestinal barrier function we 
will prevent MS-induced glucose intolerance and increased gain weight observed under 
HFHSD diet compared to control on the same diet. Those studies will confirm the role of the 
intestinal barrier dysfunction and inflammation in the onset of metabolic disease. 
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THE EFFECTS OF MATERNAL SEPARATION AFFIRM THE 
IMPORTANCE OF NEONATAL WINDOW AND THE DOHAD CONCEPT 
This PhD project underlined the early and long-term effects of early life adverse events, 
namely neonatal maternal separation in the development of different non-communicable 
diseases. 
The most significant effect we observed all along the MS model is the induction of 
modified humoral immune response against luminal content in plasma of male and female. This 
effect appears already in early life (PND15). Indeed, at PND15 IgG against commensal bacteria 
(E. coli) is decreased in male, but not in female (Figure 33A) and specific humoral IgG immune 
response against food is significantly increased (Figure 33B) in both sexes. 
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Figure 33 Specific humoral immune response measured by ELISA at post-natal day (PND) 15 in plasma of 
male and female C3H/HeN maternal separated (MS) and control pups. (A) Specific IgG against microbiota 
(E.coli lysate) (arbitrary unit (AU) of standard sample/10 µg/mL IgG). (B) Specific IgG against hydrosoluble 
fraction of food (optical density (OD) at 450 nm), Student’s unpaired t-test,* p<0.05, **p<0.01. 
Interestingly, the specific immune response against luminal antigens is reversed in MS 
model in time. Indeed, here we show that MS reduces IgG against E. coli in pups. However, in 
MS young adults (Riba et al., 2018) and aging mice (Ilchmann-Diounou et al., 2019) IgG 
against commensal microbiota is increased. In contrast, IgG against food is increased in MS 
pups and similar in young adults (Riba et al., 2018) and aging mice (Figure 34).  
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Figure 34 IgG against hydrosoluble fraction of food in plasma measured by ELISA (optical density (OD) at 
450 nm) at post-natal day (PND) 350 (A) of male and (B) female C3H/HeN mice. 
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In summary, in pups, humoral immune response against microbiota is delayed by MS, 
whereas MS pups are more sensitive to food antigens. Modified immune response towards 
luminal antigens could also be due to different microbiota composition. Indeed, Zeng et al. 
identified the potential of commensal gram-negative bacteria to induce systemic specific IgG 
response, which was protective in later infection (Zeng et al., 2016). The increased reaction to 
food antigens could perhaps be explained by the fact that MS pups start earlier to introduce 
solid food in their nutrition than control pups. One can hypothesize that this could be due to the 
disturbed relationship with their dam. To answer this question, it would be interesting to observe 
feeding behavior in MS neonates and to study microbiota changes in early life. In contrast, with 
potentially advanced solid food introduction, we observe in our model in male a retarded gut 
closure, since intestinal permeability stay increased until PND50. The combination of advanced 
introduction of solid food and concomitant microbiota changes with delayed gut closure could 
be threatening, since more potential dangerous molecules could pass the intestinal barrier and 
reach the systemic circulation. However, in female there is no delayed gut closure but decreased 
lysozyme activity and intestinal low-grade inflammation, indicating perturbation of intestinal 
physiology.  
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Figure 35 Plasma IgE concentrations (ng/mL) measured by ELISA in maternal separated (MS) and control 
C3H/HeN pups. (A) post-natal day (PND) 15. (B) PND21. Student’s t-test, *p<0.05, **p<0.01. 
IgE concentrations were significantly increased at PND15 in male and female mice 
submitted to MS (Figure 35A). This effect was transient and already resolved at PND21 
(Figure 35B). However, since pups are, during the neonatal period, immunological dependent 
on their dam it would be necessary to analyze dams milk and assess Ig content. Indeed, 
immunoglobulins are delivered from dam to pup by milk, which provide protection from 
infection during the first days of life through passive immunity. Additionally, transfer of Ig 
from lumen into circulation is possible via Fc receptors in mice (Van de Perre, 2003). IgE is 
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playing a role in allergy. Indeed, there are IgE-mediated food allergies (Berin, 2015). 
Interestingly, mice with low diversity microbiota as well as germ-free (GF) mice have elevated 
IgE concentrations in plasma. The increased IgE concentration lead to anaphylactic reactions 
in GF mice This deleterious outcome can be avoided by colonization with high diversity 
microbiota in early life (Cahenzli et al., 2013). It would be interesting to analyze microbiota in 
early life in the MS model. Perhaps MS leads to decreased gut microbial diversity. Additionally, 
it would be intriguing to set up food allergy experiments, to test if the observed effect on 
immunoglobulin repertoire has significant consequences on the allergy susceptibility. However, 
the food allergy experiment must be carried out in early life, since the observations we made in 
IgE and IgG against food resolve in time, thus highlighting the presence of an early critical 
window of opportunity.  
In conclusion, our work shows that an insult in early life can have long-lasting 
consequences on intestinal barrier and immune system. Depending on the time the effect of MS 
were analyzed, different disease susceptibilities have been highlighted. At PND350 metabolic 
disorder, at PND50 IBS (Riba et al., 2018) and at PND15 probably food allergy. Thus MS 
model is highlighting that early life adverse events can have multiple consequences on 
physiology and as a consequence increasing overall disease susceptibility. Hence, this work 
supports the concept of DOHaD and the notion of a neonatal window of opportunity. 
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MS INDUCES SEXUAL DIMORPHISM 
Interestingly in our work, we observe a MS-induced sexual dimorphism at all ages. 
Indeed, already at the age of 15 days male and female mice were different regarding immune 
response. One example is the increase in IgE concentrations in female compared to male in both 
control and MS group (Figure 36). These observations are underlining early onset of sexual 
dimorphism in the control and MS group. 
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Figure 36 Plasma IgE concentrations (ng/mL) measured by ELISA in C3H/HeN maternal separated (MS) and 
control pups at post-natal day (PND) 15, two-way ANOVA, Sidak’s multiple comparison test. 
 
Table 2 Sexual dimorphism in MS-induced phenotype at PND350 
 Male Female 
Glucose tolerance Glucose intolerant Glucose intolerant 
Insulin sensitivity Loss of insulin sensitivity No change of insulin sensitivity 
by MS 
Insulin secretion No change of insulin secretion Decreased insulin secretion in 
response to glucose stimulus 
Intestinal innate immune 
response 
Increased TNFα secretion in 
response to LPS stimulation 
Increased basal and LPS-
stimulated TNFα secretion 
Intestinal adaptive 
immune response 
Decreased IL-17, IL-22 and IL-
10 secretion in response to TcR 
stimulation  
Increased IL-17 and IL-22 
secretion in response to TcR 
stimulation 
Systemic innate immune 
response 
Increased TNFα secretion in 
response to LPS stimulation 
No modification by MS 
Systemic adaptive immune 
response 
Increased IL-17 secretion in 
response to TcR stimulation 
Increased IFNγ secretion in 
response to TcR stimulation 
Humoral immune 
response 
Decreased fecal IgG 
concentrations, increased 
plasmatic IgG specific for 
microbiota 
No modification by MS 
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The different results observed in male and female at PND350 are summarized in Table 
2. Interestingly, our observations in aging mice are similar to epidemiological observations 
highlighting diseases susceptibility depending on sex. Male MS mice develop classical 
metabolic disorder with insulin resistance, while we hypothesize that female MS mice develop 
metabolic disorder with autoimmune characteristics. Elderly men developed more often 
metabolic syndrome than female. However, today in the United States there are more women 
with metabolic diseases due to faster increase in obesity in women (Beigh and Jain, 2012). 
Similar data were obtained in other countries, as for example Russia and Korea. However, 
women suffering from metabolic diseases in comparison to men with metabolic diseases have 
higher body weight but lower plasmatic HDL, suggesting that woman need higher degree of 
obesity to reach the same metabolic disturbance than man (Dallongeville et al., 2004; Williams 
et al., 2003). Additionally, women suffer less from metabolic disorder associated 
complications, as for example coronary heart disease. This is principally due to the more 
favorable fat distribution in women (Regitz-Zagrosek et al., 2006). Additionally, men have 
higher insulin resistance than woman, associated with higher hepatic and visceral adipose tissue 
in men (Geer and Shen, 2009). These data are matching with our results, since male MS mice 
developed metabolic disorder, namely glucose intolerance and decreased insulin sensitivity 
without obesity. 
Besides metabolic disease susceptibility, there are various other diseases where male 
and female have different susceptibility.  
In human, a great sexual dimorphism is seen in the susceptibility to autoimmune 
diseases (AD). Female are more prone to develop autoimmune disease. Indeed, about 45 of 80 
identified auto-immune diseases are female-biased (Hayter and Cook, 2012). Since the onset of 
most AD is around 40 years of age, sexual hormones have been rapidly identified as the trigger 
of differences in susceptibility. However, there are also sex-biased AD with pediatric onset, 
long before puberty, as for example juvenile idiopathic arthritis (Ravelli et al., 1998).  
These data are consistent with our observations. It seems that female MS mice develop 
metabolic disorder with autoimmune characteristics, namely loss of insulin secretion that still 
need to be confirm by results of MS on diabetes incidence on NOD female mice. 
The male and female immune response are different. Female develop robust adaptive 
immune response and are as a consequences more protected from infection than males, which 
develop more easily inflammation (Fairweather et al., 2008; Klein and Flanagan, 2016). The 
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differences in the immune system have been finely documented and largely attributed to sexual 
hormones (Oertelt-Prigione, 2012). Data on pre-pubertal immune system is sparse or lacking 
(Chiaroni-Clarke et al., 2016). 
There are also differences observed in the susceptibility to mental and psychological 
disease. Indeed, women develop twice-often depression in comparison to men (Karger, 2014). 
The ratio of boys:girls diagnosed autism spectrum disorder is 3:1 (Loomes et al., 2017). 
The stress response and the HPA axis response differ between male and female. Female 
sex hormones attenuate the sympathoadrenal and HPA responsiveness, leading to slowly 
cortisol feedback on the brain and less or delayed containment of the stress response (Verma et 
al., 2011). Studies in female control, ovaroectomized and oestrogen and progesterone-replaced 
rats showed that ovarian steroids influence the HPA axis (Carey et al., 1995). Other studies 
argue that the observed HPA differences in male and female emerge from the organizational 
effects of gonadal steroids during early brain development (Patchev and Almeida, 1998). 
However, in human obtained data are conflicting. In women, cortisol concentrations were not 
correlated to menstrual cycle (Abplanalp et al., 1977).  
Additionally, glucocorticoid receptors (GR) are differentially expressed in male and 
female. On most leucocytes, GR are more expressed in male compared to female (Lu et al., 
2017). This could be one reason for modified immune response in male and female.  
What could be the reasons for sexual dimorphism apart of sex hormones? Are there 
other explications for sexual dimorphisms? 
Even if sexual hormones are similar in pre-pubertal stage, sex hormone receptor 
expression could be different. Indeed, a study in sheep showed that estrogen receptor (ER) but 
not androgen receptor (AR) were differentially expressed in male and female sheep already 
during gestation (Reddy et al., 2014). In rats, dimorphic ER expression has been found in the 
early neonatal period (Orikasa et al., 2002). ERα and ERβ are expressed in a variety of tissues 
and cells. They are present in intestinal tissue (Kawano et al., 2004), whereas ERβ is expressed 
twice times more in female colonic epithelium compared to male (Campbell-Thompson et al., 
2001; Thomas et al., 1993). They can also be found on numerous immune cells (Grimaldi et al., 
2002; Phiel et al., 2005). 
Other mechanisms, which lead to sexual dimorphism, could be due to genetics. X-
chromosome silencing or epigenetic mechanisms (Chiaroni-Clarke et al., 2016). 
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In human, sex-bias can also be due to different exposure between genders due to 
occupation, however, in our study, male and female mice were living in the same environment 
and no social gender-effect can be accused. 
There is no standard reason to choose one sex or another in animal studies for general 
purposes. Indeed, historically female animals were often excluded due to the hormonal changes 
during the sexual cycle. Researchers supposed that these hormonal changes in female would 
induce greater variability in data and a need for higher number of groups in the experiments to 
find statistical significance (Shansky, 2019). This lead to a great bias in several disciplines of 
biomedical research (Beery and Zucker, 2011). However, there were no scientific study 
proofing this assumption. Even more surprisingly, a meta-analysis of variability did not find 
that female data are more variable than male (Becker et al., 2016) but demonstrated in the 
contrary that testosterone levels in male subjects have a great variability depending on their 
social position (dominant or subordinate) in the cage (Machida et al., 1981). 
Carrying out preclinical studies in sex-biased experiments, can have important impact 
on the results and therefore adverse effects on especially women’s health. Only in 2014, but 
luckily, the NIH changed its policy to face the sex-bias in biomedical research. Indeed, the NIH 
requires now that male and female cells and animals are included in preclinical studies, except 
of applications were use of both sexes is not justified (Clayton and Collins, 2014).  
In summary, our work shows that male and female are, from young age on, biologically 
different and highlights sex as an important variable in biomedical studies. Our work 
emphasizes the need to conduct research in male and female subjects, since observed effects 
could be quite different and conclusions of studies carried out only in one sex could not 
necessarily be transposable to the other sex.  
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This PhD project identified for the first time neonatal maternal separation as a risk factor 
for Non-Communicable Diseases in male and female C3H/HeN mice. We observed a sexual 
dimorphism confirming epidemiological data: male mice developed metabolic disorder with 
insulin resistance, while female seem to develop autoimmune disorder. The results of our work 
show that sexual dimorphism is a real challenge in biomedical research and that dimorphic 
phenotype can appear already in early life.  
Our results highlight the neonatal window as a critical period for the establishment of 
immune homeostasis and a life-long appropriate interplay between microbiota, immune 
response and metabolic functions, hence strengthening the concept of Developmental Origin of 
Health and Diseases (DOHaD).  
In our work, we did not analyze any epigenetic signature, since it was beyond the aim 
of this project. Nevertheless, epigenetic regulations are potent mechanisms in the mediation of 
early life environment and later health outcomes. Further studies in the MS model are needed 
to assess the impact of early life stress on epigenetic signature and its role in the development 
of non-communicable diseases. 
Our work underlines the role of intestinal integrity in health and disease. Indeed, 
intestinal modifications are observed in intestinal and extra-intestinal diseases, in some case 
even before the onset of disease. Hence, preserving intestinal integrity should be one of personal 
and medical occupations. Indeed, preservation of overall health and prevention of disease could 
be improved and supported in taking care of our gastro-intestinal tract at early time point. Care 
and treatment could be food remediation, applications of pre- and probiotics. Indeed pre- and 
probiotics are already used in different diseases in order to regain a healthy and stable 
microbiota. Dietary intervention are still the first choice of treatment in metabolic disorder. 
Additionally, intestinal health could also be targeted via the HPA axis by stress management. 
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The concept of Developmental Origins of Health and Disease (DOHaD) highlights the importance of 
early life period and raises the hypothesis that Non Communicable Diseases (NCD) could find their origins in 
perinatal environment. Neonatal maternal separation (MS) is a stress model widely used in rodents as a 
paradigm of early life adverse events. In my PhD project, I aimed to investigate in aging male and female wild-
type mice under normal diet the long-term effects of neonatal MS on intestinal barrier function, metabolism, 
immunity, auto-immunity, as well as on microbiota. My work aimed to provide experimental data to support 
a link between early life stress and development of metabolic or autoimmune disorders with aging.  
In our first study, MS led to glucose intolerance and loss of insulin sensitivity associated with fecal 
dysbiosis in Post Natal Day (PND) 350 wild-type C3H/HeN male mice fed a standard diet. Fecal IgG 
concentrations were decreased in MS mice compared to control mice, whereas anti-E. coli IgG, representing 
humoral response toward commensal microbiota, were significantly increased in plasma of MS mice. MS 
significantly decreased IL-17 and IL-22 secretion in response to TcR stimulation in small intestine lamina 
propria (siLP) culture. Besides, TNFα secretion in response to LPS-stimulation was slightly increased. The 
same results were obtained at systemic level (spleen). For the first time, we demonstrated that early life stress 
alone is a risk factor for metabolic disorders development in aging wild type mice under normal diet. The result 
of this project gave us the opportunity to question the role of microbiota in MS-induced glucose intolerance. 
Fecal microbiota transfer of MS mice microbiota was not sufficient to induce glucose intolerance. 
In our second study in PND350 female, MS increased IL-17 and IL-22 by siLP cells in response to 
TcR stimulation. TNFα secretion with and without LPS stimulation was also increased by MS. Additionally, 
we observed systemic low-grade inflammation. MS mice developed glucose intolerance associated with 
decreased insulin secretion in response to glucose stimulus. Ratio of β-cell surface to pancreas surface was 
slightly decreased in MS mice compared to control. This ratio positively correlated with insulin secretion 
induced by glucose. Taken together, the results of our study showed that MS in wild type female mice under 
normal diet leaves a long-lasting imprinting on immune-metabolism and pancreas homeostasis.  
We compared in vivo and ex vivo intestinal permeability measurements in a model of type 1 diabetes 
(NOD – non-obese diabetic mice). Intestinal permeability was assessed in vivo by gavage and ex vivo in Ussing 
chambers with the marker FITC-Dextran 4 kDa. Surprisingly, the results of both methods were divergent. The 
difference between in vivo and ex vivo measurements could not be explained by altered renal excretion. 
Curiously, diabetic NOD mice had significantly longer small intestine than non-diabetic NOD mice and small 
intestine length positively correlated with intestinal permeability in vivo. However, there were no difference 
in intestinal transit time, feces humidity and histological appearance. Altogether, our results highlighted the 
importance to distinguish intestinal permeability, which is expressed as cm/s, measured ex vivo, and the notion 
of systemic exposition to luminal antigen, measured in vivo.  
My PhD project shows that early life adverse events are a risk factor for NCD. Interestingly, our 
observations in aging mice are similar to epidemiological observations. Indeed, preliminary results suggested 
that female MS mice develop metabolic disorders with autoimmune characteristics but male MS mice develop 
classical metabolic disorders with insulin resistance. My work in MS model highlights the importance of early 
life in the establishment of homeostasis and comforts the concept of DOHaD. 
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